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Abstract 
 
 
 
Pseudomonas aeruginosa has risen as one of the most resistant bacterial pathogens 
affecting people worldwide. Inefficacy of current antimicrobial treatments to relieve P. 
aeruginosa infections demands the need for novel antimicrobial therapies. Natural 
products such as the aqueous and alcoholic extracts of North American ginseng, as well 
as thymol and carvacrol, compounds purified from thyme and oregano, have previously 
displayed antibacterial properties against P. aeruginosa. In this study we examined the 
effect of these compounds on P. aeruginosa pathogenicity by measuring pathogenic 
markers (ie virulence factor secretion, biofilm formation) after PAO1 and Cystic Fibrosis 
clinical isolates were treated with the natural compounds. Thymol and carvacrol were 
able to attenuate the growth of P. aeruginosa clinical isolates in nutrient and minimal 
media however PAO1growth was only attenuated in the nutrient media. The alcoholic 
ginseng extract displayed no growth inhibitory action towards any strain tested; however 
the aqueous ginseng extract attenuated growth of all strains at concentrations of 8.0-7.0% 
w/v  and 3.0-2.0% w/v in the minimal and nutrient media respectively. Sub-inhibitory 
concentrations of the aqueous ginseng extract increased growth rate and bacterial 
adherence, but decreased the production of many virulence factors, while the alcoholic 
ginseng treatment increases secretion of select virulence factors. Microarray analysis 
revealed decreases in virulence factors with sub-inhibitory aqueous ginseng extract 
exposure. Treatment with sub-inhibitory concentrations of thymol or carvacrol reduced 
pigment, lipase, and protease secretion after exposure to thymol or carvacrol in a strain 
specific manner; however bacterial motility was negatively affected in all strains with 
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treatment of either compound. Microarray the thymol 6 h and carvacrol 24 h treatments 
displayed enhanced expression of pyoverdine and pyochelin synthesis genes. Enrichment 
of the ribosomal pathway was substantial after the 24 h carvacrol and aqueous extract 
exposures, findings which require further investigation. Overall reduction in pathogenesis 
was most evident with the aqueous ginseng extract however thymol and carvacrol were 
most effective at inhibiting bacterial growth. Further chemical analysis of the alcoholic 
and aqueous ginseng extracts may reveal specific extract constituents with potent 
antibacterial properties. Analysis of potential synergy between the tested plant 
components and current antibiotics of P. aeruginosa may provide a greater appreciation 
for their use in antibacterial therapies. 
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Lay Summary 
 
 
 
Faculty and students in the Department of Biology are bound together by a common 
interest in explaining the diversity of life, the fit between form and function, and the 
distribution and abundance of organisms. The research undertaken in this thesis aimed to 
better our understanding of the function of bacterial pathogen Pseudomonas aeruginosa 
under the influence of naturally derived antibacterial compounds. Through the assessment 
of virulence factor production, bacterial growth, and expression ananlysis we were able to 
determine the efficacy of these naturally produced compounds to inhibit P. aeruginosa 
pathogenicity. Further exploration of larger samples sizes from varying populations 
would help to better our understanding of the potential for these naturally produced 
compounds to act as therapeutic agents against P. aeruginosa and possibly other bacterial 
pathogens. 
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Chapter I. Thesis Overview 
 
1.1 Pseudomonas aeruginosa Characteristics 
 
 
 
Infections and disease caused by virulent bacteria are a prominent health concern 
across the world. The adaptability of bacteria to a variety of environments, host defence 
mechanisms, and antibiotic treatments has led to persistent infections with limited 
available antibiotic therapies. Of prominence is the opportunistic pathogen Pseudomonas 
aeruginosa, a highly mutable and antibiotic resistant bacterium which is a leading cause 
of nosocomial infections and chronic lung infections. 
 
P. aeruginosa is a gram negative, facultative anaerobic, motile, rod-shaped 
bacterium.  A environmentally ubiquitous organism, P. aeruginosa thrives in both 
terrestrial and aquatic environments adapting to variations of nutrient supplies, 
atmospheric oxygen concentration, salinity, and temperature (Hardalo and Edberg 1997, 
Worlitzsch, Tarran et al. 2002).  P. aeruginosa’s adaptability is largely attributed to its 
genome size of 6.3 million base pairs, larger than another other bacterial genome 
sequenced to date (Stover, Pham et al. 2000). P. aeruginosa’s genome is comprised of 
approximately 10% of regulatory genes (Stover, Pham et al. 2000, Schuster and 
Greenberg 2006), many of which are thought to function as gene expression regulators 
allowing P. aeruginosa great control and manipulation of its genome increasing the 
bacteria’s adaptability to a broad range of conditions (Schuster and Greenberg 2006). 
 
The large genome size of P. aeruginosa is attributed to an increase in genetic 
diversity, displayed through the overwhelmingly diverse number of paralogous groups 
found within the genome and not genome organization (Stover, Pham et al. 2000). Each 
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paralogous group encodes genes with specific functions such as outer membrane proteins, 
quorum sensing compounds, excreted enzymes and toxins, and virulence factors.The 
ability of P. aeruginosa to orchestrate this immense repetoir of genes has allowed it to 
thrive as an opportunistic pathogen. 
 
1.2 Pseudomonas aeruginosa and Nosocomial Infections 
 
 
 
Alongside Escherichia coli and Staphylococcus aureus, P. aeruginosa is a leading 
cause of nosocomial infections (Schaberg, Culver et al. 1991). P. aeruginosa has been 
reported to cause 12% of nosocomial urinary tract infections, 10% of bacteremias, 8% of 
wound infections from surgery, and 16% of hospital acquired pneumonia (Van Delden 
and Iglewski 1998). Those patients with compromised immune systems, such as those 
with burn wounds, transplants, cancer, and cystic fibrosis (CF) are most susceptible to 
infections caused by this pathogen (Bodey, Bolivar et al. 1983, Barbieri and Sun 2004). 
The cause of infection can often be traced back to contaminated respirators, surgical 
tools, faucets, and nebulizers for antibiotic administration (Bodey, Bolivar et al. 1983). 
Often the most detrimental infections caused by P. aeruginosa are in patients with cystic 
fibrosis. 
 
1.3 Cystic Fibrosis 
 
 
 
Cystic fibrosis (CF) is an autosomal recessive disorder and the most common 
genetic disorder within Caucasian populations (Wood, Boat et al. 1976, Tummler and 
Kiewitz 1999). The disease is characterized by mutations to the cystic fibrosis 
transmembrane conductor (CFTR) gene which is responsible for the proper synthesis of a 
transmembrane cAMP regulated channel which transports ions, primarily chloride, across 
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the membranes of exocrine epithelial cells [B (Tummler and Kiewitz 1999, Lubamba, 
Dhooghe et al. 2012). The most prominent mutation accounting for approximately 90% 
of all cases leading to CF is the ΔF508 mutation (Riordan 2008, Lubamba, Dhooghe et al. 
 
2012) in which a phenylalanine residue is deleted at the 508 position leading to improper 
folding of the protein and its early degradation (Lubamba, Dhooghe et al. 2012). 
 
Improper passage of ions and the subsequent movement of water into the 
epithelial cells from improper CFTR function, leads to an dehydrated environment which 
favours the build up of viscous mucus (Bye, Ewig et al. 1994, Lubamba, Dhooghe et al. 
2012, Lukacs and Verkman 2012). Improper ciliary clearance of the mucous leads to 
airway obstruction in the peripheral airways, causing stress on the respiration of the 
individual (Bye, Ewig et al. 1994). Continual airway obstruction creates a state of 
constant exaggerated inflammation and an excessive recruitment of pro-inflammatory 
cytokines, neutrophils, and macrophages (Elizur, Cannon et al. 2008) .  The environment 
created within the airways of CF individuals creates circumstances favouring bacterial 
infection (Govan and Deretic 1996). Bacterial colonization starts a viscious cycle of 
infection, inflammation, and destruction of the airway epithelium due toproduction of 
host and bacterial proteases and neutrophil elastase (Birrer, McElvaney et al. 1994). This 
cycle instigates lung deterioration, respiratory failure, and in many cases death (Govan 
and Deretic 1996). 
 
1.3.1 Pathogenicity of Cystic Fibrosis 
 
 
 
Bacterial lung infections begin early in life for CF individuals starting with 
infections of Staphlococcus aureus (SA) and non-encapsulated Hemophilus influenzae 
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(HI), which dominate for the first two years of life (Abman, Ogle et al. 1991). Prior to, 
and during these initial infections, the inflammatory response starts and an 
overabundance of pro-inflammatory cytokines, neutrophils, and phagocytic cells are 
signalled to the lungs (Lyczak, Cannon et al. 2002). The innate over inflammation is 
exaggerated by the early bacterial infections by SA, which produces multiple virulence 
factors (Cohen 1986). Production of bacterial virulence factors, in conjunction with the 
host cell produced elastase and proteases, causes severe lung tissue damage which further 
weakens the host cell’s ability to ward off future bacterial infection (Bye, Ewig et al. 
1994). 
 
 
Due to the efficacy of current anti-Staphlococcal treatments, primary infections 
caused by SA are kept under control, and seldom lead to long term chronic infections. 
Implementation of beta-lactam antibiotics including oxacillin and nafcillin, and long term 
prophylaxis with tetracyclins and cephalosporins has kept the majority of SA lung 
infections at bay (Michel 1988). Improvements in overall patient health are rarely seen 
following SA eradication (Lyczak, Cannon et al. 2002), and can in part be explained by 
the phenomena of continual SA antibiotic administration increasing the risk of acquiring 
more detrimental infections caused by P. aeruginosa (Bauernfeind, Emminger et al. 
1987, Ratjen, Comes et al. 2001). 
 
 
After the first two years of life, infections caused by P. aeruginosa begin to 
dominate the lungs of patients with cystic fibrosis (Abman, Ogle et al. 1991). Infections 
caused by P. aeruginosa can be acquired through hospital settings and social contact; 
however most often clinical isolates suggest an origin from the environment (Burns, 
Gibson et al. 2001).   Due to defective phagocytosis mechanisms and muscocillary 
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clearance of airway mucus, once present within the lungs, P. aeruginosa infections 
rapidly escalate. Chronic P. aeruginosa infection, often characterized by mucoid 
phenotype and biofilm formation, are difficult to fully eradicate with current 
chemotherapy options (Gilligan 1991). As infection with P. aeruginosa increases lung 
damage worsens, which can lead to a state of complete lung deterioration (Gilligan 1991, 
Bye, Ewig et al. 1994, Govan and Deretic 1996). 
 
1.4 P.aeruginosa Pathogenicity 
 
 
 
P. aeruginosa produces a wide variety of virulence factors, such as proteases, 
elastases, lipases, and pigments, which aid the bacteria in overcoming the host’s immune 
responses and out-competing other pathogens. P. aeruginosa also expresses various cell- 
associated virulence factors such as pili, flagella, and lipopolysaccharide (Wagner and 
Iglewski 2008). The overproduction of extracellular polysaccharides, such as alginate, 
has also been shown to increase P.aeruginosa’s pathogenicity by promoting mucoid 
phenotype conversion (Stapper, Narasimhan et al. 2004).The synthesis of many P. 
aeruginosa virulence factors is largely under the control of quorum sensing, a density- 
dependent signalling method employed by various bacterial species (Schuster, Sexton et 
al. 2013). 
 
1.4.1 Quorum Sensing 
 
 
 
Quorum sensing (QS) is a signalling system which employs cell density 
dependent autoinduced chemical signals to direct and coordinate mechanisms such as 
biofilm formation and virulence factor secretion (Fuqua, Winans et al. 1994, Schuster, 
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Sexton et al. 2013). This communication process is controlled through the production of 
self-synthesized molecules called autoinducers (AI) (Miller and Bassler 2001). In P. 
aeruginosa the autoinducer molecules are acyl-homoserine lactones (AHLs) which are 
synthesized and secreted under the control of the las and rhl pathways (Schuster and 
Greenberg 2006). The LasR-LasI pathway functions to send out signals via the 
production of the AHL 3-oxo-dodecaconyl-homoserine lactone (3OC12-HSL), and 
controls the function of the downstream RhlR-RhlI pathway, which sends signals via the 
production of the AHL butanoyl-homoserine lactone (C4-HSL) (Schuster, Sexton et al. 
2013). 
 
 
Over 300 genes within the P. aeruginosa genome are under the control of these 
two QS pathways including many virulence factors (Schuster, Lostroh et al. 2003, 
Wagner, Bushnell et al. 2003). Previous studies implementing animal model hosts have 
demonstrated the importance of QS control in virulence factor production for the 
establishment and persistence of P. aeruginosa infections (Rumbaugh, Griswold et al. 
1999, Pearson, Feldman et al. 2000, Wu, Song et al. 2001). The population dependence of 
QS signalling additionally promotes the organization and development of bacterial 
biofilms (Schuster, Sexton et al. 2013). 
 
1.4.2 Proteases, Elastases, and Lipases-Virulence Factors 
 
 
 
Exoenzymes are those enzymes secreted by eukaryotic and prokaryotic cells 
which function extracellularly.  P. aeruginosa produces a variety of exoenzymes 
including several elastase, protease, and lipase enzymes (Van Delden and Iglewski 1998, 
Wang, Tu et al. 2013). The alkaline proteases of P. aeruginosa are not well studied, but 
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play a role in tissue invasion and the progression of systemic infections (Van Delden and 
Iglewski 1998). However, the protease enzymes involved in the breakdown of elastin 
have been well characterized. 
 
LasA and LasB are the main elastase exoenzymes produced by P. aeruginosa 
(Galloway 1991). Combined, these enzymes break down lung epithelial tissue through 
elastin, collagen, and fibrin destruction leading to haemorrhages in the lungs during 
invasive infections (Heck, Morihara et al. 1986, Galloway 1991, Van Delden and 
Iglewski 1998). LasB has also been shown to disrupt host defence mechanisms through 
the inactivation of human immunoglobulins G and A, and the disruption of α-1- 
protinease inhibitor (Morihara, Tsuzuki et al. 1979, Heck, Alarcon et al. 1990, Hong and 
Ghebrehiwet 1992). 
 
P. aeruginosa also produces various lipase and hemolysin enzymes, such as 
phospholipase C and rhamnolipid, which together act to break down lipid and lecithin 
molecules aiding in tissue invasion (Van Delden and Iglewski 1998).  The decomposition 
of lung surfactant phospholipids is believed to play a critical role in the increased rates of 
lung collapse and airway closure associated with lung infections. The ability of ciliary 
transport to properly clear lung surfactant is also negatively impacted by the presence of 
rhamnolipids from P. aeruginosa (Read, Roberts et al. 1992). 
 
1.4.3 Excreted Pigments 
 
 
 
P. aeruginosa also produces multiple pigments which are implicated in the 
defence against phagocytosis and competing bacteria, as well as playing major roles in 
micro-nutrient acquisition. Pyoverydine is the name given to a group of green fluorescent 
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pigments excreted by Pseudomonas (Visca, Imperi et al. 2007). More than 50 different 
forms of pyoverdine have been determined, all sharing a conserved fluorescent 
dihydroxyquinoline chromophore with both an acyl and peptide side chain (Budzikiewicz 
2004). In combination with pyoverdine, P. aeruginosa also produces a second 
chromophore pigment named pyochelin, which is involved in iron sequestration for 
growth requirements (Cox, Rinehart et al. 1981). Iron is an essential nutrient of P. 
aeruginosa and pyoverdine and pyochelin are the main molecules used to acquire this 
nutrient (Visca, Imperi et al. 2007). Pyoverdine has also been linked to the regulation of 
virulence factor production and quorum sensing signalling through its involvement in 
various iron-dependent pathways (Lamont, Beare et al. 2002, Beare, For et al. 2003). 
 
Pyocyanin, a blue pigment with a tricyclic phenazine structure is another important 
virulence factor of P. aeruginosa (Wilson, Sykes et al. 1988). The redox- cycling activity 
of this pigment produces reactive oxygen species (ROS) which inhibit catalase enzymes, 
disrupt the balance of reduced/oxidized glutathione in epithelial cells, and cause severe 
tissue damage (Lau, Hassett et al. 2004). In addition, pyocyanin displays inhibitory effects 
towards epithelium ciliary beating, (Wilson, Sykes et al. 1988)(Wilson 
et al., 1988)(Wilson et al., 1988) nitric oxide production in macrophages and endothelial 
cells, increases superoxide production, disrupts α-1 protease inhibitors, and increases the 
rate of apoptosis in neutrophils (Wilson, Sykes et al. 1988, Shellito, Nelson et al. 1992, 
Muller and Sorrell 1997, Britigan, Railsback et al. 1999, Usher, Lawson et al. 2002). 
Immune modulation by pyocyanin production stimulates the release of proinflammatory 
cytokine IL-8 while repressing IL-2 (Nutman, Berger et al. 1987, Denning, Wollenweber 
et al. 1998). In animal models pyocyanin has been linked to an increase in neutrophil 
1
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influx accompanied by an increase in bronchoconstriction (Forteza, Lauredo et al. 1994, 
Lauredo, Sabater et al. 1998). 
 
1.4.4 Exotoxins 
 
 
 
A collection of exotoxins are also produced by P. aeruginosa, which act to 
damage foreign cells and/or disrupt proper cell metabolism. Exotoxins ExoS, ExoT, 
ExoU, and ExoY are all transferred via type III secretion, a process in which metabolites 
are transferred from the bacteria to the eukaryotic cell via a contact dependent mechanism 
 
(Blocker, Jouihri et al. 2001). All of the type III secreted exotoxins of P. aeruginosa aid 
in pathogenecitiy by inhibiting proper function of the host cell’s innate immune response 
(Barbieri and Sun 2004). ExoU is a phospholipase toxin primarily involved in the 
cytotoxicity of macrophages and epithelial cells, and fibroblasts (Finck-Barbancon, 
Goranson et al. 1997, Sato, Frank et al. 2003). ExoY is an adenlyate cyclase which 
increases the expression of cAMP in eurkaryotic cells causing actin cytoskeleton disorder 
(Yahr, Barbieri et al. 1996). ExoS and ExoT are structurally similar toxins both 
containing N-terminal region which functions to disrupt actin cytoskeleton organization 
through activation of Rho GTPases and a C-terminal ADP-ribosyltransferase domain 
which functions primarily to disrupt host protein synthesis (Barbieri and Sun 2004). 
ExoT’s primary pathogenic mechanism is through phagocytosis inhibition, while ExoS 
greatly increases host cell apoptosis (Kaufman, Jia et al. 2000, Barbieri and Sun 2004). 
 
P. aeruginosa also secretes the exotoxin ExoA, a toxin similar in structure and 
mechanism to the diphtheria toxin of Corynebacterium diptheriae and the cholera toxin 
of Vibrio cholera (Popoff 2005). Unlike the previously discussed toxins, ExoA is 
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secreted through a type II secretion system (Cianciotto 2005). This mono-ADP 
ribosyltransferase toxin increases bacterial virulence by causing cell death to eukaryotic 
cells through protein synthesis inhibition by blocking elongation factor 2 (eEF2) (Van 
Ness, Howard et al. 1980, Corda and Di Girolamo 2003). 
 
1.4.5 Attachment Mechanisms: Flagella and IV Pili 
 
 
 
Attachment of bacteria to host cells is critical for the initiation of infection 
(Ramos, Rumbo et al. 2004). The majority of these interactions are mediated by bacterial 
surface structures involved in attachment and motility. The singular unipolar flagella of 
P. aeruginosa generate the main motility force of the organism, but also aid in the initial 
stages of lung infections by propelling the bacteria through mucosa of the host organism, 
increasing the bacteria’s ability to reach and adhere to lung epithelial cells (Ottemann and 
Miller 1997). Although flagella aid in bacterial infectivity, monomers of the flagellar 
structure can also be detected by the host’s immune cells (Hayashi, Smith et al. 2001). 
 
In conjunction with flagella, P. aeruginosa also produces surface adhesion 
structures termed type IV pili (Strom and Lory 1993). Type IV pili aid in recognition of 
other bacterial cells, attachment to eukaryotic cells, and some forms of bacterial motility 
such as twitching (Amako and Umeda 1982, Mattick 2002). In various tissue types it has 
been shown that pilated bacteria have higher pathogenicity over their non-pilated 
counterparts (Strom and Lory 1993). Expression of type IV pili and flagella greatly 
enhances P.aeruginosa biofilm formation (O'Toole and Kolter 1998, Stoodley, Sauer et 
al. 2002). 
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1.5 Biofilm Development 
 
 
 
One of the main mechanisms which have made P. aeruginosa a successful 
opportunistic pathogen is the bacteria’s ability to thrive in a biofilm mode of growth. 
Biofilms are aggregations of microbial cells forming unified communities, which are 
attached to various abiotic and biotic surfaces (O'Toole, Gibbs et al. 2000). Chronic lung 
infections of patients with CF are dominated by P. aeruginosa biofilms. 
 
The initiation of biofilm development is thought to be triggered by environmental 
stimuli, however each bacterial species reacts differently to environmental changes and 
some, not unlike P. aeruginosa, can develop biofilms under a wide range of growth 
conditions (O'Toole and Kolter 1998, O'Toole and Kolter 1998). Interactions between 
bacterial surface structures such as pili, flagella, lipopolysaccharides (LPS), and alginate, 
with host cells or secretions such as mucin, initiate the attachment process and primary 
biofilm production (Saiman, Ishimoto et al. 1990, Simpson, Ramphal et al. 1992). 
Surface adhesion of P. aeruginosa reduces flagellar expression, but increases type IV pili 
expression causing increased twitching motility during initial biofilm development 
(Bradley 1980). Twitching motility allows bacteria to spread along the surface, eventually 
producing large microcolonies. 
 
Initial surface attachment prompts a shift in gene expression within adhered 
bacteria that is carried out largely under QS control (Davies, Parsek et al. 1998). QS 
control is so critical to biofilm formation that lasI mutants of P. aeruginosa can adhere to 
surfaces, but never develop mature biofilm architecture (Davies, Parsek et al. 1998). 
Proper QS signalling has also been linked to the increased biocide resistance found in 
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bacterial biofilms when compared to their planktonic counterparts (O'Toole, Gibbs et al. 
 
2000). P. aeruginosa with mutated lasI display a reduced biocide resistance, irrespective 
of exopolysaccharide production, which has been shown to increase biofilm resistance to 
antibiotic treatment due to the impediment of the antibiotics through the biofilm (Nickel, 
Ruseska et al. 1985, Walters, Roe et al. 2003). 
 
1.6 Antibiotic Resistance Mechanisms 
 
 
 
Antibiotic administration is the main therapy available to treat bacterial infections. 
Although generally antibiotics do an efficient job of halting and eradicating bacterial 
infections, years of exposure to such therapies has resulted in an increased resistance in 
many bacterial species. P. aeruginosa is a particularly problematic bacterium to control 
through antibiotic therapy due to a great intrinsic resistance to many forms of antibiotics 
and effortlessly acquired resistance to many others. 
 
1.6.1 Permeability and Catabolic Enzyme Expression 
 
 
 
The ability of an antibiotic drug to permeate into the target bacteria is often 
crucial to its efficacy as a therapeutic agent. P. aeruginosa’s seemingly impermeable 
outer membranes act as barriers to the impediment of some forms of antibiotics such as 
the hydrophobic macrolids (Normark and Normark 2002). P. aeruginosa’s outer 
membrane is scattered with porins, which can allow passage of some antibiotics into the 
cells (Benz and Hancock 1981), however increases in permeability to antibiotics are not 
typical with increased porin expression.  It is hypothesized that P. aeruginosa regulates 
the functionality and size of the porins in correspondence to antibiotic treatment 
(Livermore 2002).  Previous studies have shown disrupting the membrane of bacteria 
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increases the permeability of antibiotics, therefore impermeability is an important first 
line of defence against antibiotics (Li, Zhang et al. 2000). 
 
The expression of catabolic enzymes by bacterial cells can lead to the breakdown 
or reduction in efficacy of antibiotics. It is well documented that P. aeruginosa is capable 
of producing β-lactamase enzymes when treated with drugs such as cephalothin and 
ampicillin (Livermore 1995). Other enzymes secreted by P. aeruginosa have been 
characterized, which modify aminoglycoside enzymes reducing their efficacy leading to 
resistance (Livermore 1995). 
 
1.6.2 Expression of Multiple Efflux Pump Systems 
 
 
 
The presence and increased expression of efflux pump systems plays a 
substaintial role in P. aeruginosa’s resistance. P. aeruginosa expresses four separate 
multidrug efllux systems; MexAB-OprM, MexXY-OprM, MexCD-OprJ, and MexEF- 
OprN. Upregulation of the MexAB-OprM system leads to the resistance towards 
flouroquinolones, penicillins, cephalosporins and certain forms of meropenem drugs 
excluding imipenem (Li, Nikaido et al. 1995, Masuda, Gotoh et al. 1999, Masuda, 
Sakagawa et al. 2000). Increased expression of the MexXY-OprM efflux system 
decreases aminoglycoside efficacy (Livermore 2002). Finally, the increased expression of 
either MexCD-oprJ or MexEF-OprN decreases the susceptibility of P. aeruignosa to 
flouroquinolones and various forms of β-lactam antibiotics (Livermore 2002). 
 
1.6.3 Biofilm Mode of Growth 
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Increased resistance to antibiotic therapy is seen when P. aeruginosa adopts a 
biofilm mode of growth. In these instances, bacteria form a matrix fluid composed of 
extracellular polysaccharides, proteins, extra-cellular DNA, and water which holds cells 
together and protects the bacteria from environmenal stresses (Ma, Conover et al. 2009, 
Mann and Wozniak 2012). During severe chronic infections of CF patients, P. 
aeruginosa adopts a mucoid phenotype caused predominantly from a mutation to the 
mucA gene which controls the regulation of synthesis genes for(Damron and Goldberg 
2012)(Damron and Goldberg, 2012) alginate (Damron and Goldberg 2012), a linear 
polysaccharide composed of D-mannuronate and L-guluronic acid (May, Shinabarger et 
al. 1991). When overexpressed by P. aeruginosa, alginate has been shown to reduce the 
ability of host phagocytic cells to engulf bacteria and to decrease the penetration of 
antibiotics (Govan and Fyfe 1978, Slack and Nichols 1981). Impediment to antibiotic 
penetration varies between antibiotics and is alginate concentration dependent, therefore 
not all strains expressing alginate show greater resistance to antibiotic therapy 
(Thomassen, Demko et al. 1979, Demko and Thomassen 1980, Gordon, Hodges et al. 
1988). 
 
 
Resistance found in P. aeruginosa biofilms may in part be attributed to 
differential metabolic phases of bacteria within the biofilm. It is well established that 
within biofilms lie small populations of persister cells which are generally multi-drug 
resistant and not metabolically active (Lewis 2005). Under the conditions of biofilm 
growth, genomic expression changes occur, and some forms of physiological resistance 
may arise that are not found in planktonic growing cells (Whiteley, Bangera et al. 2001). 
1
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1.6.4 Highly Mutable Genome and Acquired Resistance 
 
 
 
Along with intrinsic resistance, P. aeruginosa can also acquire resistances through 
genomic mutations and horizontal gene transfer from one bacterium to another. 
Spontaneous point mutations can cause the deregulation of various efflux pump, enzyme, 
and porin expression genes (Lister, Wolter et al. 2009). The acquisition of many such 
mutations over time can lead to strains which are multidrug resistant (Lee, Mao et al. 
2000, Livermore 2002). Mutations in DNA repair protein genes and can lead to a large 
increase in the rate of acquired mutations and the adoption of a mutator phenotype. In P. 
aeruginosa, the mutator phenotype often occurs due to mutations to the mis-match repair 
(MMR) genes mutS, mutL, and uvrD (Mena, Smith et al. 2008). Environmental and 
nutritional restrictions, such as those found in chronic state infections of P. aeruginosa in 
CF patients, where an abundance of ROS are produced, may favour mutator phenotypes 
increasing the bacteria’s antibiotic resistance with time (Ciofu, Riis et al. 2005, Mena, 
Smith et al. 2008). 
 
1.7 Treatment of P.aeruginosa Lung Infections 
 
 
 
The treatment of P. aeruginosa lung infections depends heavily on the state of the 
infection, severity of the infection, and characteristics of the patient’s medical condition. 
Antibiotics can be administered in several different forms such as oral, aerosolized, and 
intravenous injections (IV) (Rogers, Hoffman et al. 2011). Patients suffering from P. 
aeruginosa lung infections are often given long term daily and continual administration 
of multiple antibiotics (Mesaros, Nordmann et al. 2007). Bacterial eradication in chronic 
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infections is highly unlikely, and therefore treatment success is often measured by lung 
function, not bacterial clearance (Flume, Mogayzel et al. 2009). 
 
1.7.1 Early/Acute Infection 
 
 
 
In situations of acute P. aeruginosa infection in patients with CF, early 
administration of antibiotics is able to eradicate the infection if treated within the first 12 
weeks (Hansen, Pressler et al. 2008). During early infection the form and type of 
administered antibiotics is not specific and a wide range of treatment options have been 
shown to be successful (Rogers, Hoffman et al. 2011). Administered therapies of 
aerosolized tobramycin with or without oral ciprofloxacin, as well as colistin with oral 
ciprofloxacin are both effective for the treatment of early P. aeruginosa infections 
(Valerius, Koch et al. 1991, Ratjen, Doring et al. 2001, Mayer-Hamblett, Burns et al. 
2010). 
 
 
1.7.2 Chronic Infections 
 
 
 
Unlike acute and early infections, the treatment of chronic P. aeruginosa 
infections is based on lung maintenance and quick recovery from acute exacerbations in 
the hopes of limiting further therapy (Rogers, Hoffman et al. 2011). Treatment of chronic 
infections is often a daily regime of multiple antibiotics for extended periods of 
time.Typical maintenance therapy consists daily inhaled antibiotics and oral azithromycin 
treatment which is paired with shorter sequences of IV administered antibiotics during 
periods of acute exascerbations (Frederiksen, Koch et al. 1997). Most often more than 
one IV antibiotic is given to those patients colonized with P.aeruginosa in order to slow 
the  build-up of resistance, and possibly enhance treatment through drug synergy 
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(Chernish and Aaron 2003, Gibson, Emerson et al. 2003). Typical course length for IV 
administered antibiotics is 10-14 days; however there is no firm evidence to support the 
efficiency of this time frame (Rogers, Hoffman et al. 2011). 
 
1.8 Novel Treatment Options: Naturally Derived Antibiotic Compounds 
 
 
 
With the rising of antibiotic resistance towards many therapies used for the 
treatment of P. aeruginosa infection, an increasing need for novel therapies and the 
development of new antibiotics is gaining prominence. Due to the necessity to fend off 
antibiotic infections, plants produce many adaptogenic compounds which act as natural 
antibiotics. Often these compounds are readily accessible from the plant and display low 
toxicity to eukaryotic cells. 
 
Oregano (Origanum vulgare) and thyme (Thymus vulgaris) are two examples of 
common herbaceous plants which contain the natural antibiotic compounds, thymol and 
carvacrol, which can be extracted from the leaves of both plants and have been shown to 
display antibiotic properties to a variety of gram negative and gram positive bacteria 
(Burt 2004). Similarly, species of the herbaceous plant ginseng (Panax ginseng, Panax 
quinquefolius) have also shown antibacterial properties (Song, Kong et al. 2010, Alipour, 
Omri et al. 2011). In conjunction with the ability to inhibit or reduce bacterial growth, 
treatment of P. aeruginosa with various ginseng components decreases the production of 
many virulence factors, and has displayed the ability to reduce mature biofilms (Song, 
Kong et al. 2010, Alipour, Omri et al. 2011, Wu, Lee et al. 2011). Further research into 
the use of these plant components as natural antibiotics or therapy adjuvants would assist 
in the elucidation of their efficacy as future treatment options. In this thesis, the effects of 
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thymol, carvacrol, and multiple extracts of the North American ginseng species, Panax 
quinquefolius, were monitored towards P. aeruginosa pathogenecity through the 
measurement of secreted virulence factors, bacterial adherence and biofilm formation, 
and whole-genome expression analysis after exposure to the plant treatments. 
2
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Thesis Objectives 
 
 
 
Recognizing the fact that plants produce many adaptogenic compounds which act 
as natural antibiotics, the antibacterial effects of the aqueous and alcoholic extracts from 
Panax quinquefolius as well as those of thymol or carvacrol from thyme or oregano, 
respectively, were examined against Pseudomonas aeruginosa in vitro. 
 
Objective 1. To further elucidate the effect of Panax quinquefolius alcoholic 
and aqueous extract exposure to Pseudomonas aeruginosa pathogenicity. Through 
the assessment of growth inhibition and growth rate in the presence of either extract the 
bacteriostatic effects will be quantified. Secretion of virulence factors such as LasB 
elastase, lipase, and pyoverdine after exposure to either extract will be measured to 
provide further evidence of the effect on P. aeruginosa pathogenicity. Additionally the 
analysis of bacterial adherence and biofilm disruption will be monitored in the presence 
of either extract. The effect of treatment on the regulation of bacterial genes will be 
assessed by microarray analysis of the laboratory strain PAO1 after exposure to the 
aqueous ginseng extract for 6 and 24 h. 
 
 
 
Objective 2. To explore the effects of Thymol or Carvacrol exposure on 
Pseudomonas aeruginosa pathogenicity. Through the assessment of growth inhibition 
and growth rate in the presence of either compound, the bacteriostatic capabilities of both 
thymol and carvacrol will be measured. Secretion of virulence factors, such as LasB 
elastase, lipase, and pyoverdine after exposure to either compound, will be analyzed to 
provide further evidence of the effect on P. aeruginosa pathogenicity. Additionally the 
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analysis of bacterial adherence and biofilm disruption will be monitored in the presence 
of either compound. The effect of treatment on the regulation of bacterial genes will be 
assessed by microarray analysis of the laboratory strain PAO1 after exposure to thymol 
for 6 and 24 h and carvacrol for 24 h. 
2
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Chapter II. The Effects of North American Ginseng (Panax 
quinquefolius) Aqueous and Alcoholic Extracts towards 
P.aeruginosa Pathogenicity 
 
 
 
2.1 Introduction 
 
 
 
2.1.1 Ginseng: An Herbaceous Plant 
 
 
 
The perennial herbaceous plant ginseng belongs to the family Araliaceae and 
genus Panax. Physical characteristics shared by the handful of species identified include 
dark green leaves, small ruby berries, and ample fleshy roots (Lemmon, Sham et al. 
2012). Geographically ginseng grows throughout North America, Northeast and central 
China and much of Korea (Attele, Wu et al. 1999, Cruse-Sanders and Hamrick 2004). In 
many parts of the world ginseng was traditionally used and still is utilized as an essential 
component of herbal medicine. 
 
2.1.2 Ginseng as a Natural Medicine 
 
 
 
For thousands of years the root of ginseng has been used in traditional Asian 
medicine (Attele, Wu et al. 1999, Wang and Yuan 2008). The effects of traditional 
ginseng treatment are alluded to include restorative, anti-aging, stress reduction, and 
immune stimulation, and are often claimed to be very powerful and all-healing (Wang 
and Yuan 2008, Lu, Yao et al. 2009)]. Several species of ginseng have been researched, 
however two prominent species used in herbal supplements today are the Asian Panax 
ginseng and the North American Panx quinquefolius (Jia and Zhao 2009). 
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2.1.3 Active Components of Ginseng 
 
 
 
Ginseing contains many active components, but much of the research conducted 
to date focuses on the polysaccharides and ginsenosides of ginseng to which most of the 
medicinal properties of the herb have been attributed (Lu, Yao et al. 2009). Structural 
analysis of ginsenosides and ginseng polysaccharides has brought about a greater 
understanding of the specific medicinal properties of these compounds; however futher 
analysis is still needed. 
 
Ginsenosides 
 
 
 
Ginsenosides are a classification of compounds produced by ginseng which all 
share a common dammarane-type backbone with a triterpenoid saponin structure (Qi, 
Wang et al. 2011). Ginsenosides are produced in many parts of the plant, but are most 
often extracted from the roots where they are found in the highest concentration (Wang, 
Wang et al. 2005). Large varieties of ginsenosides exist due to the attachment of various 
sugar moieties and the configuration, and abundance of such functional groups (Fuzzati 
2004).  Classification based on the placement of sugar residues is used to group these 
compounds into two major types; protopanaxadiols (PPD) and protopanaxatriols (PPT) 
(Yoshikawa, Murakami et al. 1998, Qi, Wang et al. 2011). 
 
The quantity and type of ginsenosides present in ginseng differs between species, 
but is influenced heavily by growth conditions and plant age (Yoshikawa, Murakami et 
al. 1998, Wang, Wang et al. 2005, Qi, Wang et al. 2011). Typically it has been found that 
P.quinquefolius has a higher concentration of ginsenosides than P.ginseng (Qi, Wang et 
al. 2011).  The most common ginsenosides found in P.quinquefolius are Re, Rb1, and Rd 
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(Wang, Wang et al. 2005, Qi, Wang et al. 2011). The variety of ginsenosides found in 
P.quinquefolius is further expanded by alterations to structure through enzymatic action, 
intestinal bacteria, and the metabolic processes of animals (Tawab, Bahr et al. 2003, 
Hasegawa 2004). With so many different structural orchestrations, it is not surprising that 
ginenosides have been shown to display a wide range of effects such as; anti- 
inflammatory, anti-bacterial, and immune modulation (Song, Johansen et al. 1997, Qi, 
Wang et al. 2011). 
 
Polysaccharides 
 
 
 
Ginsenosides are not the only reactive compounds of ginseng, purified acidic 
polysaccharides have displayed a wide range of medicinal properties. Early studies using 
ginseng polysaccharides have shown antiadhesive effects with bacterial pathogens, as 
well as being potent immune modulating compounds (Lee, Park et al. 2004, Ivanova, Han 
et al. 2006). Structural homology between ginseng polysaccharides and ligands or surface 
markers is believed to play a large role in how these compounds may interfere with 
bacterial adherence or disrupt immune responses (Lee, Shim et al. 2006). Of particular 
interest is ginsan, a pectin-like acidic polysaccharide purified from P.ginseng, which 
displays an array of immune modulatory properties and bacterial growth inhibitory 
effects (Lee, Park et al. 2004, Ahn, Choi et al. 2006, Ivanova, Han et al. 2006, Lee, Shim 
et al. 2006). 
 
2.1.4 Panax quinquefolius and Bacterial Infections 
 
 
 
Pathogenic bacteria still prominent causes of infection and disease today, with 
resistance to current antibiotic therapies becoming a growing concern. The introduction 
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of new pharmaceuticals to replace current antibiotics or to work in synergy with current 
treatments, are required to better handle bacterial infections. With a long history of 
medicinal strength, research into the use of ginseng has revealed several antibacterial 
properties that have great potential for further development. 
 
Growth Inhibition 
 
 
 
Treatments which reduce or inhibit the growth of pathogenic bacteria help greatly 
to relieve bacterial infections. The aqueous extract of P. quinquefolius has been found to 
inhibit growth of Pseudomonas aeruginosa (Alipour, Omri et al. 2011). Both the 
laboratory strain PAO1 and clinical isolates from sputum samples of CF patients were 
completly inhibited by treatment of 2.5% P. quinquefolius aqueous extract. Interestingly, 
findings also demonstrated that levels below the minimum inhibitory concentration 
increased the growth rate of P. aeruginosa, suggesting a concentration dependent effect 
of growth inhibition. Similarily the aqueous extract of P. ginseng was also shown to 
decrease the growth rate of P. aeruginosa at concentrations of 5.0% w/v, but also 
marginally increased growth at lower concentrations (Song, Kong et al. 2010). 
 
Anti-adhesive Properties and Biofilm Production 
 
 
 
Although much of the anti-adhesive studies focused on ginseng utilize compounds 
of P. ginseng, the anti-adhesive and biofilm disrupting qualities of P. quinquefolius 
extracts have been briefly explored. Previous research has shown treatment of P. 
aeruignosa with the aqueous extract of P. quinquefolius disrupts mature biofilm 
formation (Alipour, Omri et al. 2011). In general, exposure to the aqueous extract from 
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either ginseng species reduces the viability of the cells within P. aeruginosa biofilms 
leading to biofilm dispersal (Alipour, Omri et al. 2011, Wu, Lee et al. 2011) 
 
Disruption of Quorum Sensing Control 
 
 
 
The treatment of P. aeruginosa with P. ginseng aqueous extract has resulted in 
decreased levels of two acyl-homoserine lactones in culture supernatant suggesting a 
decrease in QS communication (Song, Kong et al. 2010). Additionally, QS controlled 
metabolites such as LasA and LasB proteases were reduced by P. ginseng aqueous 
extract treatment (Song, Kong et al. 2010). Similar reductions in QS controlled lipase 
enzymes and pigments pyoverdine and pyocyanin, were reduced by treatment with the 
aqueous extract P. quinquefolius suggesting this extract may also directly affect QS 
signalling (Alipour, Omri et al. 2011). A reduction in quorum sensing control and overall 
virulence factor production would greatly decrease the bacteria’s rate of infectivity. 
However, the production of alginate, which is QS controlled, was also shown to increase 
with P. ginseng aqueous extract treatment (Song, Kong et al. 2010).These findings 
suggest the timing of ginseng therapy will be crucial to its effectiveness as an 
antibacterial therapy (Song, Kong et al. 2010). 
 
Immune Modulation 
 
 
 
Treatment which increases bacterial clearance through the modulation of host 
immune responses has the potential to relieve patients of severe bacterial infections. 
Previous studies have shown animals pre-treated with P. ginseng aqueous extract had 
delayed onset of Listeria monocytogenes infection (Kim, Germolec et al. 1990).  Similar 
results were displayed with P. aeruginosa infections in healthy and athymic mice, which 
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had reduced lung pathology, bacterial titers, and mast cell counts after P. ginseng 
treatment (Song, Johansen et al. 1997, Song, Johansen et al. 1997, Song, Wu et al. 2002). 
Pre-treatment with ginsan has also showed reduced bacterial titers and increase survival 
in mice challenged with experimental sepsis of various bacterial species (Ahn, Choi et al. 
 
2006). 
 
 
Increases in bacterial clearance through ginseng treatment are attributed to 
multiple findings indicating increased phagocytic activity of peritoneal macrophages 
(PM) and polymorphonuclear leukocytes (PMNL) (Shin, Song et al. 2002, Ahn, Choi et 
al. 2006). Measurement of cytokine release after ginsan pre-treatment revealed decreased 
production of inflammatory cytokines TNF-α, IFN-γ, IL-2, IL-8, IL-6 and IL-1β, as well 
as modulation of mitogen-activated protein kinases (MAPK) and JNK1/2 signalling 
pathways, and reduced NF-κβ activation (Ahn, Choi et al. 2006).  Decreased 
phosphorylation of  ERk1/2 and reduced NF-κβ activation were also found in an 
experimental model of Helicobacter pylori gastric cell infection pre-treated with the 
aqueous extract of P. ginseng (Park, Yeo et al. 2005). 
 
Contrasting the findings of Ahn JY et al 2006, increased production of 
inflammatory cytokines and overall immune response shifts have been detailed in 
multiple other studies. Up-regulation of TNF-α, IFN-γ, IL-6, and IL-1β have been found 
with both ginsan and polysaccharide extracts of P. quinquefolius in in vitro experiments 
(Assinewe, Amason et al. 2002, Shin, Song et al. 2002, Lemmon, Sham et al. 2012). 
Lemmon HR et al (2012) also found modulation to MAPK, ERK1/2, PI3K, p38, and NF- 
κβ pathways through ginseng treatment in in vitro studies leading to a shift from a Th2- 
Th1 immune response. 
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Animal model studies have also showed evidence for a shift from a primarily Th2 
type response to a type Th1 response with ginseng treatment (Song, Johansen et al. 1997, 
Song, Johansen et al. 1997, Smolina, Solov'eva et al. 2001, Song, Wu et al. 2002). 
Athymic rats with P. aeruginosa infections treated with P. ginseng aqueous extract 
exhibited reduced rates of IgM and IgA antibodies, which is consistent with a decrease in 
the humoral immune response (Song, Johansen et al. 1997). Mice with fully functioning 
immune systems subjected to P. aeruginosa infection  also displayed decreased 
production of IgG countered by increased release of IgG2a and a shift to a more chronic 
inflammatory state (Song, Johansen et al. 1997). Reduced bacterial infectivity and 
increased bacterial clearance are prominent during Th1 immune responses, therefore 
treatment which encourages this shift could increase bacterial clearance (Johansen, 
Hougen et al. 1995, Moser, Johansen et al. 1997) 
 
2.1.5 Rationale for Future Research 
 
 
 
This study sought to improve our understanding of how P. aeruginosa is affected 
by treatment with ginseng, utilizing both an aqueous and alcoholic extract of Panax 
quinquefolius. The production of various virulence factors, bacterial adherence, and 
biofilm formation were all monitored in the presence of either extract to delineate the 
effect of P. quinquefolius on P .aeruginosa pathogenicity. To further our understanding, a 
genomic array of P.aeruginosa after exposure to P. quinquefolius was also performed to 
elucidate the gene expressional changes caused by the treatment. 
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2.2 Methodology 
 
 
 
2.2.1 Bacterial Strains and Media 
 
 
 
Bacterial Strains 
 
 
 
Pseudomonas aeruginosa PAO1 nonmucoid laboratory strain was generously 
donated by Dr. M. Ulanova (Northern Ontario School of Medicine). Clinical isolates PA3 
(mucoid) and PA4 (non-mucoid) were collected from sputum samples of regular patients 
at the Cystic Fibrosis Clinic in Sudbury, Ontario. Canada. Isolates were further purified 
and strain identity was confirmed by the Clinical Microbiology Laboratory of Memorial 
Hospital in Sudbury, Ontario, Canada. 
 
Media Composition 
 
 
 
All experiments were conducted in supplemented M9 salts media (Sigma-Aldrich, 
Oakville, Ont., Canada) with the exception of the minimum inhibitory concentration 
analysis which was performed` in both supplement M9 salts media (M9) and Mueller- 
Hinton Cation Adjusted media (MHCA) (Sigma-Aldrich). M9 salts media was 
supplemented with 0.4% w/v glucose (Fisher-Scientific Inc., Ottawa, Ont., Canada), 
0.0005% w/v Thiamine (Sigma-Aldrich), 2 mM MgSO4 (Sigma-Aldrich), and 1 mM 
CaCl2 (Fisher-Scientific Inc.). M9 supplemented media was stored at 4 ˚C while MHCA 
was stored at room temperature. Agar plates were made with either broth by the addition 
of 1.5% w/v agar (Fisher-Scientific Inc.). 
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Bacterial Storage 
 
 
 
From original freezer stocks of P. aeruginosa strains, 50 µl was used to inoculate 
 
5 ml of either M9 or MHCA broth. Cultures were incubated for 24 h at 37 ˚C and 200 
rpm shaking. Secondary freezer stocks were prepared by combining 500 µl of overnight 
culture with 500 µl of 50% glycerol solution (Sigma-Aldrich). Freezer stocks were stored 
in 2 ml cyro tubes at -80 ˚C. Fridge storage plates (4 ˚C) were streaked from secondary 
freezer stocks onto M9 or MHCA plates and incubated inverted at 37 ˚C for 24 h. For 
storage, plates were wrapped in parafilm and stored inverted in the fridge for no longer 
than 14 days. 
 
Bacterial Enumeration 
 
 
 
Bacterial strains were enumerated via the drop plate method in both types of 
media. An isolated colony from a M9 agar plate was used to inoculate 5 ml of MHCA 
broth media and was incubated for 24 h at 37 ˚C and 200 rpm. Bacterial cultures were 
further diluted 1:5 into MHCA media and re-incubated at 37 ˚C for 6 h. Using a 96 well 
plate a 10x dilution series was performed beginning with an optical density (OD) reading 
at 625 nm = 0.100±0.005 adjusted culture. From each well of the dilution series, six 10 µl 
aliquots were plated onto MHCA agar plates and incubated for 20-24 h at 37 ˚C. 
Bacterial colonies were counted, averaged, and back calculated to the adjusted 
 
0.100±0.005 OD625nm culture. All experiments were repeated in duplicate three times. A 
desired bacterial concentration of 1x10
8 
CFU/ml was achieved through adjustment of the 
culture based on the 0.100±0.005 OD625nm colony counts and subsequently re-plating and 
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counting in duplicate three times. All experiments were repeated with at an optical 
density measurement at 600 nm as well. Integrity of results was verified through 
repetition using a 10 ml volume for the 10x dilution series. 
 
2.2.2 Ginseng Extract Preparation 
 
 
 
Plant Cultivation and Extract Purification 
 
 
 
The aqueous and alcoholic ginseng extracts were prepared as previously described 
by Lemmon et al 2012. Characterization of each extract through high performance liquid 
chromatography was preformed by Azike et al 2011. 
 
Extract Solution Preparation 
 
 
 
Both aqueous and alcoholic extract powder was reconstituted directly into either 
type of media to the twice the desired testing concentration. Solutions were vortexed on 
high for ten seconds until extract was completely dissolved. Extract solutions were 
centrifuged at 12000 rpm for 10 minutes to pellet out residual insoluble components. 
Supernatants were collected and centrifuged a second time for 10 minutes at 12000 rpm. 
Solutions were sterilized by filteration through 0.2 µ pipette-or bottle top-filter. Extract 
preparations were used immediately or stored at 4 ˚C for no more than 6 h. For 
preparations of motility experiments alcoholic and aqueous extract solutions in M9 media 
were centrifuged for 30 minutes at 4500 xg twice before solutions were filter sterilized 
and stored. 
 
2.2.3 Minimum Inhibitory Concentration Determination 
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Bacterial cultures were grown by first streaking each bacterial strain onto MHCA 
agar plates and incubating for 24 h at 37 ˚C. From each plate a single colony was used to 
inoculate 5ml of MHCA broth which was incubated for 24 h at 37 ˚C with 200 rpm 
shaking. Overnight cultures were then diluted into 5ml of fresh MHCA broth and re- 
inoculated for 6 h at 37 ˚C and 200 rpm. 
 
Antimicrobial effects of the aqueous and alcoholic ginseng extracts were assessed 
through the determination of the minimum inhibitory concentration (MIC) using a 
microdilution method (Wiegand, Hilpert et al. 2008). Solutions of 10% w/v alcoholic and 
aqueous extract were prepared in MHCA broth as previously described. Dilutions from 
10%-1%w/v were prepared from the original stock solution and plated in 50 µl volumes 
into wells 1-10 of a flat bottom 96 well plate. Positive and negative growth control wells 
with untreated media were plated in 50 µl and 100 µl volumes into wells 11 and 12, 
respectively. 
 
After the 6hr incubation, bacterial cultures were removed and bacteria were 
diluted to 1x10
8 
CFU/ml according to OD625nm. This culture solution was then further 
diluted 1:100 in untreated MHCA broth before 50 µls were added into treatment and 
positive control wells for a final bacterial concentration of 5x10
5 
CFU/ml. Final 
concentrations of both extracts were from 5%-0.5% w/v. Plates were wrapped in parafilm 
and incubated for 24 h at 37 ˚C. After incubation the MIC concentration was determined 
as the lowest concentration at which no visual bacterial growth was detected. All 
experiments were repeated three times with two replicates. 
34 
 
Identical experiments were repeated in M9 media with the following changes. 
Bacterial enumeration was based on optical density readings at 600 nm rather than 625 
nm. Concentration of both aqueous and alcoholic extract was increased to final treatment 
concentrations of 10%-1% w/v. Due to a darkening of the alcoholic extract during 
incubation at higher concentrations, three 10 µl aliquots were removed from each well 
and plated onto M9 agar plates. Plates were incubated for 24 h at 37 ˚C and visual 
assessment of bacterial growth by the formation of colonies was used to verify the visual 
MIC assessment. 
 
2.2.4 Growth Curve Analysis 
 
 
 
Bacterial growth in the presence of the alcoholic and aqueous ginseng extract was 
assessed over 48 h. Bacterial cultures were produced by the inoculation of 5ml of M9 
broth with a single colony of a M9 agar streak plate. Broth cultures were incubated for 
24hrs at 37 ˚C and 150 rpm. After incubation 1ml was withdrawn and diluted into 4ml of 
M9 media and re-incubated for an additional 4hrs at 37 ˚C and 150 rpm. Both extracts 
were diluted into M9 media at 2x the 0.5 MIC concentration and further diluted to 
produce a 2x 0.25 MIC concentration. For each treatment, 5ml of treatment media was 
added into a 125 ml erlenmeyer flask containing 4ml of untreated M9 media. Bacterial 
cultures were diluted to a concentration of 1x10
8 
CFU/ml in M9 media and 1ml of diluted 
 
culture was added to the 125 ml erlenmeyer flasks. Control flasks containing 9ml and 
 
10ml of untreated M9 media were used as positive and negative controls respectively. 
 
 
Flasks were covered with tinfoil and incubated at 37 ˚C with 150 rpm shaking. At 
the following time points of 0, 6, 12, 24, and 48 h 1ml of culture were withdrawn from 
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the flasks and the absorbance was measured on a spectrophotometer at 600 nm. Due to 
the base absorbance of the alcoholic and aqueous extract treatments at 600 nm, 1 ml of 
each concentration of un-inoculated extract was pre-measured at 600 nm for each time 
point, and the value was subtracted from the absorbance values measured during the 
experiment for the corresponding treatments and time points. Growth curves were 
repeated in triplicate. 
 
2.2.5 Bacterial Adherence Assay 
 
 
 
Bacterial attachment was measured through the growth of the bacteria in the 
presence of the alcoholic and aqueous extracts, and secondly through the treatment of 48 
h attached bacteria with the alcoholic and aqueous extracts. In both experiments the 
alcoholic and aqueous extracts were prepared at 2x the 0.5 MIC concentration and further 
diluted in M9 media to produce a 2x 0.25 MIC concentration. Bacterial cultures were 
started from a single colony inoculation into 5ml of M9 broth with incubation for 24 h at 
37 ˚C and 175-200 rpm for both experiments. 
 
 
Adherence Prevention Assay 
 
 
 
After the initial culture incubation, cultures were diluted 1:5 in untreated M9 
media and re-incubated for an additional 4 h at 37 ˚C and 200-225 rpm. In triplicate wells 
of a flat bottom 96 well plate, 100 µl of each concentration of test extract was added for 
each strain. Positive and negative control wells containing 100 µl and 200 µl of untreated 
M9 media respectively were also plated in triplicate for each strain of bacteria. Wells 
containing 100 µl of either concentration of extract and 100 µl of untreated M9 media 
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were also plated in order to determine the base adherence of the extracts without bacterial 
inoculation. 
 
After the second culture incubation, all strains were diluted to an OD600nm equal to 
 
1x10
8 
CFU/ml and 1ml of this dilution was further diluted 1:5 into M9 media. The 5ml 
diluted cultures were vortexed for 5 seconds at low speed and 100 µl was added to 
treatment and positive control wells. Plates were wrapped in parafilm and incubated for 
24 h at 37 ˚C. 
 
 
After incubation, plates were washed three times with 200 µl of distilled water 
and allowed to dry in the biosafety cabinet for 30 minutes. Wells were stained with 200 
µl of 0.1% crystal violet for 10 minutes. Stain was aspirated from the plates and plates 
were again washed three times with 200 µl of distilled water and allowed to dry for 30 
minutes. Stain was solubilized with 200 µl of absolute ethanol (Commercial Alcohols, 
Brampton, Ont., Canada). Into a new flat bottom 96 well plate, 150 µl from each well 
was transferred and the absorbance was measured with an automated plate reader at 600 
nm. Triplicate wells were averaged and treatments were expressed as a percentage of the 
control values. Base adherence of the alcoholic and aqueous extract were averaged and 
subtracted from the values of the corresponding treatment wells. 
 
Biofilm Disruption Assay 
 
 
 
Post 24 h incubation, original cultures were further diluted 1:5 in M9 media and 
incubated for an additional 4hrs at 37 ˚C and 200-225 rpm shaking. Six wells of 100 µl of 
M9 media were plated for each strain as pre-treatment wells. Triplicate wells containing 
100 µl and 200 µl of M9 media were also plated as positive and negative controls for 
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each strain. After the second incubation, cultures were diluted to an OD600 equal to 1x10
8
 
 
CFU/ml and further diluted 1:5 in M9 media. Adjusted bacterial cultures were plated into 
pre-treatment and positive control wells in 100 µl volumes. Plates were wrapped in 
parafilm and incubated for 48 h at 37 ˚C. 
 
After incubation, culture was carefully removed from all wells. Wells were 
washed three times with 200 µl of distilled water to remove un-adhered bacteria. 
Triplicate pre-treatment wells were then filled with 200 µl of either2.0 MIC or 1.0 MIC 
extract solutions. Untreated medium in 200 µl volumes was added into both the negative 
and positive control wells. Wells containing 200 µl of each concentration of treatment 
were also plated as base treatment adherence controls. Plates were wrapped in parafilm 
and incubated for 24 h at 37 ˚C. Following the treatment incubation, plates were removed 
and wells were washed, stained, and analyzed as previously described in 2.2.5 Bacterial 
Adherence Assay, Adherence Prevention Assay. 
 
2.2.6 Virulence Factor Production 
 
 
 
Growth Conditions and Aliquot Storage 
 
 
 
Bacterial cultures were started from a colony inoculation into 5 ml of M9 media 
and incubated for 24 h at 37 ˚C and 150 rpm shaking. After initial incubation, cultures 
were diluted 1:5 into M9 media and incubated a second time for 4 h at the same 
parameters. Extracts were prepared at 5x the 0.5 MIC and 0.25 MIC values and diluted 
into 9 ml of M9 media in a 125 ml erlymer flask. After the second incubation, cultures 
were diluted to a concentration of 1x10
8 
CFU/ml at OD600nm and 1 ml was added to each 
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treatment and positive control flask containing 9 ml of untreated M9 media. Flasks were 
covered in aluminum foil and incubated at 37 ˚C and 150 rpm for 24 h. 
 
After treatment incubation, 1ml of culture was removed and immediately the 
absorbance at 600 nm was measured to provide a growth control value. The rest of the 
culture was transferred to a 15 ml tube and centrifuged at 4000 xg for 30 minutes. The 
supernatant was removed from the pellet and filtered through a 0.2 µ synringe or bottle 
top filter. Four 1 ml aliquots were transferred to sterile 2 ml cryogenic vials (Fisher- 
Scientific Inc.), labelled, and immediately stored at -20 ˚C. 
 
Pyoverdine Measurement 
 
 
 
Immediately following the storage of the supernatant samples pyoverdine 
absorbance was measured in a spectrophotometer (Genesys 10uv, Thermo Scientific). 
1ml aliquots from each sample were measured directly at 405 nm. A 1 ml aliquot of 
untreated M9 media was used to blank the spectrophotometer and the absorbance of 1 ml 
of each treatment concentration was also measured and subtracted from the 
corresponding supernatant sample absorbance readings. Experiments were repeated three 
times with duplicate and values were normalized by the growth control absorbance at 
OD600nm and represented as a percentage of the control. 
 
LasA Protease Assay 
 
 
 
Petri dishes containing 1% skim milk powder and 1.5% agar were prepared, and a 
well was cut in the center with a sterilized glass pipette. Freezer supernatant aliquots were 
thawed to room temperature and 50 µl was added to the well of duplicate plates. Plates 
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were incubated for 24 h at 37 ˚C. Protease activity was assessed through the measurement 
 
of the zone of clearance using a ruler (mm). Treatments were expressed as a percentage 
of the control. Experiments were repeated three times with duplicate plates for each trial. 
 
Lipase Production Assay 
 
 
 
In 15 ml glass test tubes the following volume of solutions were combined; 2.3 ml 
of 0.05 M tris buffer (pH 7.6) (Fisher Scientific Inc.), 100 µl of both 0.1 M CaCl2 and 
10% tween 20 in tris buffer (pH 7.6) (Fisher Scientific Inc., Sigma-Aldrich), and 0.5 ml 
 
of supernatant sample. Test tubes were incubated at 37 ˚C with 150 rpm shaking for 4 h. 
Negative controls were created containing 0.5 ml of M9 media in place of 0.5 ml of 
supernatant. After incubation, the absorbance of each treatment and controls were 
measured at 400 nm, blanking with 1 ml of M9 media. The absorbance of the negative 
control was subtracted from all treatments and positive controls, and all values were 
normalized to the original growth control absorbance at 600 nm. Base absorbance 
measurements of un-inoculated extract treatment absorbance at 400 nm were also 
subtracted from the corresponding treatment values. Data were expressed as a percentage 
of the control and all experiments were repeated three times with duplicate 
measurements. 
 
 
2.2.7 Motility Assay 
 
 
 
Bacterial cultures grown from plate inoculation in 5 ml of M9 media were 
incubated for 24 h at 37 ˚C and 150 rpm shaking. Overnight cultures were then diluted 
1:5 in M9 media and incubated again at the same parameters for 4 h. M9 plates were 
prepared containing 0.3% agarose and aqueous or alcoholic extract at 0.25 MIC and 
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0.125 MIC concentrations. When incubation was complete, bacterial cultures were 
diluted to an absorbance at 600 nm equal to 1x10
8 
CFU/ml in M9 media. At the center of 
the plate and piercing into the media, 1 µl of bacterial culture was inoculated. Plates were 
incubated inverted at 32 ˚C for 18 h (PAO1) or 36 h (clinical isolates). Using a ruler, the 
diameter of the distance traveled from the point of inoculation was recorded (mm). All 
data are expressed as a percentage of the control, and all experiments were repeated three 
times with duplicate plates. 
 
2.2.8 Genomic Expression Analysis 
 
 
 
Treatment Parameters 
 
 
 
Inoculation from an agar M9 plate into 5 ml of M9 media was used to create a 24 
h culture of PAO1 grown at 37 ˚C and 150 rpm shaking. Overnight culture was diluted 
1:5 into fresh M9 media and allowed to incubate for an addition 4 h at the same 
parameters. During the second incubation a solution of the aqueous extract was prepared 
in M9 media at 5x the desired concentration of 0.25 MIC. After the second incubation, 
PAO1 culture was diluted to an absorbance at 600 nm equivalent to 1x10
8 
CFU/ml. To a 
125 ml erlymer flask, 1 ml of diluted bacterial culture was added to 9 ml of 0.25 MIC 
 
aqueous extract treatment in M9 media. Flasks were covered with aluminum foil and 
incubated for 6 h or 24 h at 37 ˚C and 150 rpm shaking. Positive control flasks containing 
untreated media were also analyzed. Experiments were repeated three times. 
 
RNA Isolation 
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From the 24 h treatment and control flasks, 2 ml of culture was centrifuged at 
 
10000 xg for 2 minutes in 2 ml Eppendorf tubes. Pellets were re-suspended in 500 µl of 
M9 media and combined to form one culture aliquot. Combined culture aliquots were 
centrifuged and washed two additional times with 1ml volumes of M9 media. Final 
culture pellets were re-suspended to a total volume of 2 ml with M9 media and optical 
density of the culture was measured at 600 nm From the absorbance measurement the 
culture samples were diluted to the appropriate amount (~2 ml @ OD600nm = 1.2) for 
RNA extraction. Samples were transferred to RNase free 2 ml centrifuge tubes and RNA 
was extracted using the Bio-Rad RNeasy Mini Kit as per manufacturer’s instructions with 
the following exceptions. Lysozyme was added into the reaction tube at volumes of 150 
µl not 100 µl. RNA was eluted with nuclease free water (Sigma-Aldrich) instead of 
elution solution. Final extraction samples were aliquoted and stored at -20 ˚C before 
shipment. 
 
RNA Quality and Quantity Validation 
 
 
 
RNA integrity, concentration, and quantity were assessed through the Experion 
RNA StdSens analysis kit (Bio-Rad) using the Experion Automated Electrophoresis 
Station (Bio-Rad). In brief, denatured RNA samples and ladder were added in 1 µl 
volumes to a microfluidic StdSens chip. The microfluid chip has a network of channels 
that when primed with the provided gel solution permitted the detection, staining, and 
data collection of the samples through the measurement of the 16S and 23S RNA peaks. 
Only RNA samples which met the quality, quantity and concentration requirements of the 
array analysis were further subjected to absorbance analysis. 
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The purity of the extracted RNA samples was assessed through the absorbance 
ratio at 260 nm/230 nm. A 1 µl aliquot of RNA sample was measured at 260 nm and 230 
nm on the BioTek Powerwave XS microplate reader using a Take3 Multi-Volume plate. 
A reference blank was set with 1 µl of nuclease free water (Sigma-Aldrich). Only 
samples with a 260 nm/230 nm ratio of  ≥ 1.5 were approved for shipment and further 
analysis. 
 
2.2.9 Microarray Processing 
 
 
 
All sample labelling and GeneChip processing was completed at the London 
regional Genomics Centre (Robarts Research Institute, London, Ontario, Canada). 
 
RNA Integrity Analysis 
 
 
 
RNA sample quality was assessed using the Aligent 2100 Bioanlyzer (Aligent 
Technologies Inc., Palo Alto, CA) as well as the RNA 6000 Nano kit (Caliper Life 
Sciences, Mountain View, CA). RNA samples were only labelled and hybridized to a 
Genechip if the sample was not degraded and the quality was high. 
 
cDNA Synthesis and GeneChip Hybridization 
 
 
 
From 10 µl of total RNA, single stranded complementary DNA (sscDNA) was 
prepared according to the Affymetrix GeneChip Expression Analysis Technical manual, 
Chapter 4 – Prokaryotic Target Peparation (Affymetrix, Santa Clara, CA). Initially, using 
random primers, RNA was converted to cDNA and subsequently fragmented and end 
labelled. For 16 h at 50 ˚C the cDNA cocktail was hybridized to a P. aeruginosa Genome 
array. All liquid handling steps were performed by a GeneChip Fluidics Station 450 and 
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GeneChips were scanned with a GeneChip Scanner 3000 7G (Affymetrix) using 
 
Command Console v3.2.4. 
 
 
Data Analysis 
 
 
 
An initial data quality assessment was performed via the Affymetrix Expression 
Console. Probe level data (.CEL files) were generated using the Affymetrix Command 
Console v3.2.4. and summarized to the gene level data provided in Partek Genomics 
Suite v6.6 (Partek, St. Louis, MO) using the RMA algorithm (Irizarry, Hobbs et al. 
2003). Both the fold-change and p-value of each gene was calculated using Partek’s 
multi-way ANOVA. Using a 2-fold change of expression as a significant change, gene 
lists were created containing only those genes with a ± 2-fold change. Such lists were 
then analyzed for enriched Gene Ontology (GO) terms and KEGG Pathways using a 
Fisher’s Exact test to determine significance. 
 
2.2.10 Statistics 
 
 
 
Data were displayed as averaged values of 3 independent experiments (n=3) ± 
SEM and data analysis was performed through Graph Pad Prism v5.01. Statistical 
significance was determined through a one-way ANOVA (repeated measures ANOVA 
for growth curves) test with a p-value of < 0.05 considered significant when compared to 
untreated controls.  ANOVA analysis was followed by a Tukey’s Post-hoc analysis to 
determine between which groups the significant difference(s) occurred.  All data were 
presented as a percent of the untreated control with the exception of the MIC and growth 
curve experiments. All array data were analyzed as previously described in 2.2.9 
Microarray Processing, Data Analysis. 
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2.3 Results 
 
 
 
2.3.1 Minimum Inhibitory Concentration of Aqueous or Alcoholic Ginseng 
Extracts 
 
 
 
Through a microdilution assay the minimum inhibitory concentration of both the 
aqueous and alcoholic ginseng extract was determined for the laboratory PAO1 strain and 
two clinical isolates. Bacteria were cultured and tested in both MHCA and M9 
supplemented media for MIC determination. It was found that the aqueous extract was 
able to inhibit bacterial growth of all strains at 3.0-2.0% w/v and 8.0-7.0% w/v in MHCA 
and M9 media respectively (Table 1.1 A, Table 1.1 B). In either media, bacterial growth 
was not inhibited by the presence of the alcoholic extract at any concentration. 
 
Table 1.1: Minimum inhibitory concentrations (MIC) of P. aeruginosa treated with 
either aqueous or alcoholic ginseng extracts. MIC values were determined through 
microdilution series of either extract in 96 well plates, denoting the MIC value by visual 
growth assessment. Experiments were repeated three times (n=3) in duplicate in either 
both Mueller-Hinton cation adjusted broth (MHCA) (Table 1.1) and M9 supplemented 
media (Table 1.2) 
 
Table 1.1 A Minimum inhibitory concentration of ginseng extract treatment in 
MHCA media 
Aqueous Ginseng Extract Alcoholic Ginseng Extract 
  Strain  (%w/v)  (%w/v)   
PAO1 3.0 >5.0 
Mucoid Isolate 2.5 >5.0 
   Non-mucoid Isolate  2.0  >5.0   
 
Table 1.1 B Minimum inhibitory concentration of ginseng extract treatment in M9 
media 
Aqueous Ginseng Extract Alcoholic Ginseng Extract 
  Strain  (%w/v)  (%w/v)   
PAO1 8.0 - 7.0 >10.0 
Mucoid Isolate 7.0 >10.0 
   Non-mucoid Isolate  8.0 - 7.0  >10.0   
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2.3.2 Effect of Aqueous or Alcoholic Ginseng Treatment on Bacterial 
Growth 
 
 
 
Growth of P. aeruginosa in the presence of the aqueous ginseng extract resulted 
in a significant increase in growth rate for all strains when exposed at a 0.5 MIC 
concentration (Figure 1.1). Treatment of the bacteria with the alcoholic extract displayed 
mixed results with no significant changes to growth rate in comparison to untreated 
controls. Both PAO1 and the mucoid clinical isolate grew slower at both concentrations 
after 24 and 48 h of incubation (Figure 1.2 A, B). Both clinical isolates grew faster than 
the control with the 0.5 MIC concentration treatment during the first six hours (Figure 
1.2: B, C). 
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Figure 1.1: Growth curve analysis in the presence of the aqueous ginseng extract. 
Growth in the presence of sub-inhibitory concentrations of the aqueous ginseng extract 
was assessed for 48 h at 37 ˚C with 150 rpm shaking. After 0, 6, 24, and 48 h of 
incubation, 1ml of culture was removed and the absorbance at 600 nm was measured. 
Values normalized to the time 0 absorbance and adjusted based on background aqueous 
extract absorbance at 600 nm for each time point was used both for the statistical 
interpretation and presentation of results. Experiments were repeated three times (n=3) 
and data is represented as an average ± SEM. Statistical comparisons to the untreated 
control for each treatment were done through a repeated-measures ANOVA and 
subsequent Tukey’s post-hoc test (p-value < 0.05=*). 
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Figure 1.2: Growth curve analysis in the presence of the alcoholic ginseng extract. 
Growth in the presence of the sub-inhibitory concentrations of the alcoholic ginseng 
extract was assessed for 48 h at 37 ˚C with 150 rpm shaking. After 0, 6, 24, and 48 h of 
incubation, 1ml of culture was removed and the absorbance at 600 nm was measured. 
Values normalized to the time 0 absorbance and adjusted based on background alcoholic 
extract absorbance at 600 nm for each time point were used for the statistical 
interpretation of the data,  however raw values normalized to time point zero were used 
for results presentation. Experiments were repeated three times (n=3) and data are 
represented as an average ± SEM. Statistical comparisons to the untreated control for 
each treatment were done through a repeated- measures ANOVA and subsequent Tukey’s 
post-hoc test. 
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2.3.3 Effect of Aqueous or Alcoholic Ginseng Treatment on Preventing 
Bacterial Attachment 
 
 
 
The adherence ability of P. aeruginosa in the presence of either ginseng extract 
was assessed in 96 well flat bottom plates. PAO1 adherence decreased slightly with 
aqueous extract exposure at 0.25 MIC concentration, but significactly increased 
adherence with a 0.50 MIC concentration exposure was found (Figure 1.3 A) with similar 
results found with both clinical isolates as well (Figure 1.3: B, C). Adherence in the 
presence of the alcoholic extract for either clinical isolate caused a significant reduction, 
however PAO1 was unaffected (Figure 1.3). Reduced adherence of the clinical isolates 
lower than the adherence found for the alcoholic extract controls leading to negative 
adherence values when normalized for the alcoholic control (Figure 1.2: B, C). 
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Figure 1.3: The effect of aqueous and alcoholic ginseng treatment on the prevention 
of P. aeruginosa adherence. Bacteria were grown in the presence of 0.25 MIC and 0.50 
MIC concentrations of either extract in 96 well flat bottom plates for 24 h at 37 ˚C. Post 
incubation, plates were washed with distilled water and adhered bacteria were stained 
with a 0.1% crystal violet stain and solubilized stain was measured at an absorbance of 
600 nm. Experiments were repeated three times in triplicate (n=3) and expressed as an 
average percentage of the untreated control ± SEM. Statistical comparisons to the 
untreated control for each treatment was done through a one-way ANOVA and 
subsequent Tukey’s post-hoc test (p-value < 0.05= *, p-value < 0.01= **, p-value < 
0.001= ***). 
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2.3.4 Effects of Ginseng Treatment on Preformed Biofilms 
 
 
 
The effect of ginseng extract treatment on 48 h old preformed biofilms was 
assessed by measuring the rate of adherence after 24 h of ginseng treatment. With regards 
to PAO1, the alcoholic extract had no effect on the adherence of the preformed biofilms 
(Figure 1.4 A). The aqueous extract significantly increased PAO1 adherence at a 1.0 MIC 
concentration, however reduced adherence at the 2.0 MIC concentration (Figure 1.4: A). 
For either clinical bacterial isolate the aqueous extract decreased the adherence of the 
preformed biofilms at both concentrations (Figure 1.4: B, C).  Treatment of the clinical 
isolates with the alcoholic extract showed varied results. The adherence of the mucoid 
clinical isolate was significantly reduced at both concentrations (Figure 1.4: B), while the 
non-mucoid clinical isolate showed reduced adherence only at the 1.0 MIC concentration 
(Figure 1.4: C). 
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Figure 1.4: The effect of aqueous and alcoholic ginseng treatment on 48 h P. 
aeruginosa biofilms. Bacteria were allowed to adhere to a 96 well flat bottom plates for 
48 h at 37 ˚C. Post incubation, wells were washed with distilled water and bacteria were 
treated with either extract at 1.0 MIC and 2.0 MIC concentrations for 24 h at 37 ˚C. After 
treatment, wells were washed with distilled water and adhered bacteria were stained with 
a 0.1% crystal violet stain and solubilized stain was measured at an absorbance of 600 
nm. Experiments were repeated three times in triplicate and expressed as an average 
percentage of the untreated control ± SEM. Statistical comparisons to the untreated 
control for each treatment was done through a one-way ANOVA and subsequent Tukey’s 
post-hoc test (p-value < 0.05= * and p-value < 0.01= **). 
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2.3.5 Effect of Ginseng Extract Treatment on P.aeruginosa Pigment 
Production 
 
 
 
The absorbance of pyoverdine at 405 nm was measured from culture supernatants 
treated with sub-inhibitory concentrations of either ginseng extract. Significant decreases 
in pyoverdine with both 0.5 MIC and 0.25 MIC concentrations of either aqueous or 
alcoholic extract were measured for PAO1 (Figure 1.5 A).  The mucoid clinical isolate 
showed similar results to PAO1, with even greater decrease in pyoverdine found with the 
aqueous ginseng treatment (Figure 1.5 B). The non-mucoid clinical isolate displayed the 
same results for the aqueous ginseng treatment as the other two strains; however the 
alcoholic ginseng treatment significantly increased the expression of pyoverdine at either 
concentration (Figure 1.5 C). 
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Figure 1.5: The effect of aqueous and alcoholic ginseng extract treatment on the 
production of the pigment pyoverdine. Bacterial cultures of were prepared and 
incubated in the presence of 0.25 MIC and 0.5 MIC concentrations of either extract for 24 
h at 37 ˚C & 150 rpm. Cultures were then centrifuged to remove cells, filtered, and 1ml 
of supernatant was assayed in a spectrometer at 405 nm. Data represents averaged mean 
values of three independent experiments preformed in duplicate, and expressed as a 
percentage of untreated controls ± SEM. Statistical significance was determined through 
one-way ANOVA analysis followed by Tukey’s post-hoc test to determine significance 
relative to the untreated controls ( p-value < 0.01= ** and p-value < 0.001= ***). 
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2.3.6 The Outcome of Aqueous or Alcoholic Ginseng Treatment on 
Bacterial Protease and Lipase Production 
 
 
 
The production and secretion of proteases into the bacterial culture media was 
measured by the zone of clearance formed on a milk agar plate. Neither the aqueous nor 
the alcoholic extract had a significant effect towards the measured protease production in 
PAO1 (Figure 1.6: A). Statistically significant changes were found for both extract 
treatments using the clinical isolates, with the alcoholic ginseng treatment  some what 
increasing the measured protease in both isolates (Figure 1.6: B, C).  Exposure to the 
aqueous extract significantly reduced or prevented the protease production in both 
clinical isolates. Protease production in the non-mucoid isolate treated with aqueous 
extract was reduced to an undetectable amount (Figure 1.5: C), as was the 0.25 MIC 
treated mucoid isolate (Figure 1.5: B). 
 
The synthesis and production of lipase was measured in treated culture 
supernatants using a tween 20 hydrolysis. For all strains tested, growth in the presence of 
the alcoholic ginseng extract caused increases in the measurement of lipase (Figure 1.7). 
In contrast, growth of all strains in the presence of the aqueous ginseng extract caused 
significant decreases in the lipase production by the bacteria (Figure 1.7), with the 
greatest reductions found in both clinical isolates. 
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Figure 1.6: Protease production in the presence of aqueous or alcoholic ginseng 
extract.  Bacterial cultures were prepared and incubated in the presence of 0.25 MIC and 
0.5 MIC concentrations of either extract for 24 h at 37 ˚C & 150 rpm. Cultures were then 
centrifuged to remove cells and remaining supernatants were filter sterilized. To a single 
center well of a 1% skim milk plate (1.5% agar), 50 µl of filtered supernatant was added 
and plates were incubated at 37 ˚C for 24 h. The zone of clearance around the inoculation 
well was measured with a ruler (mm). Data are represented as the average of three 
separate experiments conducted in duplicate ± SEM. Statistical significance was 
determined through one-way ANOVA analysis followed by Tukey’s post-hoc test to 
determine significance relative to the untreated controls ( p-value<0.05= * and  p-value < 
0.01= **). 
56 
 
A
b
s
o
rb
a
n
c
e
 
(%
 ) 
(O
D
4
0
0
n
m
) 
A
b
s
o
rb
a
n
c
e
 (
%
 ) 
(O
D
4
0
0
n
m
)  
A
b
s
o
rb
a
n
c
e
 
(%
 ) 
(O
D
4
0
0
n
m
) 
 
A 
 
 
150 
 
 
 
 
100 
 
 
PAO1 
 
 
 
** ** 
 
 
 
 
 
Aqueous 
Alcoholic 
 
 
 
*** 
50 
 
*** 
 
 
 
0 
Control  0.25MIC  0.50MIC 
Treatment Concentration (%w/v) 
 
 
 
B 
 
150 
 
 
100 
 
Mucoid CI 
 
 
 
Aqueous 
Alcoholic 
C 
 
400 
 
300 
 
200 
 
Non-mucoid  CI 
 
 
** 
 
 *  
 
 
 
Aqueous 
Alcoholic 
 
50 
 
*** 
0 
 
 
 
*** 
 
100 
 
0 
 
 
 
*** 
***
 
Control 0.25MIC 0.50MIC 
Treatment Concentration (% w/v) 
Control  0.25MIC  0.50MIC 
Treatment Concentration  (% w/v) 
 
 
Figure 1.7: Lipase production in the presence of aqueous or alcoholic ginseng 
extract.  Bacterial cultures were prepared and incubated in the presence of 0.25 MIC and 
0.5 MIC concentrations of either extract for 24 h at 37 ˚C & 150 rpm. Cultures were then 
centrifuged to remove cells and remaining supernatants were filter sterilized. To a glass 
test tube, 2.3 ml of 0.50 M tris buffer (pH 7.6), 0.1 ml 0.1 M CaCl2 in tris buffer (pH 7.6), 
0.1 ml tween 20 in tris buffer (pH 7.6), and 0.5 ml filtered supernatant were combined 
and incubated at 37 ˚C & 150 rpm for 4 h. After incubation, 1 ml was removed and 
measured in a spectrophotometer at 400 nm.  Data represents the mean value of three 
independent experiments preformed in duplicate and expressed as a percentage of the 
control ± SEM. Statistical significance was determined through one-way ANOVA 
analysis followed by Tukey’s post-hoc test to determine significance relative to the 
untreated controls (p-value<0.05= *, p-value < 0.01= **, and p-value < 0.001= ***). 
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2.3.7 Influence of Aqueous and Alcoholic Ginseng Treatment on 
P.aeruginosa Motility 
 
 
 
Flagellum-mediated motility of P .aeruginosa was measured through the point 
inoculation of plates containing 0.125 MIC and 0.25 MIC concentrations of either 
ginseng extract, and the measurement of the distance travelled from the point of 
inoculation. Motility trends were similar for both the mucoid clinical isolate and the 
PAO1 laboratory strain which both showed statistically significant decreases in motility 
in the presence of either ginseng extract (Figure 1.8: A, B). Results were less conclusive 
for the non-mucoid isolate, which showed no significant change in motility with either 
treatment (Figure 1.8: C). 
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Figure 1.8: Motility in the presence of aqueous and alcoholic ginseng extracts.  Plates 
comprising 0.125 MIC and 0.25 MIC concentrations of either aqueous or alcoholic 
ginseng extracts, and 0.3% agarose were point inoculated with bacterial cultures. Plates 
were incubated at 37 ˚C for 12 h (A) or 36 h (B & C). Distance travelled through the 
media was measured with a ruler (mm) after incubation. Data are represented as the 
average of three separate experiments conducted in duplicate ± SEM. Statistical 
significance was determined through one-way ANOVA analysis followed by Tukey’s 
post-hoc test to determine significance relative to the untreated controls ( p-value<0.05= 
* and  p-value < 0.01= **). 
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2.3.8 Effects of Aqueous Ginseng Treatment on P. aeruginosa Gene 
Expression 
 
 
 
Gene expression changes with aqueous extract exposure after 6 h and 24 h was 
assessed through microarray analysis. Overall, deviations in expression from the control 
grown in untreated media were far more varied after the 6 h aqueous exposure than after 
the 24 h exposure. Significant changes (relative to controls at either 6 h or 24 h) are 
presented in Table 1.2. 
 
Many genes involved in the metabolism of varying organic compounds were 
increased in expression with the 6 h aqueous treatment (Table 1.2 A). Multiple genes 
involved in the citrate cycle (TCA cycle) (acnB, acnA, sdhB, fdnG),), nitrogen 
metabolism (nirS, nosZ, norB, norC, fdnH, napA, napB, nosD, ccpR, nirC, nirM, nirN, 
glnA), propanoate metabolism (prpB, prpC, prpD), and glyoxylate and dicarboxylate 
metabolism (glcD, fdnG) increased in expression. Multiple genes involved in heme 
biosynthesis (nirJ, nirL, nirF) also increased RNA transcripts the after aqueous extract 
exposure for 6hrs. 
 
Several genes displayed decreased expression with the 6 h aqueous treatment. 
Among these genes involved in phenazine syntheses were; phzC1/phzC2, phzE1/phzE2, 
and phzF1/phzF2 which decreased in expression of -3.05, -3.91, and -4.91 fold 
respectively. Similarily, transcripts for biosynthetic proteins for two other pigments 
produced by P.aeruginosa, pyochelin (pchG, pchB, pchC) and pyoverdine (pvdE, pvdJ, 
pvdL, pvdH, pvdA, pvdD) decreased. Two genes (fptA, fpvA) involved in pigment iron 
transport into the cell and pchA and pchB (genes involved in the biosynthesis of 
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pyochelin precursor salicylate) also decreased expression after the 6 h aqueous extract 
exposure. 
 
Other virulence associated genes decreased expression after the 6 h aqueous 
extract treatment. Translocator protein genes (popD and popB) as well as a type III export 
protein (pscE) decreased in expression. Virulence factors ExoT and ExoS showed 
decreases in expression of -2.16 and -3.45 respectively after 6 h aqueous exposure. Gene 
rhlA rhamnolipidtransferase gene and cupA1 fimbraie gene were both similarly 
decreased. Finally, several genes involved in oxidative phosphorylation and oxygen- 
dependent carbon metabolism were reduced after the 6 h aqueous extract treatment. 
 
Treatment of the bacteria with the aqueous extract for 24 h showed a much 
different gene expression profile.  Increased expression of iron-associated genes for 
flavohemoprotein (fhp), ferreodoxin (fxd2), ferripyochelin receptor (fptA), and TonB were 
all found after 24 h aqueous extract treatment. Three genes encoding cysteine desulferase 
(iscA, iscS, iscU) and two related chaperon proteins (hscA, hscB) were upregulated. 
 
Exposure of the bacteria to the aqueous extract for 24 h caused significant 
increases in multiple genes involved in the synthesis (accB, accC) and metabolism (fabA, 
fabB) of fatty acids, and nitrogen and carbon metabolism (antA, antB). A regulatory gene, 
cbrB, involved in the orchestration of multiple metabolic pathways was also increased 
after the 24 h aqueous extract incubation. 
 
The great majority of those genes with a significant increase in expression after 
the 24 h treatment are involved in ribosomal structure and function. 10 genes involved in 
50s ribosomal proteins, 7 in 30s ribosomal proteins and a ribosome modulation factor 
61 
 
were all increased following 24 h aqueous extract treatment. Transcription termination 
factor (rho), ribonuclease protein (rnpA), and ribonuclear modulation factor (rmf ) 
transcripts were all also increased. Also significantly increased were a flagellar capping 
protein (fliD), a transcriptional regulator (anr), and a negative regulator of the lasl QS 
system (rsaL). A single trasncriptioal regulator (dnr) was minimally decreased with the 
24 h aqueous treatment. Overall, far fewer genes were affected by the 24 h aqueous 
treatment than the 6hr treatment. 
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Table 1.2: Significant gene expression changes after exposure to the aqueous ginseng 
extract. RNA isolated from bacteria grown in the presence of the aqueous ginseng 
extract for 6 or 24 h at a 1.5% w/v concentration was analysed through the Affymetrix 
Pseudomonas aeruginosa GeneChip array. Partek multi-way ANOVA analysis was 
performed to assess significant differences in the expression of genes when compared to 
RNA from untreated controls. Only genes displaying increased or decreased expression 
of a ≥2.0 fold change were considered significant. 
 
Table 1.2 A: Significant gene expression changes with 6 h aqueous ginseng 
treatment (n=3) when compared to 6 h control (n=3) 
 
Probeset ID Gene 
Symbo 
l 
 Gene Title p-value Fold 
Change 
PA0519_nirS_at nirS nitrite reductase precursor 3.78E-11 13.289 
PA0518_nirM_at nirM cytochrome c-551 precursor 9.00E-10 9.87022 
PA0263_hcpC_s 
_at 
hcpA / 
hcpB / 
hcpC 
secreted protein Hcp 3.78E-06 6.94621 
PA2338_at --- ---  2.81E-05 6.06149 
PA0517_nirC_at nirC probable c-type cytochrome 
precursor 
6.08E-09 6.03595 
PA3392_nosZ_at nosZ nitrous-oxide reductase 
precursor 
1.16E-07 5.54854 
PA1657_at --- ---  2.20E-05 4.85483 
PA1556_at --- ---  0.0114198 4.57164 
PA4133_at --- ---  1.83E-10 4.53765 
PA0795_prpC_at prpC citrate synthase 2 0.00014342 
5 
4.23113 
PA4587_ccpR_at ccpR cytochrome c551 peroxidase 
precursor 
6.73E-06 4.19885 
PA0516_nirF_at nirF heme d1 biosynthesis protein 
NirF 
1.30E-09 4.06298 
PA1658_at --- ---  8.93E-05 3.97869 
PA5100_hutU_at hutU urocanase  2.37E-09 3.95938 
PA1555_at --- ---  0.00399444 3.94427 
PA0887_acsA_at acsA acetyl-coenzyme A synthetase 4.87E-05 3.87622 
PA0918_at --- ---  1.53E-07 3.5942 
PA3922_at --- ---  1.93E-06 3.42735 
PA3570_mmsA_ 
at 
mmsA methylmalonate-semialdehyde 
dehydrogenase 
0.00115913 3.42713 
PA2015_at gnyD Citronelloyl-CoA 
dehydrogenase, GnyD 
0.00078598 
2 
3.4167 
PA3920_at --- ---  5.22E-06 3.33524 
PA4366_sodB_at sodB superoxide dismutase 0.00016931 3.30562 
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8 
PA4430_at --- --- 0.00033669 
6 
3.27291 
PA1551_at --- --- 0.00066606 
5 
3.23781 
PA2265_at --- --- 1.36E-07 3.15793 
PA0796_prpB_at prpB carboxyphosphonoenolpyruvat 
e phosphonomutase 
0.0026867 3.14881 
PA1659_at --- --- 1.29E-05 3.14021 
PA2340_at --- --- 3.64E-05 3.11368 
PA5355_glcD_at glcD glycolate oxidase subunit GlcD 2.48E-05 3.10712 
PA0524_norB_at norB nitric-oxide reductase subunit B 3.50E-11 3.09339 
PA2016_at gnyR Regulatory gene of 
gnyRDBHAL cluster, GnyR 
0.00023871 
5 
3.07871 
PA0523_norC_at norC nitric-oxide reductase subunit C 0.00028647 
4 
3.07407 
PA2014_at gnyB beta subunit of geranoyl-CoA 
carboxylase, GnyB 
0.00022355 
8 
3.06297 
PA4812_fdnG_at fdnG formate dehydrogenase-O, 
major subunit 
0.00065314 
2 
3.04728 
PA2264_at --- --- 6.55E-08 3.04089 
PA1562_acnA_at acnA aconitate hydratase 1 0.00029749 
2 
3.01044 
PA2013_at gnyH gamma-carboxygeranoyl-CoA 
hydratase, GnyH 
0.00295466 2.95937 
PA0514_nirL_at nirL heme d1 biosynthesis protein 
NirL 
2.09E-07 2.95519 
PA0515_at --- --- 1.09E-07 2.91782 
PA0958_oprD_at oprD Basic amino acid, basic peptide 
and imipenem outer membrane 
porin OprD precursor 
0.00500756 2.87338 
PA0511_nirJ_at nirJ heme d1 biosynthesis protein 
NirJ 
3.54E-06 2.86918 
PA4431_at --- --- 0.00054933 
4 
2.85503 
PA1174_napA_at napA periplasmic nitrate reductase 
protein NapA 
2.76E-06 2.85168 
PA1173_napB_at napB cytochrome c-type protein 
NapB precursor 
9.87E-08 2.83419 
PA1984_s_at --- --- 0.00037437 
6 
2.78421 
PA3235_at --- --- 0.00193917 2.71325 
PA2339_at --- --- 0.00037110 
2 
2.69236 
PA1666_at --- --- 6.85E-05 2.63224 
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PA2341_at --- --- 1.93E-05 2.61542 
PA1667_at --- --- 2.01E-08 2.59932 
PA2554_at --- --- 0.00256784 2.59254 
PA4578_at --- --- 0.00382733 2.57081 
PA0510_at --- --- 0.0011197 2.57062 
PA1288_at --- --- 0.00438429 2.56853 
PA0513_at --- --- 5.13E-09 2.54968 
PA5429_aspA_at aspA aspartate ammonia-lyase 5.02E-05 2.5308 
PA4500_at --- --- 0.016752 2.51823 
PA0794_at --- --- 0.00040810 
2 
2.48682 
PA0291_oprE_at oprE Anaerobically-induced outer 
membrane porin OprE 
precursor 
0.00888121 2.48605 
PA3393_nosD_at nosD NosD protein 8.44E-05 2.46591 
PA3923_at --- --- 4.98E-08 2.45018 
PA0132_at --- --- 4.55E-05 2.37414 
PA3188_at --- --- 0.00429773 2.36035 
PA4236_katA_at katA catalase 0.00978967 2.34582 
PA2646_nuoK_a 
t 
nuoK NADH dehydrogenase I chain 
K 
0.00028315 
4 
2.32897 
PA0509_nirN_at nirN probable c-type cytochrome 6.55E-05 2.32641 
PA4811_fdnH_at fdnH nitrate-inducible formate 
dehydrogenase, beta subunit 
1.71E-05 2.30058 
PA4131_at --- --- 0.00204047 2.30044 
PA3524_gloA1_ 
at 
gloA1 lactoylglutathione lyase 7.55E-05 2.29328 
PA3189_at --- --- 0.00398028 2.27678 
PA5461_at --- --- 0.0258161 2.26625 
PA4661_at pagL Lipid A 3-O-deacylase 0.00101846 2.25616 
PA1584_sdhB_at sdhB succinate dehydrogenase (B 
subunit) 
0.020709 2.25449 
PA2112_at --- --- 9.12E-06 2.21727 
PA3234_at --- --- 0.00032233 
6 
2.2153 
PA2249_bkdB_at bkdB branched-chain alpha-keto acid 
dehydrogenase (lipoamide 
component) 
0.0018092 2.21266 
PA1787_acnB_at acnB aconitate hydratase 2 0.0156434 2.20273 
PA5119_glnA_at glnA glutamine synthetase 0.0111685 2.19902 
PA4429_at --- --- 0.00183448 2.1969 
PA5266_at --- --- 3.28E-06 2.18529 
PA5490_cc4_at cc4 cytochrome c4 precursor 0.00024529 
6   
2.18296 
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PA3187_at --- --- 0.0280127 2.1781 
PA0526_at --- --- 9.21E-06 2.17524 
PA5153_at --- --- 0.00035625 
2 
2.16278 
PA1074_braC_at braC branched-chain amino acid 
transport protein BraC 
0.0016183 2.14659 
PA3519_at --- --- 0.00118905 2.13953 
PA1665_at --- --- 2.38E-06 2.1369 
PA1195_at --- --- 1.42E-07 2.13571 
PA2648_nuoM_a 
t 
nuoM NADH dehydrogenase I chain 
M 
0.00167441 2.13213 
PA2482_at --- --- 0.00011569 
4 
2.12997 
PA0512_at --- --- 5.40E-06 2.11553 
PA2126_at --- --- 1.96E-05 2.11198 
PA3569_mmsB_ 
at 
mmsB 3-hydroxyisobutyrate 
dehydrogenase 
0.00672201 2.09497 
PA2553_at --- --- 0.0228512 2.08739 
PA3190_at --- --- 0.0115915 2.08506 
PA5099_at --- --- 0.00088904 
8 
2.06348 
PA2128_at cupA1 fimbrial subunit CupA1 0.00060125 
8 
2.04294 
PA3038_at --- --- 0.0101208 2.03553 
PA1511_at --- --- 2.80E-05 2.01785 
PA5167_at --- --- 7.78E-05 2.01087 
PA1550_at --- --- 0.00456837 2.00806 
PA1718_pscE_at pscE type III export protein PscE 0.00762587 -2.01391 
PA5027_at --- --- 0.0125507 -2.01742 
PA4916_at --- --- 0.01634 -2.01773 
PA3531_bfrB_at bfrB bacterioferritin 0.0257969 -2.03242 
PA0211_mdcD_a 
t 
mdcD malonate decarboxylase beta 
subunit 
0.00120954 -2.04803 
PA2404_at --- --- 0.00950382 -2.05336 
PA1914_at --- --- 9.20E-05 -2.05828 
PA0534_at --- --- 0.0161202 -2.07925 
PA2034_at --- --- 0.00272246 -2.11222 
PA3690_at --- --- 0.0191532 -2.11784 
PA3479_rhlA_at rhlA rhamnosyltransferase chain A 0.0133196 -2.12425 
PA1876_at --- --- 0.00013079 -2.13998 
PA3842_at --- --- 0.00430214 -2.15196 
PA1318_cyoB_at cyoB cytochrome o ubiquinol 
oxidase subunit I 
0.0165511 -2.15297 
PA4467_at --- --- 0.00899147 -2.15659 
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PA1001_phnA_a 
t 
phnA anthranilate synthase 
component I 
0.00190017 -2.16079 
PA0044_exoT_at exoT exoenzyme T 3.03E-05 -2.16469 
PA1707_pcrH_at pcrH regulatory protein PcrH 0.00012388 
2 
-2.17814 
PA4142_at --- --- 0.00031226 -2.21003 
PA4917_at --- --- 0.00015709 
7 
-2.21668 
PA0792_prpD_at prpD propionate catabolic protein 
PrpD 
0.00662303 -2.26371 
PA1875_at --- --- 3.61E-06 -2.26537 
PA4306_at --- --- 3.35E-05 -2.2731 
PA3584_glpD_at glpD glycerol-3-phosphate 
dehydrogenase 
0.019293 -2.28816 
PA2501_at --- --- 0.0140032 -2.33496 
PA5436_at --- --- 0.00559478 -2.40766 
PA2405_at --- --- 0.00074615 
4 
-2.41224 
PA2033_at --- --- 0.0126758 -2.44053 
PA3195_gapA_at gapA glyceraldehyde 3-phosphate 
dehydrogenase 
5.01E-05 -2.45955 
PA1874_at --- --- 3.37E-06 -2.47945 
PA2452_at --- --- 0.0151902 -2.68475 
PA1196_at --- --- 0.0131888 -2.7019 
PA4211_g_at phzB1 
/ 
phzB2 
probable phenazine 
biosynthesis protein 
0.00169332 -2.73589 
PA0210_mdcC_a 
t 
mdcC malonate decarboxylase delta 
subunit 
0.00034057 
8 
-2.80477 
PA2389_at --- --- 0.00206801 -2.81264 
PA0208_mdcA_a 
t 
mdcA malonate decarboxylase alpha 
subunit 
0.00299533 -2.82689 
PA2398_fpvA_at fpvA ferripyoverdine receptor 0.0404226 -2.89529 
PA2433_at --- --- 2.46E-05 -2.91184 
PA2427_at --- --- 0.00280955 -3.00129 
PA0209_at --- --- 0.00013447 
7 
-3.00585 
PA1901_s_at phzC1 
/ 
phzC2 
phenazine biosynthesis protein 
PhzC 
1.68E-05 -3.05613 
PA0122_at --- --- 0.00090848 
7 
-3.05739 
PA4229_pchC_at pchC pyochelin biosynthetic protein 
PchC 
0.00037407 -3.07568 
PA4217_at phzS flavin-containing 0.00099136 -3.1247 
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monooxygenase 
PA1709_popD_a 
t 
popD Translocator outer membrane 
protein PopD precursor 
6.43E-06 -3.23647 
PA4226_pchE_at pchE dihydroaeruginoic acid 
synthetase 
0.00109602 -3.3663 
PA2397_pvdE_at pvdE pyoverdine biosynthesis protein 
PvdE 
0.0322414 -3.3833 
PA1317_cyoA_at cyoA cytochrome o ubiquinol 
oxidase subunit II 
4.56E-06 -3.42533 
PA3841_exoS_at exoS exoenzyme S 1.50E-06 -3.45172 
PA4175_at prpL Pvds-regulated endoprotease, 
lysyl class 
1.03E-06 -3.50964 
PA3361_at lecB fucose-binding lectin PA-IIL 0.00200522 -3.5439 
PA0315_at --- --- 3.98E-06 -3.54514 
PA3181_at --- --- 8.85E-07 -3.7041 
PA2394_at pvdN PvdN 0.0020704 -3.80565 
PA2386_pvdA_a 
t 
pvdA L-ornithine N5-oxygenase 0.0111724 -3.82158 
PA1903_s_at phzE1 
/ 
phzE2 
phenazine biosynthesis protein 
PhzE 
5.75E-06 -3.91308 
PA2393_at --- --- 0.00549147 -4.12925 
PA4221_fptA_at fptA Fe(III)-pyochelin outer 
membrane receptor precursor 
0.00567876 -4.19199 
PA2411_at --- --- 2.42E-05 -4.34107 
PA1708_popB_at popB translocator protein PopB 1.67E-08 -4.53525 
PA2402_at --- --- 1.34E-05 -4.55376 
PA2413_at pvdH L-2,4-diaminobutyrate:2- 
ketoglutarate 4- 
aminotransferase, PvdH 
0.00025913 -4.76076 
PA4470_fumC1_ 
at 
fumC1 fumarate hydratase 0.0092648 -4.76918 
PA1904_s_at phzF1 
/ 
phzF2 
probable phenazine 
biosynthesis protein 
1.12E-06 -4.91159 
PA1245_at --- --- 9.59E-08 -4.92912 
PA3407_hasAp_ 
at 
hasAp heme acquisition protein 
HasAp 
4.70E-06 -5.00349 
PA4218_at --- --- 2.53E-05 -5.29589 
PA4222_at --- --- 1.58E-08 -5.3744 
PA3183_zwf_at zwf glucose-6-phosphate 1- 
dehydrogenase 
2.45E-08 -5.40556 
PA4223_at --- --- 4.66E-09 -5.54624 
PA2399_pvdD_a 
  t   
pvdD pyoverdine synthetase D 1.45E-06 -5.64402 
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PA4469_at --- --- 0.00039574 
9 
-5.79569 
PA2401_at --- --- 4.08E-05 -5.89781 
PA3182_at pgl 6-phosphogluconolactonase 2.70E-08 -6.10826 
PA4231_pchA_at pchA salicylate biosynthesis 
isochorismate synthase 
1.08E-10 -6.19586 
PA2412_at --- --- 0.00049003 
7 
-6.20121 
PA1905_s_at phzG2 probable pyridoxamine 5'- 
phosphate oxidase 
5.39E-09 -6.58124 
PA4468_sodM_a 
t 
sodM superoxide dismutase 4.73E-06 -6.60205 
PA2424_at pvdL PvdL 4.78E-09 -7.04124 
PA4141_at --- --- 0.00019411 
1 
-7.70085 
PA2400_at pvdJ PvdJ 4.64E-06 -8.01899 
PA4225_pchF_at pchF pyochelin synthetase 4.22E-07 -8.11832 
PA4224_at pchG pyochelin biosynthetic protein 
PchG 
5.00E-07 -8.92838 
PA4230_pchB_at pchB salicylate biosynthesis protein 
PchB 
1.87E-09 -11.6901 
 
 
Table 1.2 B: Significant gene expression changes with 24 h aqueous ginseng 
treatment (n=3) when compared to 24 h control (n=3) 
 
Probeset ID Gene 
Symbol 
 Gene Title p-value Fold 
Change 
PA2664_fhp_at fhp flavohemoprotein 1.03E-08 17.8077 
PA3813_iscU_a 
t 
iscU probable iron-binding protein 
IscU 
6.30E-05 11.7175 
PA2663_at --- ---  1.71E-07 11.6566 
PA3815_at --- ---  7.29E-07 7.77983 
PA3361_at lecB fucose-binding lectin PA-IIL 3.53E-05 7.52668 
PA3811_hscB_a 
t 
hscB heat shock protein HscB 1.42E-05 7.20502 
PA1847_at --- ---  0.00010909 
2 
6.46437 
PA3812_iscA_a 
t 
iscA probable iron-binding protein 
IscA 
0.00015793 
9 
6.41803 
PA2662_at --- ---  2.62E-05 6.27684 
PA3814_iscS_at iscS L-cysteine desulfurase 
(pyridoxal phosphate- 
dependent) 
0.00085771 
9 
5.96988 
PA3584_glpD_a 
  t   
glpD glycerol-3-phosphate 
dehydrogenase   
0.00024175 
5   
4.71812 
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PA5531_tonB_a 
t 
tonB TonB protein 0.00094424 
6 
4.37658 
PA0179_at --- --- 0.00081482 
8 
3.75166 
PA4257_rpsC_a 
t 
rpsC 30S ribosomal protein S3 0.0327932 3.56291 
PA1178_oprH_ 
at 
oprH PhoP/Q and low Mg2+ 
inducible outer membrane 
protein H1 precursor 
0.00307541 3.42063 
PA4241_rpsM_ 
at 
rpsM 30S ribosomal protein S13 0.0294963 3.34495 
PA3049_rmf_at rmf ribosome modulation factor 0.00018426 3.29575 
PA1610_fabA_a 
t 
fabA beta-hydroxydecanoyl-ACP 
dehydrase 
0.00897408 3.2276 
PA1431_rsaL_a 
t 
rsaL regulatory protein RsaL 0.00865849 3.10445 
PA4273_rplA_a 
t 
rplA 50S ribosomal protein L1 0.028352 3.04697 
PA4258_rplV_a 
t 
rplV 50S ribosomal protein L22 0.0179047 3.01569 
PA3656_rpsB_a 
t 
rpsB 30S ribosomal protein S2 0.0432387 2.9873 
PA2513_antB_a 
t 
antB anthranilate dioxygenase small 
subunit 
0.00023090 
7 
2.96269 
PA2840_at --- --- 0.00750856 2.78178 
PA0456_at --- --- 0.0394716 2.78129 
PA5030_at --- --- 0.00021931 
1 
2.71799 
PA4221_fptA_a 
t 
fptA Fe(III)-pyochelin outer 
membrane receptor precursor 
0.0397513 2.6925 
PA4259_rpsS_a 
t 
rpsS 30S ribosomal protein S19 0.0164566 2.69021 
PA3930_cioA_a 
t 
cioA cyanide insensitive terminal 
oxidase 
0.00931686 2.6884 
PA5570_rpmH_ 
at 
rpmH 50S ribosomal protein L34 0.02924 2.68469 
PA3190_at --- --- 0.00181828 2.656 
PA3808_at --- --- 0.00237087 2.63236 
PA4256_rplP_at rplP 50S ribosomal protein L16 0.0430538 2.6301 
PA4935_rpsF_a 
t 
rpsF 30S ribosomal protein S6 0.0363297 2.59759 
PA1774_at --- --- 0.00079348 
8 
2.59662 
PA4262_rplD_a 
t 
rplD 50S ribosomal protein L4 0.0390145 2.56978 
PA1609_fabB_a fabB beta-ketoacyl-ACP synthase I 0.00053737 2.55104 
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t   3  
PA4253_rplN_a 
t 
rplN 50S ribosomal protein L14 0.025885 2.55052 
PA4847_accB_a 
t 
accB biotin carboxyl carrier protein 
(BCCP) 
0.0233972 2.54003 
PA1775_at --- --- 0.00025433 
1 
2.5127 
PA0505_at --- --- 0.00173712 2.47089 
PA4843_at --- --- 0.00021981 
5 
2.46765 
PA0122_at --- --- 0.00430983 2.46544 
PA4261_rplW_ 
at 
rplW 50S ribosomal protein L23 0.0417189 2.46124 
PA3809_fdx2_a 
t 
fdx2 ferredoxin [2Fe-2S] 0.00216273 2.45535 
PA4244_rplO_a 
t 
rplO 50S ribosomal protein L15 0.0259151 2.45125 
PA3533_at --- --- 0.0309253 2.43241 
PA4726_at cbrB two-component response 
regulator CbrB 
0.00082454 
5 
2.42429 
PA4944_at --- --- 0.00888775 2.41197 
PA4251_rplE_at rplE 50S ribosomal protein L5 0.0395769 2.40326 
PA4751_ftsH_at ftsH cell division protein FtsH 0.00332574 2.38314 
PA0579_rpsU_a 
t 
rpsU 30S ribosomal protein S21 0.0105975 2.35959 
PA3349_at --- --- 0.00033583 
9 
2.3489 
PA0176_at --- --- 0.00085413 
1 
2.32553 
PA2512_antA_a 
t 
antA anthranilate dioxygenase large 
subunit 
0.00019695 
9 
2.27617 
PA2788_at --- --- 0.00227802 2.25694 
PA2642_nuoG_ 
at 
nuoG NADH dehydrogenase I chain G 0.00905427 2.25505 
PA5374_betI_at betI transcriptional regulator BetI 0.00592773 2.24552 
PA5569_rnpA_ 
at 
rnpA ribonuclease P protein 
component 
0.0230047 2.23946 
PA1544_anr_at anr transcriptional regulator Anr 0.0124458 2.23672 
PA1777_oprF_a 
t 
oprF Major porin and structural outer 
membrane porin OprF precursor 
0.0167288 2.22495 
PA3009_at --- --- 0.00087111 
6 
2.21905 
PA2604_at --- --- 0.0388175 2.2067 
PA3530_at --- --- 0.00108567 2.19214 
PA2622_cspD_ cspD cold-shock protein CspD 0.00458832 2.17943 
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at 
PA2638_nuoB_ 
at 
nuoB NADH dehydrogenase I chain B 0.0466691 2.14697 
PA4563_rpsT_a 
t 
rpsT 30S ribosomal protein S20 0.0203625 2.14338 
PA3810_hscA_ 
at 
hscA heat shock protein HscA 0.00128999 2.14236 
PA4848_accC_a 
t 
accC biotin carboxylase 0.0260101 2.13322 
PA0839_at --- --- 0.00253363 2.13078 
PA2621_at --- --- 0.00128594 2.12855 
PA1094_fliD_at fliD flagellar capping protein FliD 0.0456645 2.11167 
PA3031_at --- --- 0.0373232 2.09272 
PA4515_at --- --- 0.00513476 2.0829 
PA5438_at --- --- 0.00257018 2.04864 
PA3581_glpF_a 
t 
glpF glycerol uptake facilitator 
protein 
0.0124227 2.04369 
PA2741_rplT_at rplT 50S ribosomal protein L20 0.0470199 2.03743 
PA1093_at --- --- 0.0293185 2.02944 
PA1584_sdhB_ 
at 
sdhB succinate dehydrogenase (B 
subunit) 
0.0404479 2.01949 
PA2897_at --- --- 0.00282981 2.01785 
PA3326_at --- --- 0.00313689 2.01496 
PA5239_rho_at rho transcription termination factor 
Rho 
0.0488799 2.0044 
PA0527_dnr_at dnr transcriptional regulator Dnr 0.0471663 -2.00957 
PA1789_at --- --- 0.0277343 -2.12231 
PA5232_at --- --- 0.0116958 -2.17726 
PA1673_at --- --- 0.0121 -2.36053 
PA5427_adhA_ 
at 
adhA alcohol dehydrogenase 0.037982 -2.65738 
PA5475_at --- --- 0.00407286 -2.7331 
PA3572_at --- --- 0.00437332 -2.77132 
PA1557_at --- --- 0.0416549 -3.22679 
PA1546_hemN_ 
at 
hemN oxygen-independent 
coproporphyrinogen III oxidase 
0.00643591 -3.23242 
PA3309_at --- --- 0.00385956 -3.29413 
PA4067_oprG_ 
at 
oprG Outer membrane protein OprG 
precursor 
0.00220388 -3.59858 
PA5170_arcD_a 
t 
arcD arginine/ornithine antiporter 0.00636456 -4.70364 
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2.3.9 Gene-Ontology Enrichment Analysis of P. aeruginosa Treated with 
Aqueous Ginseng Extract 
 
 
 
Gene ontology analysis of the 6 h aqueous ginseng extract treatment revealed that 
a large fraction of genes related to iron and heme binding, iron homeostasis, siderophore 
transmembrane transport activity, and iron-sulfur clustering were significantly affected 
by the treatment (Table 1.3 A). Most significantly of these were those genes with the 
common function of heme binding with an enrichment score of 17.795 with 42.30% of 
the genes present significantly affected by the 6 h aqueous extract treatment. Other gene 
groups enriched by the 6 h treatment include; oxidation and reduction processes, glucose 
metabolism, ATP synthesis coupled electron transport, fermentation, NADH 
dehydrogenase activity, and peroxidase activity. 
 
After 24 h of aqueous ginseng treatment iron binding, transport, and iron-sulfur 
cluster assembly and binding were still among the most greatly affected groups of genes 
(Table 1.3 B). Of these, iron-sulfur cluster assembly had the greatest enrichment of 12.95 
with 100% of the genes in the pathway affected significantly. Gene groups involved in 
ribosomal structure, RNA binding, translation, and translation regulation were all 
enriched with the 24 h treatment. Genes involved in RNA binding and ribosomal 
structure, displayed enrichment scores of 21.35 and 29.54 respectively. Multiple gene 
groups involved in amino acid transport, nucleic acid binding, and DNA-template 
transcription and termination were significantly affected by the 24 h aqueous treatment as 
well. Additionally, gene groups involved with fatty acid synthesis and metabolism, lipid 
metabolism, and carbohydrate derivative metabolism and synthesis showed significant 
enrichment after 24 h treatment. 
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Table 1.3: Gene ontology (GO) enrichment analysis of P. aeruginosa after exposure 
to the aqueous ginseng extract. From the sample of genes deemed significantly 
increased by a factor of ≥2.0 fold change, genes were grouped based on similar GO 
functions and differences in overall group enrichment compared to the control was 
performed through a Fisher’s Exact Test. Only those gene groups with an enrichment p- 
value > 0.05 are displayed. 
 
Table 1.3 A: GO-enrichmen of 6 h aqueous ginseng treatment (n=3) compared to 6 h 
control (n=3) 
 
Function Type Enrichment 
Score 
Enrichment 
p-value 
% genes 
in group 
that are 
present 
heme binding molecular 
function 
17.795 1.86943E-08 42.3077 
oxidation-reduction process biological 
process 
15.6217 1.64276E-07 13.4529 
iron ion binding molecular 
function 
11.1763 1.40023E-05 26.3158 
extracellular region cellular 
component 
10.505 2.73999E-05 36.8421 
antibiotic biosynthetic process biological 
process 
9.48148 0.000076251 50 
glucose metabolic process biological 
process 
6.61556 0.00133937 60 
siderophore transmembrane 
transporter activity 
molecular 
function 
5.96136 0.0025764 50 
ATP synthesis coupled electron 
transport 
biological 
process 
5.96136 0.0025764 50 
peroxidase activity molecular 
function 
5.44061 0.00433683 42.8571 
ACP phosphopantetheine 
attachment site binding involved 
in fatty acid biosynthetic process 
molecular 
function 
4.81687 0.00809209 66.6667 
glucose-6-phosphate 
dehydrogenase activity 
molecular 
function 
4.81687 0.00809209 66.6667 
chorismate metabolic process biological 
process 
4.81687 0.00809209 66.6667 
glyceraldehyde-3-phosphate 
dehydrogenase (NAD+) 
(phosphorylating) activity 
molecular 
function 
4.81687 0.00809209 66.6667 
iron ion homeostasis biological 
process 
4.81687 0.00809209 66.6667 
copper ion binding molecular 
function 
4.64261 0.00963249 33.3333 
iron-sulfur cluster binding molecular 4.4674 0.0114771 14.5833 
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function 
fumarate hydratase activity molecular 
function 
4.15875 0.0156271 50 
glutamate-ammonia ligase 
activity 
molecular 
function 
4.15875 0.0156271 50 
glycerol-3-phosphate metabolic 
process 
biological 
process 
4.15875 0.0156271 50 
glutamine biosynthetic process biological 
process 
4.15875 0.0156271 50 
molybdenum ion binding molecular 
function 
4.15875 0.0156271 50 
fermentation biological 
process 
4.15875 0.0156271 50 
isoleucine catabolic process biological 
process 
3.68281 0.0251522 40 
leucine catabolic process biological 
process 
3.68281 0.0251522 40 
valine catabolic process biological 
process 
3.68281 0.0251522 40 
oxidoreductase activity, acting 
on the aldehyde or oxo group of 
donors, NAD or NADP as 
acceptor 
molecular 
function 
3.36837 0.0344459 21.4286 
NADH dehydrogenase 
(quinone) activity 
molecular 
function 
3.36837 0.0344459 21.4286 
glycerol metabolic process biological 
process 
3.31208 0.0364402 33.3333 
hydrolase activity, hydrolyzing 
  O-glycosyl compounds   
molecular 
function   
3.01021 0.0492815 28.5714 
 
 
Table 1.3 B: GO-enrichment of 24 h aqueous ginseng treatment (n=3) compared to 
24 h control (n=3) 
 
Function Type Enrichment 
Score 
Enrichment 
p-value 
% genes 
in group 
that are 
present 
structural constituent of ribosome molecular 
function 
29.547 1.47191E-13 33.3333 
RNA binding molecular 
function 
21.3596 5.29206E-10 23.2877 
intracellular cellular 
compone 
nt 
20.2277 1.64146E-09 23.5294 
translation biological 
process   
19.0256 5.46098E-09 18.9474 
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cellular protein metabolic process biological 
process 
13.2523 1.75629E-06 12.1212 
iron-sulfur cluster assembly biological 
process 
12.9548 2.36476E-06 100 
iron-sulfur cluster binding molecular 
function 
9.54333 7.16781E-05 18.75 
fatty acid metabolic process biological 
process 
8.19847 0.000275075 31.25 
iron ion binding molecular 
function 
7.48839 0.000559543 18.4211 
regulation of translation biological 
process 
7.445 0.000584359 60 
glycerol metabolic process biological 
process 
6.78082 0.00113534 50 
siderophore transmembrane 
transporter activity 
molecular 
function 
6.78082 0.00113534 50 
2 iron, 2 sulfur cluster binding molecular 
function 
5.57408 0.00379497 23.5294 
glucose-6-phosphate 
dehydrogenase activity 
molecular 
function 
5.3698 0.00465506 66.6667 
fatty acid biosynthetic process biological 
process 
5.14664 0.00581894 21.0526 
cellular aromatic compound 
metabolic process 
biological 
process 
5.10453 0.0060692 30 
oxidoreductase activity, acting on 
NAD(P)H 
molecular 
function 
5.10453 0.0060692 30 
biotin carboxylase activity molecular 
function 
4.70284 0.0090695 50 
glycerol-3-phosphate metabolic 
process 
biological 
process 
4.70284 0.0090695 50 
DNA-templated transcription, 
termination 
biological 
process 
4.70284 0.0090695 50 
protein catabolic process biological 
process 
4.70284 0.0090695 50 
carbohydrate derivative 
metabolic process 
biological 
process 
4.70284 0.0090695 50 
carbohydrate derivative 
biosynthetic process 
biological 
process 
4.70284 0.0090695 50 
organic substance biosynthetic 
process 
biological 
process 
4.70284 0.0090695 50 
organophosphate metabolic 
process 
biological 
process 
4.70284 0.0090695 50 
phosphorus metabolic process biological 
process 
4.70284 0.0090695 50 
phosphate-containing compound 
  metabolic process   
biological 
process   
4.70284 0.0090695 50 
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organophosphate biosynthetic 
process 
biological 
process 
4.70284 0.0090695 50 
biosynthetic process biological 
process 
4.70284 0.0090695 50 
oxidoreductase activity, acting on 
paired donors, with incorporation 
or reduction of molecular oxygen 
molecular 
function 
4.21812 0.0147263 40 
organic cyclic compound 
metabolic process 
biological 
process 
4.21812 0.0147263 40 
cellular metabolic process biological 
process 
4.21812 0.0147263 40 
small molecule metabolic process biological 
process 
4.21812 0.0147263 40 
single-organism process biological 
process 
4.21812 0.0147263 40 
single-organism metabolic 
process 
biological 
process 
4.21812 0.0147263 40 
single-organism cellular process biological 
process 
4.21812 0.0147263 40 
cellular aromatic compound 
metabolic process 
biological 
process 
4.21812 0.0147263 40 
organic substance metabolic 
process 
biological 
process 
4.21812 0.0147263 40 
metabolic process biological 
process 
4.21812 0.0147263 40 
cellular process biological 
process 
4.21812 0.0147263 40 
NADH dehydrogenase (quinone) 
activity 
molecular 
function 
4.10963 0.0164139 21.4286 
amino acid transmembrane 
transporter activity 
molecular 
function 
3.83869 0.0215217 33.3333 
ATP synthesis coupled electron 
transport 
biological 
process 
3.83869 0.0215217 33.3333 
biological_process biological 
process 
3.83869 0.0215217 33.3333 
dioxygenase activity molecular 
function 
3.73595 0.0238506 18.75 
nucleic acid binding molecular 
function 
3.63346 0.0264245 13.7931 
amino acid transmembrane 
transport 
biological 
process 
3.52818 0.0293583 28.5714 
cellular lipid metabolic process biological 
process 
3.29219 0.0371722 10.6383 
3-oxoacyl-[acyl-carrier-protein] 
synthase activity 
molecular 
function 
3.26638 0.0381443 25 
arginine catabolic process biological 3.26638 0.0381443 25 
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process 
metalloendopeptidase activity molecular 
function 
3.04087 0.0477934 22.2222 
cell adhesion biological 
process 
3.04087 0.0477934 22.2222 
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2.3.10 Pathway Enrichment Analysis of P. aeruinosa treated with Aqueous 
Ginseng Extract 
 
 
 
Pathway enrichment analysis provided further elucidation of the effects of both 6 
h and 24 h aqueous ginseng treatment of P. aeruginosa (Table 1.4). With the 6 h 
treatment, the pathway most enriched was that of the biosynthesis of siderophore group 
nonribosomal peptides. This pathway had an enrichment score of 13.29 with 83.33% of 
the genes within the pathway significantly altered in expression. Microbial metabolism in 
diverse environments pathway was enriched by a factor of 9.18, however only 12.02% of 
the genes in this pathway were significantly altered. Other pathways significantly 
enriched through 6hr treatment include nitrogen, propanoate, glyoxlate and dicarboxylate 
metabolism, carbon metabolism, the citrate acid cycle, and oxidative phosphorylation. 
 
After 24 h of aqueous ginseng treatment far fewer pathways were significantly 
affected. The most prominently effected pathway was that of the ribosome with an 
enrichment score of 31.24 with 32.07% of the pathway genes significantly affected. Fatty 
acid biosynthesis and metabolism were the next two pathways with the greatest 
enrichment with scores of 6.89 and 5.66 respectively. Aminobenzoate degradation and 
oxidative phosphorylation were also significantly enriched with the 24 h treatment. 
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Table 1.4: Pathway enrichment analysis of P. aeruginosa after exposure to the 
aqueous ginseng extract. From the sample of genes deemed significantly increased by a 
factor of ≥2.0 fold change, genes were grouped based similarity in the pathways which 
they function through KEGG pathway analysis. Differences in pathway enrichment 
compared to the control were performed through a Fisher’s Exact Test. Only those 
pathways with an enrichment p-value > 0.05 are displayed. 
 
Table 1.4 A: Pathway analysis of 6 h aqueous ginseng treatment (n=3) compared to 
6 h control (n=3) 
 
Pathway Name Enrichment 
Score 
Enrichment 
p-value 
% genes in 
pathway that are 
present 
Biosynthesis of siderophore group 
nonribosomal peptides 
13.2934 1.68559E-06 83.3333 
Microbial metabolism in diverse 
environments 
9.1831 0.000102761 12.0253 
Nitrogen metabolism 9.13212 0.000108136 29.1667 
Propanoate metabolism 9.13059 0.000108302 35.2941 
Glyoxylate and dicarboxylate 
metabolism 
8.56927 0.000189852 26.9231 
Carbon metabolism 6.6063 0.00135182 13.9241 
Citrate cycle (TCA cycle) 3.78648 0.0226752 18.1818 
Valine, leucine and isoleucine 
degradation 
3.67554 0.0253358 23.0769 
Oxidative phosphorylation 3.20965 0.0403709 13.1579 
 
 
Table 1.4 B: Pathway analysis of 24 h aqueous ginseng treatment (n=3) compared to 
24 h control (n=3) 
 
Pathway Name Enrichment 
Score 
Enrichment 
p-value 
% genes in 
pathway that are 
present 
Ribosome 31.2444 2.69603E-14 32.0755 
Fatty acid biosynthesis 6.89769 0.00101012 28.5714 
Fatty acid metabolism 5.66985 0.00344839 21.0526 
Aminobenzoate degradation 3.51728 0.0296802 25 
Oxidative phosphorylation 3.19965 0.0407764 10.5263 
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2.4 Discussion 
 
 
 
Ginseng is globally recognized as the “king” of medicinal plants displaying a 
plethora of medicinal uses including anti-bacterial properties (Cruse-Sanders and 
Hamrick 2004). Panax quinquefolius is the native ginseng species of North America and 
has been less intensly studied for its medicinal properties than the Asian P. ginseng. 
Published research on the medicinal properties of P. quinquefolius has shown various 
anti-bacterial mechanisms against opportunistic pathogen P. aeruginosa (Alipour, Omri 
et al. 2011). To further elucidate the efficacy of extracts from P. quinquefolius against P. 
aeruginosa pathogenicity, the effects of both the aqueous and alcoholic extracts of the 
plant were investigated against bacterial growth, biofilm formation, virulence factor 
production, and bacterial genetic expression. 
 
To analyze the bacteriostatic effects of either ginseng extract towards P. 
aeruginosa, bacteria were subjected to MIC assays. Results from the MIC experiments 
revealed an inhibitory effect against P. aeruginosa when treated with the aqueous ginseng 
extract in either MHCA broth or M9 broth (Table 1.1.1, Table 1.1.2). Values for growth 
inhibition were lower in the MHCA (2.0-3.0% w/v) broth than in the M9 (7.0-8.0% w/v). 
Differences in the MIC concentrations found for each media may be attributed to the 
rate/amount of specific components dissolving in the media, or interactions of extract 
components with the media component(s) such as the ginsenosides of each extract (Rios, 
Recio et al. 1988, Burt 2004). 
 
MIC experiments with the alcoholic ginseng extract presented no visible growth 
attenuation of any strain of P. aeruginosa for concentrations up to 5.0% w/v in MHCA 
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and 10.0% w/v in M9 media (Table 1.1). To our knowledge, no data are available on the 
antibacterial effects of P. quinquefolius alcoholic extract. The higher MIC values of the 
alcoholic extract might be attributed to its composition; it is largely composed of 
ginsenosides which have been reported to have weak growth inhibitory action against 
other species of pathogenic bacteria (Sung and Lee 2008). 
 
Growth curve analysis of the bacteria in the presence of subinhibitory 
concentrations of either ginseng extract revealed growth stimulatory effects of the 
aqueous ginseng extract, while the alcoholic extract displayed mild inhibitory action 
(Figure 1.1, 1.2). For all strains significant increases in growth were found in the 
presence of the aqueous extract at a 0.5 MIC concentration, while growth was only 
minimally increased with a 0.25 MIC concentration. In regards to pathogenicity, 
increased growth rate could increase P. aeruginosa survival within a host. Similar 
increase in growth rate with aqueous extract treatment of P. aeruginosa has been 
previously described by Alipour et al (2011). In constrast to the treatment with the 
aqueous extract, the alcoholic extract reduced growth of both the mucoid clinical isolate 
and PAO1, with minimal effect towards the non-mucoid clinical isolate. Experimentation 
with specific components of either extract would improve our understanding of which 
component(s) influence growth rate. 
 
The explanation(s) regarding the stimulatory effects of aqueous extract on 
bacterial growth are not clear at the present time. Gene expression analysis (Table 1.2) 
showed that 6 h of aqueous extract treatment, increased expression of propanoate (prpB, 
prpC, prpD), glycoxylate and dicarboxylate metabolism (glcD, fdnG), TCA cycle (acnB, 
acnA, sdnB, fdnG), and most significantly nitrogen metabolism (glnA, fdnH, nirN, nirM, 
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nirC, ccpR, nosD, napB, napA, norB, norC, nosZ, nirS) which are all involved in energy 
metabolism. Heme biosynthesis genes (nirJ, nirL, nirF) specific for cytochrome c d1, the 
electron donor for nitrite reductase (nirS), showed comparable increases in expression. 
Increases in biochemical components of bacterial metabolism may be indicative of the 
bacteria preparing for increases in growth rate by producing necessary metabolites and 
ATP. 
 
After 24 h of exposure to the aqueous extract, genes involved in both nitrogen and 
carbon (antA, antB) metabolism were increased in expression, as well as genes involved 
in the synthesis (accB, accC) and metabolism (fabA, faB) of fatty acids (Table 1.2 B). 
Interestingly the regulatory protein encoded by the cbrB, which when expressed allows 
for the utilization of multiple carbon and nitrogen sources simultaneously also displayed 
increased expression. Increases in such a wide variety of energy metabolism pathways 
after both the 6 h and 24 h incubations may partially explain the increased growth 
associated with the aqueous extract treatment. In regards to an infectious state, increased 
growth would result in a more aggressive infection. 
 
P. aeruginosa is classified as a facultative anaerobic organism and often depends 
heavily on anaerobic metabolism during states of chronic infection in CF patients where 
anaerobic biofilms dominate (Yoon, Hennigan et al. 2002). However, several genes 
involved in nitrogen metabolism were decreased after the 24 h incubation. Gene dnr, an 
anaerobic transcription regulator of denitrification enzyme production (Arai et al., 1997), 
such as hemN and hemF heme biosynthesis genes, was down regulated after the 24 h 
incubation. A reduction in the anaerobically induced hemeN was similarly decreased after 
the 24hr (Rompf, Hungerer et al. 1998). The control of dnr is under transcriptional 
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regulator anr (Arai, Kodama et al. 1997), was significantly increased after 24 h. Gene anr 
controls for the regulation of hydrogen cyanide biosynthesis, and arginine deiminase and 
denitrification pathways (Zimmermann, Reimmann et al. 1991, Ye, Haas et al. 1995). As 
previously discussed, genes involved in the denitrifying pathway were increased after 6 h 
of incubation, but not the 24 h incubation with the aqueous extract. Support for increased 
denitrification during the exponential growth phase was found through increased 
expression of flavohemoglobin, fhp, after 24 h of incubation with the aqueous extract. fhp 
is involved in the detoxification of nitric oxide from within cells in the presence of 
oxygen (Arai, Hayashi et al. 2005). This suggests anaerobic nitrogen metabolism was 
 
most heavily expressed during the exponential growth phase (6 h incubation), but reduced 
in expression once the bacteria entered the stationary phase (24 h incubation). 
 
Gene ontology (GO) and pathway enrichment analysis from the microarray data 
mimic the findings detailed for genes involved in metabolism (Table 1.3). Pathways 
analysis for the 6 h incubation showed enrichment of nitrogen, propanoate, glycoxylate 
and dicarboxylate, and carbon metabolism. Enrichment in pathways of the TCA cycle, 
valine, leucine, and isoleucine degradation, oxidative phosphorylation, and microbial 
metabolism in diverse environments were also significantly affected. After 24 h of 
incubation fatty acid biosynthesis and metabolism, oxidative phosphorylation, and 
aminobenozate degradation pathways were all enriched, which correlates directly to the 
up-regulated genes previously described. 
 
Although the pathway analysis displayed enrichment of the oxidative 
phosphorylation pathway at both incubation times, genes within the pathway were both 
significantly increased and decreased therefore it is unlikely that as an entire pathway 
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oxidative phosphorylation was increased. Rather a shift to anaerobic metabolism after the 
 
6 h incubation is evident. Treatment with the aqueous extract may limit P. aeruginosa’s 
ability to utilize oxygen forcing the bacteria to increase the expression of alternative 
pathways for energy production. Anaerobic metabolism is often utilized by P. aeruginosa 
during chronic infections when a biofilm mode of growth is adopted (Yoon, Hennigan et 
al. 2002). Increased anaerobic metabolism from aqueous extract exposure may encourage 
a transition towards biofilm formation, adding to P. aeruginosa’s pathogenicitiy. 
 
Biofilm formation is a prominent mechanism through which P. aeruginosa 
becomes resistant to antibiotic therapies (Costerton, Stewart et al. 1999, Hoiby, Krogh 
Johansen et al. 2001). Compounds which reduce bacterial surface adherence or disrupt 
preformed biofilms have potential to both increase the clearance of chronic P. aeruginosa 
infections and increase the efficacy of available antibiotics. When grown in the presence 
of the aqueous extract, PAO1 adherence was significantly increased with a 0.5 MIC 
concentration treatment, but minimally decreased with a 0.25 MIC concentration 
treatment (Figure 1.3 A). Increases in adherence with aqueous ginseng extract treatment 
have been previously described for the PAO1 strain (Alipour, Omri et al. 2011). The 
alcoholic ginseng extract also increased adherence of PAO1, however the effects were 
not as great as with the aqueous extract. 
 
 
Adherence of either clinical isolate in the presence of the aqueous extract 
displayed increased attachment at a 0.50 MIC concentration (Figure 1.3: B, C). Results 
from the alcoholic ginseng extract treatment display significant reduction in bacterial 
attachment for either strain. Adherence of either clinical isolate in the presence of the 
alcoholic extract was below the background adherence of the extract alone. A possible 
85  
explanation of this observation could be the alcoholic extracts reduces bacterial 
 
adherence by binding directly to the bacteria preventing either from further binding to the 
surface. There is no information available with regards to the effects of either ginseng 
extract towards clinical strains of P. aeruginosa beyond growth inhibition, and this is the 
first report addressing such interactions. Further research implementing a larger sample 
size of clinical isolates is necessary to support the findings of this study. 
 
Biofilm disruption was monitored through 48 h old biofilms treated for 24 h with 
either ginseng extract at an inhibitory (MIC) or 2x inhibitory concentrations (Figure 1.4). 
Increases in biofilm adherence of PAO1 were found with the aqueous extract treatment at 
the MIC concentration, suggesting that the adoption of biofilm growth increased the 
bacteria’s resistance to the treatment. An increase in biofilm disruption was found with 
the treatment at 2x the inhibitory concentration and may be attributed to the toxic effects 
of the extract towards the bacteria. Viability was not assessed in our study -and therefore 
bacterial cells not adhering may or may not have been viable. Previously, Alipour et al 
(2011) concluded that the higher concentrations of the aqueous extract did have a toxic 
effect towards preformed biofilms of P. aeruginosa, and the sloughing of dead bacterial 
cells may be responsible for the decreased in adhesion. The aqueous extracts of both P. 
quinquefolius and P. ginseng contain a mixture of compounds including polysaccharides. 
Purified polysaccharide extracts from P. ginseng have displayed reduced bacterial 
adherence of Helicobacter pylori to epithelial and gastric cells, as well as human 
erythrocytes (Belogortseva, Yoon et al. 2000, Lee, Park et al. 2004). Future studies 
utilizing purified polysaccharide fractions from P. quinquefolius may reveal specific 
fractions with similar anti-adhesive properties. 
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In regards to the clinical isolates, both were significantly decreased in adherence 
with either concentration of aqueous extract treatment (Figure 1.4: B, C). Increased 
resistance to treatment may not have been seen in the clinical isolates due to the slower 
rates of growth, or because biofilm formation was still naïve. Further analysis of mature 
biofilms of clinical isolates may reveal different results due to more robust biofilm 
architecture. Evidence to date suggests the adoption of a mucoid phenotype provides 
advantageous characteristics towards biofilm formation and added immune and antibiotic 
resistance (Hentzer, Teitzel et al. 2001, Hoiby, Krogh Johansen et al. 2001) In our 
experiments, there was no evidence of the mucoid phenotype providing any increases in 
adherence or biofilm resistance to either ginseng extract. It is uncertain if this lack of 
enhanced adherence or resistance is relavent to the mucoid phenotype. Supplementary 
studies on clinical isolates with large sample sizes may result in alternative findings. 
 
Preformed biofilms of the clinical isolates treated with the alcoholic extracts 
displayed substantial decreases in adherence, below the background adherence of the 
extract alone for the mucoid isolate. As previously hypothesized, reduction below the 
extract absorbance may be due to a physical interaction between the extract and bacteria 
preventing either from binding to the surface. Reduced biofilm adherence of the mucoid 
strain may also be due to reduced growth in the presence of sub-inhibitory concentrations 
of the alcoholic extract. The 2x MIC treatment may have been toxic towards the bacteria 
(Figure 1.4: B, C), which may have contributed to the reduced adherence at this 
concentration of treatment. 
 
The ability of the aqueous extract to inhibit preformed biofilms is substantiated 
by data obtained from the gene array analysis which displayed decreased lecB expression 
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with 6 and 24 h aqueous treatments, as well as increased expression of a fimbrae (cupA1) 
and flagellar (fliD) gene after 6 and 24 h of exposure respectively. Gene lecB encodes a 
surface sugar- binding lectin of P. aeruginosa (Sonawane, Jyot et al. 2006) which plays a 
role in airway epithelial cell adhesion (Alverdy, Holbrook et al. 2000), formation of 
biofilms (Tielker, Hacker et al. 2005), and cell injury (Laughlin, Musch et al. 2000). 
Decreased lecB expression may be involved in the decreased biofilm formation found 
with the aqueous extract treatment. lecB is also involved in pilus biogenesis and previous 
studies have shown that blocking expression of lecB reduces twitching motility 
(Sonawane, Jyot et al. 2006) Pilus production is critical for early bacterial adherence and 
biofilm formation (Strom and Lory 1993, O'Toole and Kolter 1998). 
 
In addition to IV pili surface fimbrae and flagella also aid in bacterial adherence to 
various substrates (Arora, Ritchings et al. 1998, Vallet, Olson et al. 2001). As stated only 
a single gene for the synthesis of either surface structure was increased with aqueous 
extract treatment. Full production of either structure involved several genes, and therefore 
it is unlikely that increased expression of only a single gene had a great effect on 
complete formation of P. aeruginosa fimbrae or flagella. 
 
 
Direct analysis of flagellar swimming motility was measured on 0.3% agarose 
plates infused with the alcoholic and aqueous ginseng extract. Against PAO1, both 
compounds were capable of reducing bacterial motility, although the reduction was 
greater for the alcoholic extract (Figure 1.8 A). Previous studies by Alipour et al (2011) 
show a reduction in PAO1 motility when exposed to aqueous ginseng extract. Similar 
reductions in motility with either extract was also observed in the mucoid clinical isolate 
(Figure 1.8 B), however neither extract caused significant effects towards the motility of 
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the non-mucoid isolate (Figure 1.8 C). Differences in the effect against the clinical 
isolates will require further exploration to determine if mucoidy plays a role in the 
differential outcomes. Regardless, reduced flagellar associated motility at an early stage 
of infection could greatly impede the advancement of the infection. The potential of these 
ginseng extracts to disrupt P. aeruginosa swimming motility in clinical isolates should be 
further explored in order to build on the results of Alipour et al (2011) which studied all 
three forms of motility against PAO1 in the presence of the aqueous extract. Findings 
from this study revealed decreases in both swimming and swarming motility, but an 
increase in twitching motility in the presence of the aqueous ginseng extract. 
 
Exoenzymes which act as virulence factors are an important part of P. 
aeruginosa’s pathogenicity. Exotoxins S, T, U, and Y are all secreted through type III 
(Lee, Smith et al. 2005) secretion systems, whereas exotoxin A  is secreted through type 
II systems (Pavlovskis 1972). Multiple genes involved in the type III secretory system 
were significantly decreased after the 6 h exposure to the aqueous extract (Table 1.2 A). 
Gene pscE, a needle assembly protein was reduced in expression, along with two key 
translocator protein genes, popB and popA (Frithz-Lindsten, Holmstrom et al. 1998). 
Reduction in these genes may be linked to decreases in the expression of ExoS and ExoT 
found after the 6 h incubation with the aqueous extract.The production and excretion of 
ExoT and ExoS play a significant role during P. aeruginosa infections by disrupting hot 
cell protein synthesis increasing apoptosis (Barbieri and Sun 2004)and inhibiting 
phagocytosis (Kaufman, Jia et al. 2000). Decreases in the production of these enzymes 
with treatment could reduce bacterial virulence during an infection, particularly during 
early stages when inhibiting phagocytosis is essential in infection establishment. 
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Rhamnolipids, an additional important virulence factor that was not measured 
directly from P. aeruginosa supernatants, was found to be reduced in expression 
following the 6 h incubation (Table 1.2 A). Rhamnolipids lyse PMNs  (Jensen, Bjarnsholt 
et al. 2007) and macrophages derived from monocytes through their enzymatic activity 
(McClure and Schiller 1992).The rhlA gene, which was decreased after the 6 h exposure, 
encodes an essential rhamnosyltransferase (Van Gennip, Christensen et al. 2009). 
Without expression of this gene, rhamnolipid production does not comense and therefore 
the protection from PMNs and macrophages is disabled (Van Gennip, Christensen et al. 
2009). Combined reductions of rhamnolipids and ExoT and ExoS would create a 
situation in which P. aeruginosa is disabled from protecting its self from the host 
immune system and subsequent phagocytosis. 
 
Also secreted by P. aeruginosa are numerous protease, lipase, and elastase 
enzymes which act to break down proteins, lipids, and elastin respectively (Van Delden 
and Iglewski 1998, Wang, Tu et al. 2013).  In this study extracellular protease was 
measured in the supernatant of P. aeruginosa cultures grown in the presence of the either 
ginseng extract. Neither extract at sub-inhibitory concentrations caused a significant 
effect on protease production of PAO1 (Figure 1.6 A), findings similar to those reported 
previously by Alipour et al (2011). Utilizing an aqueous extract of P. ginseng, Song et al 
(2010) measured complete attenuation of LasB protease, a protease which specifically 
breaks down elastin, with treatment at a concentration of 5.0% w/v. It is possible that 
higher concentrations of the aqueous extract may display inhibitory actions towards LasB 
 
protease production in PAO1 as well. 
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Interestingly, the aqueous extract caused drastic decreases in the protease 
production of both clinical isolates at sub-inhibitory concentrations (Figure 1.6: B, 
C).While exposure to the alcoholic extract caused significant increases in protease 
production at sub-inhibitory concentrations. Such results suggest a fundamental 
difference in how these extracts are affecting the clinical strains in comparison to the 
laboratory PAO1 (Figure 1.6 A). Possible differences might arise in the permeability of 
the clinical isolates in comparison to the laboratory strain which may allow components 
of either extract past the cellular membrane affecting transport and other processes of 
protease synthesis. In terms of pathogenicity, the ability of the aqueous extract to reduce 
the production of proteases in the clinical isolates would decrease protein cleaving 
resulting in a reduction of host tissue damage. Further exploration into the effect on LasA 
and LasB elastase production would provide a more unified interpretation of protease 
function in the presence of these ginseng extracts, as these enzymes work in conjunction 
with one another to catabolize elastin (Heck, Morihara et al. 1986, Galloway 1991). 
Decreases in the production of both elastases with aqueous extract treatment could 
greatly decrease the bacteria’s pathogenic capabilities against the host. Previous data 
collected by Song et al (2010) demonstrated decreases in both enzymes with treatment of 
the aqueous extract of P. ginseng suggesting that LasA may also be decreased with P 
.quinquefolius aqueous extract exposure. 
 
 
P. aeruginosa also secretes lipases which hydrolyse triacylglycerol (Gupta, Gupta 
et al. 2004). Lipase production in the presense of the aqueous extract caused significant 
decreases, while the alcoholic extract caused significant increases in measured lipase for 
all strains (Figure 1.7).  Decreased production of lipases with the aqueous extract 
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treatment would decrease P. aeruignosa’s pathogenicity. The production of lipase by 
PAO1 in the presence of the aqueous was analyzed previously by Alipour et al (2011), 
who found similar decreases in lipase production. Alipour et al (2011) showed reduced 
concentrations also decreased lipase production, though to a lesser degree. An additional 
study monitoring the production lipase enzymes in a larger sample of clinical isolates 
may reveal that lower concentrations of the aqueous extract, which do not significantly 
increase growth, can significantly decrease lipase production. To be applicable for use as 
treatments against P. aeruginosa infections, rigorous testing with large populations of 
clinical isolates will need to be performed to determine the correct concentration at which 
to utilize these extracts for treatment purposes. 
 
As with the production of excreted protease enzymes, the alcoholic extract caused 
increased production of the lipase enzymes, especially for the non-mucoid isolate (Figure 
1.7 C). Increases in the production of these virulence factors with treatment could greatly 
increase the severity of the bacterial infection. Therefore, as important as concentration is 
to treatment efficacy the timing of treatment administration will also play a role in 
treatment efficacy. Administration early on in infection when virulence factors are being 
produced in large quantities could further increase the production of such virulence 
factors leading to an increase in infection progression, while treatment in a later chronic 
phase may be beneficial, as displayed by the decreased attachment and biofilm disruption 
caused by the alcoholic ginseng treatment discussed previously. 
 
Virulence factor production is largely under QS control. Previous research 
conducted by Song et al (2010) demonstrated reduced levels of two acyl-homoserine 
lactones involved in quorum sensing after exposure to the aqueous extract of P.ginseng. 
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No such reductions in acyl-homoserine lactones were detected in the aqueous extract 
induced gene expression analysis (Table 1.2); however negative regulator of lasl RNA 
increased in expression after 24 h of incubation . Increases in rsaL expression can cause 
decreases in expression of all LasR PAI-1 related virulence factors (de Kievit, Seed et al. 
1999), which include lasA and lasB, alkaline protease (aprA) , as well as exotoxin A 
(toxA) (Gambello and Iglewski 1991, Gambello, Kaye et al. 1993).  No expression 
decreases in any of the PAI-1 virulence genes listed were found after the 6 or 24 h 
incubation, which suggests the increase in rsaL expression, was not high enough to create 
a significant effect. 
 
Other secreted factors of P. aeruginosa include a variety of pigments. Of these 
pyoverdine, a fluorescent green pigment, is a molecule involved both in iron aquistion 
and iron-dependent pathways which affect the production of other virulence factors 
(Lamont, Beare et al. 2002, Beare, For et al. 2003).  Reduced production of pyoverdine 
decreases the bacteria’s ability to sequester iron, a crucial step in colonization and the 
initial development of infection (Cox and Adams 1985). 
 
Treatment of P. aeruginosa with sub-inhibitory concentrations of the aqueous 
ginseng extract caused significant decreases in pyoverdine production. (Figure1.5). Our 
data corroborates the findings Alipour et al 2011, who showed lower concentrations still 
caused significant decreases in pyoverdine levels in PAO1. Diminishing the production 
and release of pyoverdine could slow the bacteria’s ability to sequester iron, leading to 
reduced growth (Martinez, Delgado-Iribarren et al. 1990). These sub-inhibitory 
concentrations of aqueous extract increased bacterial growth, however the metabolic 
growth requirements within a host are limited compared to a monitored lab setting, 
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especially iron which is bound to iron sequestering molecules and heme proteins as a 
form of host defence mechanism (Litwin and Calderwood 1993). Therefore, although 
aqueous extract treatment increases growth rate of the bacteria in the presence of 
sufficient iron availability, it may act negatively towards the bacteria in an environment 
with reduced iron where increased pyoverdine expression is necessary for adequate iron 
acquisition. 
 
Reductions in pyoverdine were also found for PAO1 and the mucoid clinical 
isolate treated with the alcoholic ginseng extract (Figure 1.5: A, B). Contrastingly, 
treatment of the non-mucoid isolate caused significant increases in the pyoverdine 
measured (Figure 1.5 C). Inconsistencies in the outcome of pyoverdine production 
between the clinical isolates suggest that the mechanism through which this extract 
affects individual bacterial strains may vary. Different forms of pyoverdine exist due to 
structural variations with the greatest differences occurring between strains of P. 
aeruginosa (Meyer, Stintzi et al. 1997). Reduction of one particular form of pyoverdine 
during an interaction with either extract may not correlate with reductions of all forms of 
the pigment and therefore not all strains may display reduced pyoverdine. Utilizing a 
larger sample size of clinical and laboratory strains of bacteria would produce data with 
more significance. 
 
The effects of aqueous ginseng extract on pyoverdine levels are further correlated 
with the data collected from the microarray analysis. Several genes involved in 
pyoverdine synthesis were significantly decreased after treatment for 6 h with the 
aqueous extract (Table 1.2 A).  These genes include; pvdD, a peptide synthase 
(Merriman, Merriman et al. 1995), pvdA, an L-Ornithine N
5
-oxigenase (Visca, Ciervo et 
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al. 1994), pvdE, pvdJ, and pvdL, peptide synthases (McMorran, Merriman et al. 1996, 
Lamont and Martin 2003), pvdH, an aminotransferase (Vandenende, Vlasschaert et al. 
2004), and fvdA a ferric-pyoverdine outer membrane receptor (Poole, Neshat et al. 1993). 
The products of these genes are synthesized without the utilization of ribosomes as 
demonstrated by enrichment of the biosynthetic pathway for siderophore group 
nonribosomal peptides after the 6 h aqueous extract incubation (Table 1.4 A). 
 
Several genes involved in the synthesis of pyochelin, another siderophore pigment 
of P. aeruginosa, were also reduced after the 6 h aqueous extract treatment (Table 1.2 A). 
Genes pchA and pchB encode isocrosimate synthase (Serino, Reimmann et al. 1995) and 
isochorismate pyruvate –lyase/chrosimate mutase respectively (Gaille, Kast et al. 2002). 
These genes are essential for the production of salicylate, a precursor of pyochelin 
(Serino, Reimmann et al. 1995).  The gene pchC  product is a thioesterase, which aids in 
the optimal production of pyochelin (Reimmann, Patel et al. 2004).  The surface 
pyochelin receptor encoded by the fptA gene was also reduced in expression (Heinrichs 
and Poole 1996). Decreased expression of these essential pyochelin biosynthesis genes 
after aqueous extract exposure suggests similar decreases in the direct measurement 
pyochelin would likely be found. After 24 h of incubation with the aqueous extract the 
ftpA gene expression increased, which may reflect a time dependent suppression of 
pyochelin with the extract exposure (Table 1.2 B). 
 
Additionally, after the 24 h incubation period with the aqueous extract, three 
genes, iscS, iscA, and iscU, expression increased. These encode cysteine desulfurase and 
two scaffold proteins, which are required during the formation of Fe-S clusters (Mihara 
and Esaki 2002). The expression of ferredoxin, fdx2, a protein which binds iron and 
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sulphur (2Fe-2S) was also increased (Mihara and Esaki 2002). Two heat shock proteins 
(hscA/hscB) which act as chaperons to iscA/iscU during iron-sulphur cluster formation 
also increased (Vickery and Cupp-Vickery 2007). Iron-sulphur clusters are used in the 
synthesis of various important biological molecules such as biotin and thiamine (Birch, 
Fuhrmann et al. 1995, Lauhon and Kambampati 2000). Increased expression in 
biosynthesis genes involved in Fe-S cluster formation paired with decreases in 
siderophore biosynthesis genes suggests changes to iron availability and use. Increases in 
Fe-S clustering (Table 1.2B, 1.3B) may indicate compensation by the bacteria in order to 
continue regular metabolic functioning with decreased iron acquisition abilities after 
exposure to the aqueous extract. 
 
In addition to the siderophore pigments P. aeruginosa also produces pyocyanin, a 
phenazine pigment which acts as a virulence factor for the bacteria causing host immune- 
modulation and tissue damage due to enhanced production of ROS (Wilson, Sykes et al. 
1988, Lau, Hassett et al. 2004). Expression analysis suggests decreases in the production 
of this pigment after 6 h exposure to the aqueous extract with decreased expression of 9 
phenazine biosynthesis genes; phzG2, phzF1/phzF2, phzE1/phzE2, phzC1/phzC2, and 
phzB1/phzB2 (Table 1.2 A). These genes belong to the 
phzA1B1C1D1E1F1G1/phzA2B2C2D2E2F2G2 operons which produce the compound 
phenazine-1-carboxylic acid, an essential pyocyanin precursor (Mavrodi, Bonsall et al. 
2001). Therefore reduction in the aforementioned genes could lead to a reduction in 
pyocyanin. A previous study demonstrated a reduction of pyocyanin with aqueous 
ginseng extract treatment against PAO1 (Alipour et al 2011), however no evidence has 
been produced for clinical isolates or for the effect with alcoholic ginseng treatment. 
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The final major alterations to P. aeruginosa after exposure to the aqueous extract 
involved ribosomal structure assembly and function. After the 24 h incubation with the 
aqueous extract, 10 genes involved in 50S ribosomal structure and 7 genes involved in 
30S ribosomal structure were significantly increased (Table 1.2 B).  Genes for a 
ribonuclease protein (rnpA), a transcription terminator (rho), and a ribosome modulation 
factor gene (rmf) were similarly expressed at elevated levels. These findings were 
reflected in the GO- and pathway enrichment analysis (Tables 1.3 B, 1.4 B). GO- 
enrichment presented enrichment of genes involved in structural constituents of 
ribosomes, RNA binding, translation, regulation of translation, DNA templated 
transcription, termination, and nucleic acid binding. Pathways analysis suggested 
enrichment of the ribosome pathway with a score of 31.24 and ~32% of the genes in the 
pathway affected. 
 
Increases in ribosomal assembly, and subsequent translation and transcription 
suggest increased turnover of proteins. Such changes normally occur when bacteria enter 
the transition from exponential to stationary growth (Kolter, Siegele et al. 1993). As 
previously discussed evidence of a shift in metabolism was evident in the expression 
analysis between the 6 h and 24 h incubation, which would involve large changes in 
protein requirements. At 24 h, the aqueous extract treatment stimulated significantly 
increased growth compared to control, which could also contribute to the increases in 
protein turnover emphasized in the analysis of the 24 h aqueous incubation treatments. 
 
In conclusion, the treatment of P. aeruginosa with the aqueous extract increased 
growth rates and displayed a shift to anaerobic metabolism state during the exponential 
growth phase. Increased growth was accompanied by increased attachment of the bacteria 
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in the presence of the aqueous extract. However, treatment of preformed biofilms with 
the aqueous extract diminished bacterial adherence which could greatly reduce the 
bacteria’s virulence in chronic infections. Aqueous extract exposure also reduced ExoT 
and ExoS, rhamnolipid, and lipase expression, as well as LasB protease production in 
both clinical strains. Increased expression of a lasl negative regulator and decreased 
expression of type III secretion system genes were revealed through the microarray 
analysis. Significant reduction in both pyoverdine and pyochelin synthesis were resulted 
from aqueous extract treatment. Evidence for the reduction in pyocyanin synthesis was 
also shown through the microarray analysis.  Motility of PAO1 was negatively impacted 
by the presence of the aqueous extract, while results for the clinical isolates were 
inconclusive. Incubation with the aqueous extract for 24 h caused significant up- 
regulation of ribosomal pathways when compared to the control, causes may include 
increased growth rate, transition to stationary growth phase, and interactions of the 
extract and the bacteria which are presently unknown. 
 
Results from the treatment of the P. aeruginosa with the alcoholic extract lead to 
mixed results regarding growth, with minimal decreases in growth rate observed. 
Reduced growth may partially account for the decreased adherence of the clinical isolates 
in the presence of the alcoholic extract, as well as the reduced biofilm adherence revealed 
when 48 h old clinical isolate biofilms were treated with the extract. Treatment with the 
alcoholic extract increased protease production in the clinical strains, while not affecting 
PAO1. Increases in lipase production were found for all strains. Both pyoverdine 
secretion and bacterial swimming motility by P. aeruginosa after alcohol extract 
exposure showed strain specific results. 
98  
In general, it seems that the aqueous extract is the more promising extract of 
ginseng for further development and research. Continued exploration into the components 
of either extract may allow for use of specific extract components as targeted therapies. 
Concentrations used in this study were too high for use in a clinical application, however 
further research into the may reveal potent components with beneficial attributes which 
are effective at lower concentrations. The use of ginseng for medicinal purposes may still 
provide an economical and safe choice for P. aeruginosa infection therapy. 
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Chapter III. The Effect of Thymol or Carvacrol on P. 
aeruginosa Pathogenicity. 
 
 
 
3.1 Introduction 
 
 
 
3.1.1 Sources of Thymol and Carvacrol 
 
 
 
Thymol and carvacrol, phenolic compound isomers (Figure 2.1), represent the 
main constituents of the essential oil of herbaceous plants thyme and oregano, 
respectively (Burt 2004, Nostro, Sudano Roccaro et al. 2007). Both plants also contain 
smaller percentages of the other isomer (Bagamboula, Uyttendaele et al. 2004, Burt 
2004). Concentrations of each isomer vary depending on the species, climate, process of 
extraction, and seasonal variations (Santoyo, Cavero et al. 2006, Oussalah, Caillet et al. 
2007). Distillation and purification of thymol and carvacrol can be achieved directly from 
plant essential oil or a purified form can be purchased from various chemical 
manufacturing companies (Sigma Aldrich, Fisher Scientific). 
 
3.1.2 Chemical Structure and Function 
 
 
 
Thymol and carvacrol are monoterpenoid compounds (Trombetta, Castelli et al. 
 
2005), with a structure of a single phenolic ring formed from the bonding of two isoprene 
molecules with three functional group substituents (Figure 2.1).  In both structures the 
hydroxyl group is attached at the C-1 position. In thymol (a) the methyl group is attached 
at the C-2 position and the isopropyl group is attached at the C-5 position, while in 
carvacrol (b) the methyl group is attached at the C-5 position and the isopropyl group is 
attached at the C-2 position. 
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(a) (b) 
 
 
Figure 2.1: Chemical structure of thymol (a) and carvacrol (b) 
 
 
These compounds are produced as part of the plant secondary metabolism 
(Oussalah, Caillet et al. 2007). Typically these compounds concentrate in specific organs 
such as the leaves and fruit, with the amount and composition differing between organs 
(Oussalah, Caillet et al. 2007). The function of these compounds within the plants is 
mainly as defense mechanisms against bacterial, viral, and fungal infections (Regnault- 
Roger, Hamraoui et al. 1993). High concentrations of these compounds may also act as 
deterrents to herbivores due to their strong flavour and aroma (Trombetta, Castelli et al. 
2005). Most of the antibacterial action of thymol and carvacrol essential oil is imparted 
by thymol and carvacrol, which are two of the most effective antimicrobial plant 
compounds known today (Sivropoulou, Papanikolaou et al. 1996, Nevas, Korhonen et al. 
2004). 
 
 
3.1.2 Antimicrobial Properties and Mechanisms 
 
 
 
Growth Inhibition 
 
 
 
Thymol and carvacrol have both been shown to be potent antibiotic agents against 
a wide range of bacteria (Helander, Alakomi et al. 1998, Walsh, Maillard et al. 2003, 
Oussalah, Caillet et al. 2007). Treatment with either compound has been shown to inhibit 
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the growth of pathogenic bacteria such as Staphlococcus aureus, Esherichia coli, 
Salmonella typhimurium, Listeria monocytogenes, and Shigella sonnei (Helander, 
Alakomi et al. 1998, Bagamboula, Uyttendaele et al. 2004, Trombetta, Castelli et al. 
2005, Oussalah, Caillet et al. 2007). Concentrations below the MIC can reduce the 
growth rate of the bacterial species, even those which were not completly attenuated by 
higher concentrations such as P. aeruginosa (Walsh, Maillard et al. 2003, Nazer, 
Kobilinsky et al. 2005, Oussalah, Caillet et al. 2007). 
 
The mechanism through which these compounds inhibit and reduce growth is 
attributed to their effects on the bacterial cell membrane, as both thymol and carvacrol are 
potent outer membrane damaging compounds (Helander, Alakomi et al. 1998). Due to the 
hydrophobic nature of thymol and carvacrol, these compounds have the ability to 
integrate into the bacterial cell membranes, causing disruption and disturbance to normal 
membrane function (Lambert, Skandamis et al. 2001, Gill and Holley 2006) leading to 
increased permeability of ATP and an increased release of components from within the 
cells (Helander, Alakomi et al. 1998, Walsh, Maillard et al. 2003). The ability to disrupt 
bacterial cell membranes causing cell instability and lysis is a recognized mechanism 
through which phenolic compounds act as antimicrobial agents (Lambert and Hammond 
1973). 
 
 
The ability of phenolic compounds to penetrate through bacterial membranes is 
highly dependent on multiple factors such as: net charge of the membrane surface, the 
ability to travel through aqueous medium, lipid composition of the membrane, and the 
presence and concentration of lipopolysaccharide (LPS) (Trombetta, Castelli et al. 2005). 
Although increasing membrane permeability has been shown to be a main mechanism of 
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thymol and carvacrol action, the ability of these compounds to pass into the cells suggests 
intracellular targets may also be linked to the antimicrobial properties (Denyer and 
Stewart 1998, Ultee, Kets et al. 1999, Trombetta, Saija et al. 2002). Further exploration 
into the interactions of thymol and carvacrol with intracellular bodies may reveal novel 
mechanisms through which these compounds act as antimicrobials. 
 
Biofilm Reduction 
 
 
 
When bacteria adopt a biofilm mode of growth an increase in resistance towards 
antibiotics and host defense mechanisms is found (Nickel, Ruseska et al. 1985, O'Toole, 
Gibbs et al. 2000, Walters, Roe et al. 2003, Lewis 2005). Treatments which can decrease 
this resistance or continue to be effective against biofilm bacteria would greatly improve 
treatment of chronic state infections. Using Staphylococcus aureus and Staphlococcus 
epidermis as model organisms, the ability of these bacteria to form biofilms in the 
presence of thymol or carvacrol, as well as the effect of either treatment on established 
biofilms was monitored (Nostro, Sudano Roccaro et al. 2007). Bacteria grown in the 
presence of subinhibitory concentrations of the two compounds displayed a reduced 
capability to form biofilms, with a greater effect observed at higher concentrations 
(Nostro, Sudano Roccaro et al. 2007). Decreasing established biofilms through treatment 
with thymol or carvacrol has the potential to increase the efficacy of current antibiotics. 
Future research with gram-negative species, such as P. aeruginosa would improve our 
understanding of thymol and carvacrol effects on bacterial biofilms. 
 
3.1.3 Current Development of Thymol and Carvacrol Uses 
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Although interest in thymol and carvacrol as antimicrobial agents has heightened 
recently, both compounds have been used commercially for many years. Their potent 
fragrance and flavour have made thymol and carvacrol common food and beverage 
additives (Cowan 1999, Oussalah, Caillet et al. 2007). The food production industry is 
one of the largest industries in the world. Every year food spoilage due to fungal, viral, 
and bacterial infection leads to large economic losses for the industry, but more 
importantly leads to thousands of cases of food borne illness worldwide (Burt 2004). 
Natural products which could be added directly to food or into the packing of food 
products are appealing options for methods of reducing food spoilage and potential food 
borne illness (Nazer, Kobilinsky et al. 2005). Research continues into the possibility of 
directly applying thymol/carvacrol to various food products, or incorporating either 
compound into plastic packaging to deter the growth of mircoorganisms and to further 
preserve perishable products (Bagamboula, Uyttendaele et al. 2004, Nazer, Kobilinsky et 
al. 2005, Castillo, Perez-Alfonso et al. 2014). 
 
Although commercially available antibiotics based on thymol or carvacrol has not 
yet been developed, health products have incorporated thymol into their formulations. 
Thymol has been used in dental applications such as mouthwash and dental sealers for 
years (Marsh 1992, Cowan 1999, Ouhayoun 2003). Incorporation of thymol into these 
medicinal products was based on research which revealed the ability of this compound to 
inhibit the growth of common oral pathogens (Botelho, Bezerra Filho et al. 2007) 
Continued investigation into the the antibacterial properties of thymol and/or carvacrol 
has the potential for further incorporation into future medical and health related products. 
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3.1.4 Rationale for Further Exploration of the Antibacterial Properties of 
Thymol and Carvacrol 
 
 
 
. In this study, both thymol and carvacrol were assessed in their abilities to inhibit 
P. aeruginosa growth, and also their effects on the production of bacterial virulence 
factors. The ability of these compounds to disrupt biofilm formation and inhibit bacterial 
adherence were also monitored. Finally, to benefit our understanding of drug interactions 
with bacterial expression, microarray analysis of P. aeruginosa in the presences of either 
compound was also analyzed. 
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3.2 Methodology 
 
 
 
3.2.1 Bacterial Strains and Media 
 
 
 
The same bacterial strains noted in Chapter 2 were used for all experiments in 
Chapter 3. Media composition and bacterial sample storage were prepared and performed 
as outlined in Chapter 2. 
 
3.2.2 Compound Solution Preparation 
 
 
 
Both thymol and carvacrol (Sigma-Aldrich) were dissolved into absolute ethanol 
(Sigma-Aldrich) prior todilution into either media. For all experiments stock solutions of 
either compound were made at 200x the desired test concentration and diluted into media, 
so that the final testing solutions was ≤0.9% (v/v)  absolute ethanol, which showed no 
significant effect on growth rate of the bacteria (data not shown). Solutions were filter 
sterilized with a 0.2 µ syringe filter and stored at 4 ˚C until needed or used immediately. 
 
3.2.3 Minimum Inhibitory Concentration Determination 
 
 
 
Minimum inhibitory concentration (MIC) was determined as specified in Chapter 
 
2 with the following changes. Thymol and Carvacrol were originally tested against all 
three strains of bacteria at concentration dilutions from 2000 µg/ml – 200 µg/ml. Final 
results were taken from the treatment of PAO1 and the mucoid clinical isolate with 2000 
µg/ml-200 µg/ml and the non-mucoid isolate with 1000 µg/ml-100 µg/ml. 
 
 
3.2.4 Growth Curve Analysis 
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Growth curve analysis was monitored as specified in Chapter 2 with the following 
additions. Flasks containing 0.45% (v/v) absolute ethanol in M9 media was prepared as 
vehicle controls. 
 
3.2.5 Bacterial Adherence Assays 
 
 
 
Attachment assays were performed as detailed in Chapter 2 with the following 
addition. Triplicate vehicle control wells were plated containing 0.45% (v/v) absolute 
ethanol for each trial in both assays. 
 
3.2.6 Virulence Factor Production 
 
 
 
Virulence factor production was measured as outlined in Chapter 2 with minor 
addition of a vehicle control flasks containing M9 media supplemented with 0.45% (v/v) 
abolsute ethanol. 
 
3.2.7 Motility Assays 
 
 
 
Motility experiments were performed as stated in Chapter 2 with the addition of 
plates containing 0.45% (v/v) absolute ethanol produced as vehicle controls. 
 
3.2.8 Genomic Expression Analysis 
 
 
 
Expression analysis was performed and analyzed as outlined in Chapter 2 with the 
following exemptions. Thymol at a 0.5 MIC concentration was repeated for 3 trials at 
both 6 h and 24 h of incubation. Carvacrol treatment was only repeated twice at 0.5 MIC 
 
concentration for 24 h. 
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3.2.9 Microarray Processing 
 
 
 
Microarray processing and data analysis was completed as specified in Chapter 2. 
 
 
3.2.10 Statistics 
 
 
 
Statistical analysis was performed as outlined in Chapter 2 with the additions of 
vehicle control data compared to untreated controls to determine the presence of 
statistical differences. 
108  
3.3 Results 
 
 
 
3.3.1 Minimum Inhibitory Concentration of Thymol or Carvacrol 
 
 
 
Through microdilutions of both thymol and carvacrol and visual growth 
assessment, the MIC concentration of either compound was determined. Both compounds 
were unable to inhibit growth of PAO1 up to concentrations of 2000 µg/ml in the M9 
media (Table 2.1B). For both compounds in the M9 media, the mucoid clinical isolate 
showed greater tolerance with MIC values higher than that of the non-mucoid isolate. 
The mucoid isolate had MIC values of 1200 µg/ml and 1000 µg/ml for thymol and 
carvacrol respectively (Table 2.1B).  The non-mucoid isolate gave MIC values of 600 
µg/ml and 800 µg/ml for thymol and carvacrol, respectively, in the M9 media (Table 2.1 
 
B). Treatment in the MHCA media reduced MIC values for all strains, however general 
trends between strains remained (Table 2.1A). 
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Table 2.1: Minimum inhibitory concentrations (MIC) of P. aeruginosa treated with 
thymol or carvacrol. MIC values were determined through microdilution series of either 
extract in 96 well plates, denoting the MIC value by visual growth assessment. 
Experiments were repeated three times (n=3) in duplicate in either both Mueller-Hinton 
cation adjusted broth (MHCA) (Table 2.1 A) and M9 supplemented media (Table 2.1 B) 
 
Table 2.1A  Minimum inhibitory concentration of thymol or carvacrol in MHCA 
  media   
  Strain  Thymol (µg/ml)  Carvacrol (µg/ml)   
PAO1 1200-1050 1200-1050 
Mucoid Isolate 150 450 
  Non-mucoid Isolate  150  300   
 
 
 
Table 2.1 B Minimum inhibitory concentration of thymol or carvacrol in M9 
  media   
  Strain  Thymol (µg/ml)  Carvacrol (µg/ml)   
PAO1 >2000 >2000 
Mucoid Isolate 1200 1000 
  Non-mucoid Isolate  600  800   
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3.3.2 Effect of Thymol or Carvacrol Treatment on Bacterial Growth 
 
 
 
Growth of P. aeruginosa in the presence of either thymol or carvacrol was 
assessed for 48 h and no statistically significant influence on growth rate were found for 
either treatment on any of the strains tested (Figure 2.2, 2.3). 
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Figure 2.2: Growth curve analysis in the presence of the sub-inhibitory 
concentrations of thymol. Growth in the presence of sub-inhibitory concentrations of 
thymol was assessed for 48 h at 37 ˚C with 150 rpm shaking. After 0, 6, 24, and 48 h of 
incubation, 1ml of culture was removed and the absorbance at 600 nm was measured. All 
values were normalized to the time 0 absorbance. Experiments were repeated three times 
(n=3) and data is represented as an average ± SEM. Statistical comparisons to the 
untreated control for each treatment was done through a repeated-measures ANOVA and 
subsequent Tukey’s post-hoc test. 
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Figure 2.3: Growth curve analysis in the presence of sub-inhibitory oncentrations of 
carvacrol. Growth in the presence of sub-inhibitory concentrations of carvacrol was 
assessed for 48 h at 37 ˚C with 150 rpm shaking. After 0, 6, 24, and 48 h of incubation, 1 
ml of culture was removed and the absorbance at 600 nm was measured. All values were 
normalized to the time 0 absorbance. Experiments were repeated three times (n=3) and 
data is represented as an average ± SEM. Statistical comparisons to the untreated control 
for each treatment was done through a repeated-measures ANOVA and subsequent 
Tukey’s post-hoc test. 
113  
3.3.3 Effect of Thymol or Carvacrol Treatment on Preventing Bacterial 
Attachment 
 
 
 
The assessment of bacterial adherence in the presence of either thymol or 
carvacrol was measured by crystal violet staining of the adhered bacteria. For both PAO1 
and the non-mucoid clinical isolates, no significant differences in adherence were 
measured under any treatment (Figure 2.4: A, C). No significant differences were 
measured between bacteria grown in the untreated controls or ethanol vehicle controls for 
either strain as well. A significant reduction in bacterial adherence was measured for the 
mucoid clinical isolate challenged with carvacrol at either concentration (Figure 2.4: B), 
while a significance increase was found with the ethanol vehicle alone. 
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Figure 2.4: The effect of thymol and carvacrol treatment on the prevention of P. 
aeruginosa adherence. Bacteria were grown in the presence of 0.25 MIC and 0.50 MIC 
concentrations of either compound in 96 well flat bottom plates for 24 h at 37 ˚C. Post 
incubation, plates were washed with distilled water and adhered bacteria were stained 
with a 0.1% crystal violet stain and solubilized stain was measured at an absorbance of 
600 nm. Average adherence of the ethanol vehicle is also shown as a percentage of the 
untreated control ± SEM (n=3). Statistical comparisons to the untreated control for each 
treatment were performed through an ANOVA analysis and Tukey’s post hoc test (p- 
value < 0.05=*, p-value < 0.01=**). 
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3.3.4 Effect of Thymol or Carvacrol Treatment on Preformed Biofilms 
 
 
 
The treatment of 48 h old biofilms with thymol or carvacrol at 1.0 MIC and 2.0 
 
MIC concentrations was assessed and measured through crystal violet stain absorbance at 
 
600 nm. Treatment of the mucoid clinical isolate with either compound at both 
concentrations caused significant decreases in biofilm adherence (Figure 2.5: B). The 
increased biofilm adherence of the mucoid isolate ethanol vehicle control was again 
observed (Figure 2.5: B). Both the laboratory PAO1 and non-mucoid strain showed no 
significant changes with either treatment (Figure 2.5: A, C), as well as no differences 
between the vehicle control and untreated control. 
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Figure 2.5: The effect of thymol and carvacrol treatment on 48 h P. aeruginosa 
biofilms. Bacteria were allowed to adhere to a 96 well flat bottom plates for 48 h at 37 
˚C. Post incubation, wells were washed with distilled water and bacteria were treated with 
either compound at 1.0 MIC and 2.0 MIC concentrations for 24 h at 37 ˚C. After 
treatment, wells were washed with distilled water and adhered bacteria were stained with 
a 0.1% crystal violet stain and solubilized stain was measured at an absorbance of 600 
nm. Experiments were repeated three times in triplicate and expressed as an average 
percentage of the untreated control ± SEM. Average adherence of the ethanol vehicle is 
also displayed as a percentage of the untreated control ± SEM (n=3). Statistical 
comparisons to the untreated control for each treatment was done through a one-way 
ANOVA and subsequent Tukey’s post-hoc test (p-value < 0.05= *, p-value < 0.01= **, 
p-value < 0.001= ***). 
117  
3.3.5 Effect of Thymol or Carvacrol Treatment on P. aeruginosa Pigment 
Production 
 
 
 
Pyoverdine production by P. aeruginosa was measured by an absorbance reading 
of the supernatant of cultures grown in the presence of either compound at sub-inhibitory 
concentrations. Either treatment had very minimal effects towards the production of 
pyoverdine in PAO1 (Figure 2.6: A). The mucoid isolate displayed significant decreases 
in pyoverdine measurement with treatment of either compounds at both concentrations 
(Figure 2.6: B). Like the PAO1 strain, no difference between untreated controls and 
vehicle controls were found for the mucoid isolate. In contrast, the non-mucoid isolate 
displayed decreases in pyoverdine with the vehicle control and treatment of either 
compound at 0.50 MIC concentrations (Figure 2.6: C). Treatment of the non-mucoid 
strain with 0.25 MIC concentrations caused a significant decrease in pyoverdine with 
thymol exposure, but had no significant effect with carvacrol exposure (Figure 2.6: C). 
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Figure 2.6: The effect of thymol and carvacrol treatment on the production of the 
pigment pyoverdine. Bacterial cultures were prepared and incubated in the presence of 
0.25 MIC and 0.5 MIC concentrations of either compound for 24 h at 37 ˚C & 150rpm. 
Cultures were then centrifuged to remove cells, filtered, and 1 ml of supernatant was 
assayed in a spectrometer at 405 nm. Data represents averaged mean values of three 
independent experiments preformed in duplicate, and expressed as a percentage of 
untreated controls ± SEM. Average absorbance of the ethanol vehicle is also displayed as 
a percentage of the untreated control ± SEM (n=3). Statistical significance was 
determined through one-way ANOVA analysis followed by Tukey’s post-hoc test to 
determine significance relative to the untreated controls (p-value <0.05= *, p-value < 
0.01= **, and p-value < 0.01= ***). 
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3.3.6 Outcome of Thymol or Carvacrol Treatment on Bacterial Lipase and 
Protease Production 
 
 
 
Milk agar plate hydrolysis was used to measure the production and secretion of 
protease in cultures grown in the presence of either thymol or carvacrol. Significant 
decreases in protease measurement were found for PAO1 when grown in the presence of 
either compound at a 0.5 MIC concentration (Figure 2.7: A). Less definitive results were 
found for the mucoid clinical isolate in which neither treatment had a significant effect on 
the protease production (Figure 2.7: B). The greatest effect of treatment was found 
towards the non-mucoid strain, for which both the vehicle control and 0.50 MIC 
concentration of either compound reduced protease production to a level below 
measurement (Figure 2.7: C). 
 
Lipase Tween 20 hydrolysis assays was used to measure the production of such 
enzyme under the influence of thymol or carvacrol treatment.  Treatment of PAO1 with 
either compound at sub-inhibitory concentrations caused significant increases in the 
lipase production (Figure 2.8: A). In contrast, reductions in lipase were found for the 
mucoid clinical isolate when subjected to either treatment at both concentrations, as well 
as with the vehicle control (Figure 2.8: B). Results for the non-mucoid isolate displayed 
decreases with vehicle control for both treatments, increases with carvacrol treatment at 
0.25 MIC concentration, and decreases with carvacrol and thymol exposure at 0.50 MIC 
 
and 0.25 MIC concentrations respectively (Figure 2.8: C). 
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Figure 2.7: Protease production in the presence of thymol or carvacrol.  Bacterial 
cultures were prepared and incubated in the presence of 0.25 MIC and 0.5 MIC 
concentrations of either compound for 24 h at 37 ˚C & 150 rpm. Cultures were then 
centrifuged to remove cells and remaining supernatants were filter sterilized. To a single 
center well of a 1% skim milk plate (1.5% agar), 50 µl of filtered supernatant was added 
and plates were incubated at 37 ˚C for 24 h. The zone of clearance around the inoculation 
well was measured with a ruler (mm). Data is represented as the average of three separate 
experiments conducted in duplicate ± SEM. Average zone of clearance of the ethanol 
vehicle is also displayed as a percentage of the untreated control ± SEM (n=3).  Statistical 
significance was determined through one-way ANOVA analysis followed by Tukey’s 
post-hoc test to determine significance relative to the untreated controls (p-value<0.05= * 
and p-value < 0.01= **). 
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Figure 2.8: Lipase production in the presence of thymol or carvacrol.  Bacterial 
cultures were prepared and incubated in the presence of 0.25 MIC and 0.5 MIC 
concentrations of either compound for 24 h at 37 ˚C & 150 rpm. Cultures were then 
centrifuged to remove cells and remaining supernatants were filter sterilized. To a glass 
test tube, 2.3 ml of 0.50 M tris buffer (pH 7.6), 0.1 ml 0.1 M CaCl2 in tris buffer (pH 7.6), 
0.1 ml tween 20 in tris buffer (pH 7.6), and 0.5 ml filtered supernatant were combined 
and incubated at 37 ˚C & 150 rpm for 4 h. After incubation, 1 ml was removed and 
measured in a spectrophotometer at 400 nm.  Data represents the mean value of three 
independent experiments preformed in duplicate and expressed as a percentage of the 
control ± SEM. Average absorbance of the ethanol vehicle is also displayed as a 
percentage of the untreated control ± SEM (n=3). Statistical significance was determined 
through one-way ANOVA analysis and Tukey’s post hoc test (p-value < 0.05=*, p-value 
< 0.01=**, p-value < 0.001=***). 
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3.3.7 Influence of Thymol or Carvacrol Treatment on P. aeruginosa Motility 
 
 
 
The addition of either compound to media plates containing 0.3% agarose was 
used to determine the motility of bacteria in the presence of thymol or carvacrol. 
Significant decreases in motility with either treatment at sub-inhibitory concentrations, 
and with the vehicle control, were observed with PAO1 (Figure 2.9: A). Interestingly, the 
vehicle control did not cause statistically significant decreases in swimming motility for 
either clinical isolate. Significant decreases in motility with treatment of either thymol or 
carvacrol at a 0.50 MIC concentration was found for both clinical strains (Figure 2.9: B, 
C). At the 0.25 MIC concentration thymol significantly decreases motility in the mucoid 
isolate, while carvacrol at the same concentration caused decreases in the non-mucoid 
isolate (Figure 2.9: B, C). 
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Figure 2.9: Motility in the presence of thymol and carvacrol.  Plates comprising 0.125 
MIC and 0.25 MIC concentrations of either thymol or carvacrol and 0.3% agarose were 
point inoculated with bacterial cultures. Plates were incubated at 37 ˚C for 12 h (A) or 36 
h (B, C). Distance travelled through the media was measured after incubation with a ruler 
(mm). Data is represented as the average of three separate experiments conducted in 
duplicate ± SEM. Average distance travelled of the ethanol vehicle is also displayed as a 
percentage of the untreated control ± SEM (n=3). Statistical significance was determined 
through one-way ANOVA analysis followed by Tukey’s post-hoc test to determine 
significance relative to the untreated controls (p-value < 0.01= ** and p-value < 0.001= 
***). 
124  
3.3.8 Effects of Thymol and Carvacrol Treatment on P. aeruginosa Gene 
Expression 
 
 
 
Gene expression changes from the microarray analysis of the laboratory PAO1 
strain revealed significant expressional changes with thymol treatment at both 6 h and 24 
h, as well as carvacrol treatment at 24 h. Treatment of the bacteria for 24 h with carvacrol 
had the greatest influence on bacterial gene expression, while the 24 h treatment of 
thymol displayed the least. The 6 h thymol exposure caused the greatest population of 
genes to decrease their expression, many of which are involved in virulence factor 
production. 
 
With the 6 h thymol treatment a pair of genes involved in pyochelin biosynthesis 
(pchC, pchD) was significantly upregulated (Table 2.2 A). Additionaly, four genes 
involved in pyoverdine biosynthesis (pvdA, pvdO, pvdH, and pvdS) were likewise 
upregulated after 6 h exposure to thymol (Table 2.2 A). As seen with the 6hr aqueous 
treatment multiple genes involved in iron binding (hitA), and heme acquisition (TonB, 
phuR) were significantly upregulated with the 6hr thymol treatment. 
 
Of these genes down regulated by the 6 h thymol treatment, 4 genes involved in 
the biosynthesis of phenazine were down regulated in expression. The virulence factor 
elastase gene lasB was also negatively affected by exposure to thymol for 6 h. 
Additionally, the 6 h thymol treatment reduced the expression of chitin-binding protein 
precursor gene cbpD and fucose-binding lectin gene lecB, two genes involved in bacterial 
adherence during host interactions (Table 2.2 A). Treatment of P. aeruginosa for 24 h 
with thymol only induced significant changes to three genes. Notably, bacterioferritin 
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gene bfrB and a low Mg
2+ 
inducible outer membrane protein precursor gene oprH were 
significantly upregulated (Table 2.2 B). 
 
In contrast to the 24 h thymol treatment, 96 genes were significantly affected by 
the treatment of P. aeruginosa with carvacrol for 24 h (Table 2.2 C). The only down 
regulated gene with known function was the narH gene which codes for a respiratory 
nitrate reductase protein involved in nitrogen metabolism. Significantly upregulated were 
18 genes encoding 50S ribosome structure components and 9 encoding 30S ribosome 
structure components. Multiple genes involved in protein synthesis and folding (fusA1, 
rpoA) were also significantly upregulated after 24 h treatment (Table 2.2 C). Several 
genes involved in iron acquisition and storage (bfrB, pchA, pchF, pchG, pvdH, pvdJ, 
pvdD, and pvdL) were found to be upregulated with the 24 h carvacrol treatment, of 
which bacterioferritin was upregulated the most. Two genes involved in bacterial flagella 
production, fliF a flagella M-ring outer membrane protein precursor and fliD a flagellar 
capping protein were both increased with the 24 h carvacrol treatment (Table 2.2 C). 
Comparisons of the carvacrol 24 h treatment and the thymol 24 h treatment mainly 
displayed increased changes to gene expression in the carvacrol over thymol treatment. 
The 24 h thymol treatment had a greater expression than 24 h carvacrol treatment for only 
a single gene, fis, a gene coding for a DNA-binding protein. 
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Table 2.2: Significant gene fold changes after exposure to thymol or carvacrol. RNA 
isolated from bacteria grown in the presence of the either thymol for 6 or 24 h and 
carvacrol for 24 h at a 500 µg/ml concentration was analysed through the Affymetrix 
Pseudomonas aeruginosa GeneChip array. Partek multi-way ANOVA analysis was 
performed to assess significant differences in the expression of genes when compared to 
RNA from untreated controls. Only genes displaying increased or decreased expression 
of a ≥2.0 fold change were considered significant. 
 
Table 2.2 A: Significant gene expression changes with 6 h thymol treatment (n=3) 
when compared to 6 h control (n=3) 
 
Probeset ID Gene 
Symbo 
l 
 Gene Title p-value Fold 
Chang 
e 
PA4228_pchD_a 
t 
pchD pyochelin biosynthesis protein 
PchD 
0.00580222 3.4389 
1 
PA1983_exaB_a 
t 
exaB cytochrome c550 0.0133731 3.2090 
6 
PA2386_pvdA_a 
t 
pvdA L-ornithine N5-oxygenase 0.0278372 3.0750 
9 
PA4570_at --- ---  0.0107843 3.0014 
6 
PA4761_dnaK_a 
t 
dnaK DnaK protein 0.00818894 2.7996 
PA4385_groEL_ 
at 
groEL GroEL protein 0.0125542 2.7418 
7 
PA4229_pchC_a 
t 
pchC pyochelin biosynthetic protein 
PchC 
0.00098617 
6 
2.7141 
2 
PA2452_at --- ---  0.014839 2.6963 
7 
PA4710_at phuR Haem/Haemoglobin uptake outer 
membrane receptor PhuR precursor 
0.00803246 2.6877 
1 
PA4471_at --- ---  0.0432388 2.6723 
9 
PA4386_groES_ 
at 
groES GroES protein 0.0153828 2.6118 
6 
PA2426_pvdS_a 
t 
pvdS sigma factor PvdS 0.0264479 2.4496 
8 
PA5559_atpE_at atpE atp synthase C chain 0.0464143 2.4198 
2 
PA4370_at icmP Insulin-cleaving metalloproteinase 
outer membrane protein precursor 
0.0218232 2.3783 
PA4469_at --- ---  0.0428466 2.3033 
4 
PA2395_at pvdO PvdO  0.0139955 2.3019 
PA4762_grpE_at grpE heat shock protein GrpE 0.00116947 2.2858 
2   
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PA0070_at --- --- 0.00163887 2.2453 
2 
PA5531_tonB_at tonB TonB protein 0.0442122 2.1671 
2 
PA2413_at pvdH L-2,4-diaminobutyrate:2- 
ketoglutarate 4-aminotransferase, 
PvdH 
0.0288235 2.1650 
8 
PA1982_exaA_a 
t 
exaA quinoprotein alcohol 
dehydrogenase 
0.0132604 2.1583 
5 
PA0085_at --- --- 5.27E-05 2.1529 
6 
PA3720_at --- --- 0.00441056 2.1339 
3 
PA0083_at --- --- 0.00159987 2.1308 
2 
PA1718_pscE_at pscE type III export protein PscE 0.00474154 2.1274 
3 
PA1719_pscF_at pscF type III export protein PscF 0.00093621 
8 
2.1124 
1 
PA3785_at --- --- 0.00143257 2.0998 
6 
PA1984_s_at --- --- 0.00440302 2.0961 
7 
PA4687_hitA_at hitA ferric iron-binding periplasmic 
protein HitA 
0.00747976 2.0864 
9 
PA0905_csrA_at rsmA RsmA, regulator of secondary 
metabolites 
0.0120737 2.0515 
7 
PA1151_imm2_ 
at 
imm2 pyocin S2 immunity protein 0.0392814 2.0374 
PA3570_mmsA_ 
at 
mmsA methylmalonate-semialdehyde 
dehydrogenase 
0.0331027 2.0315 
3 
PA4467_at --- --- 0.0147382 2.0219 
5 
PA0400_at --- --- 0.027226 2.0114 
PA0179_at --- --- 0.0407447 - 
2.0006 
5 
PA1789_at --- --- 0.0396622 - 
2.0024 
4 
PA4306_at --- --- 0.00015321 
9 
- 
2.0137 
5 
PA2069_at --- --- 0.00411611 - 
2.0290 
2   
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PA3724_lasB_at lasB elastase LasB 0.0170161 - 
2.0542 
5 
PA1914_at --- --- 9.35E-05 - 
2.0556 
5 
PA0852_cpbD_a 
t 
cbpD chitin-binding protein CbpD 
precursor 
0.00847351 - 
2.0620 
9 
PA5475_at --- --- 0.0259862 - 
2.0667 
1 
PA5232_at --- --- 0.0155643 - 
2.0927 
9 
PA1876_at --- --- 0.00015564 
4 
- 
2.1095 
5 
PA1874_at --- --- 1.14E-05 - 
2.2460 
6 
PA3309_at --- --- 0.0326791 - 
2.2533 
8 
PA4211_g_at phzB1 / 
phzB2 
probable phenazine biosynthesis 
protein /// probable phenazine 
biosynthesis protein 
0.00578668 - 
2.3212 
PA5027_at --- --- 0.00320747 - 
2.3964 
2 
PA2788_at --- --- 0.00075687 
8 
- 
2.5611 
5 
PA1901_s_at phzC1 / 
phzC2 
phenazine biosynthesis protein 
PhzC /// phenazine biosynthesis 
protein PhzC 
5.28E-05 - 
2.7065 
4 
PA1746_at --- --- 0.0123516 - 
2.7302 
8 
PA1903_s_at phzE1 / 
phzE2 
phenazine biosynthesis protein 
PhzE /// phenazine biosynthesis 
protein PhzE 
5.07E-05 - 
3.0101 
2 
PA4352_at --- --- 0.00525222 - 
3.4892 
7 
PA1561_aer_at aer aerotaxis receptor Aer 0.00065044 - 
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5 3.6924 
3 
PA4141_at --- --- 0.00497458 - 
3.8329 
8 
PA0122_at --- --- 0.00015714 - 
3.9471 
3 
PA4217_at phzS flavin-containing monooxygenase 0.00020329 
7 
- 
3.9569 
4 
PA1904_s_at phzF1 / 
phzF2 
probable phenazine biosynthesis 
protein /// probable phenazine 
biosynthesis protein 
4.09E-06 - 
4.1142 
8 
PA1905_s_at phzG2 probable pyridoxamine 5'- 
phosphate oxidase 
6.19E-08 - 
4.6534 
1 
PA3361_at lecB fucose-binding lectin PA-IIL 0.00018876 
3 
- 
5.4199 
  6   
 
 
Table 2.2 B: Significant gene expression changes with 24 h thymol treatment (n=3) 
when compared to 24 h control (n=3) 
 
Probeset ID Gene 
Symbol 
Gene Title p-value Fold 
Change 
PA3531_bfrB_ 
at 
bfrB bacterioferritin 0.0021764 
3 
2.92487 
PA0122_at --- --- 0.0048760 
7 
2.42434 
PA1178_oprH_ 
at 
oprH PhoP/Q and low Mg2+ inducible 
outer membrane protein H1 
precursor   
0.0468215 2.10623 
 
 
Table 2.2 C: Significant gene expression changes with 24 h carvacrol treatment 
(n=2) when compared to 24 h control (n=3) 
 
Probeset ID Gene 
Symbol 
 Gene Title p-value Fold 
Chang 
e 
PA4272_rplJ_at rplJ 50S ribosomal protein L10 0.002359 7.2286 
PA4257_rpsC_at rpsC 30S ribosomal protein S3 0.00793631 6.4436 
9 
PA4141_at --- ---  0.00116285 6.3133 
3   
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PA4258_rplV_at rplV 50S ribosomal protein L22 0.00143535 6.2667 
5 
PA4273_rplA_at rplA 50S ribosomal protein L1 0.00363265 5.9756 
3 
PA4260_rplB_at rplB 50S ribosomal protein L2 0.00220167 5.5979 
PA1592_i_at --- --- 0.0311538 5.4882 
PA4251_rplE_at rplE 50S ribosomal protein L5 0.00212694 5.1397 
3 
PA4256_rplP_at rplP 50S ribosomal protein L16 0.00537229 4.9950 
1 
PA3531_bfrB_at bfrB bacterioferritin 0.00021249 
3 
4.9517 
4 
PA4250_rpsN_at rpsN 30S ribosomal protein S14 0.00743626 4.8928 
7 
PA4274_rplK_at rplK 50S ribosomal protein L11 0.0129355 4.7288 
1 
PA4220_i_at --- --- 0.0101216 4.6633 
4 
PA2840_at --- --- 0.00095053 
1 
4.6513 
5 
PA4262_rplD_at rplD 50S ribosomal protein L4 0.00559478 4.5892 
6 
PA4240_rpsK_at rpsK 30S ribosomal protein S11 0.00744515 4.4808 
8 
PA3337_rfaD_at rfaD ADP-L-glycero-D-mannoheptose 
6-epimerase 
0.00092957 
5 
4.4382 
8 
PA0999_fabH1_ 
at 
pqsD 3-oxoacyl-[acyl-carrier-protein] 
synthase III 
5.11E-05 4.3116 
7 
PA5427_adhA_a 
t 
adhA alcohol dehydrogenase 0.00989624 4.1693 
6 
PA2976_rne_at rne ribonuclease E 0.00014523 
8 
4.1566 
9 
PA3692_at --- --- 0.00111357 4.1097 
4 
PA4933_at --- --- 0.00715716 4.0187 
1 
PA3309_at --- --- 0.00299713 3.9871 
3 
PA4263_rplC_at rplC 50S ribosomal protein L3 0.00416207 3.8682 
3 
PA4352_at --- --- 0.00697342 3.8026 
7 
PA4254_rpsQ_at rpsQ 30S ribosomal protein S17 0.0207891 3.7252 
9 
PA4244_rplO_at rplO 50S ribosomal protein L15 0.00663231 3.6196 
5   
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PA4266_fusA1_ 
at 
fusA1 elongation factor G 0.0383887 3.5775 
9 
PA4261_rplW_a 
t 
rplW 50S ribosomal protein L23 0.0139266 3.5464 
6 
PA0998_at pqsC Homologous to beta-keto-acyl- 
acyl-carrier protein synthase 
0.00027327 
8 
3.4492 
1 
PA3691_at --- --- 0.0052331 3.4420 
3 
PA2853_oprI_at oprI Outer membrane lipoprotein OprI 
precursor 
0.00071742 
3 
3.3225 
7 
PA4259_rpsS_at rpsS 30S ribosomal protein S19 0.0112981 3.2716 
6 
PA4264_rpsJ_at rpsJ 30S ribosomal protein S10 0.0184413 3.2388 
3 
PA2400_at pvdJ PvdJ 0.00270135 3.1571 
6 
PA0836_at --- --- 0.00083156 
4 
3.0813 
3 
PA4245_rpmD_ 
at 
rpmD 50S ribosomal protein L30 0.0328426 3.0407 
6 
PA4248_rplF_at rplF 50S ribosomal protein L6 0.0283239 3.0181 
5 
PA4247_rplR_at rplR 50S ribosomal protein L18 0.0304193 3.0138 
3 
PA0997_at pqsB Homologous to beta-keto-acyl- 
acyl-carrier protein synthase 
0.00025980 
2 
3.0065 
9 
PA2412_at --- --- 0.0283858 2.9782 
6 
PA0962_at --- --- 0.036133 2.9601 
2 
PA2753_at --- --- 0.00190587 2.9554 
7 
PA4222_at --- --- 1.00E-05 2.8990 
1 
PA2399_pvdD_a 
t 
pvdD pyoverdine synthetase D 0.00051869 
3 
2.8983 
3 
PA4238_rpoA_a 
t 
rpoA DNA-directed RNA polymerase 
alpha chain 
0.0299189 2.8399 
7 
PA2411_at --- --- 0.00137807 2.8341 
8 
PA4464_ptsN_at ptsN nitrogen regulatory IIA protein 0.0024572 2.8122 
PA1094_fliD_at fliD flagellar capping protein FliD 0.0172256 2.8064 
3 
PA0763_mucA_ 
at 
mucA anti-sigma factor MucA 0.0109717 2.7511 
6 
PA1777_oprF_at oprF Major porin and structural outer 0.00895102 2.7191 
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membrane porin OprF precursor 5 
PA4935_rpsF_at rpsF 30S ribosomal protein S6 0.0497944 2.6889 
PA4253_rplN_at rplN 50S ribosomal protein L14 0.0363175 2.6422 
1 
PA2248_bkdA2 
_at 
bkdA2 2-oxoisovalerate dehydrogenase 
(beta subunit) 
0.00366905 2.6218 
7 
PA2413_at pvdH L-2,4-diaminobutyrate:2- 
ketoglutarate 4-aminotransferase, 
PvdH 
0.0196846 2.5458 
5 
PA4246_rpsE_at rpsE 30S ribosomal protein S5 0.0365724 2.5124 
4 
PA4249_rpsH_at rpsH 30S ribosomal protein S8 0.00609997 2.4977 
9 
PA1245_at --- --- 0.00011786 
2 
2.4973 
6 
PA2742_rpmI_at rpmI 50S ribosomal protein L35 0.0489776 2.4707 
PA4577_at --- --- 0.0244596 2.4646 
2 
PA2427_at --- --- 0.0201159 2.4243 
1 
PA4225_pchF_a 
t 
pchF pyochelin synthetase 0.00416639 2.3969 
7 
PA5232_at --- --- 0.0130006 2.3479 
7 
PA1561_aer_at aer aerotaxis receptor Aer 0.0249822 2.2948 
6 
PA2741_rplT_at rplT 50S ribosomal protein L20 0.0415698 2.2703 
9 
PA2401_at --- --- 0.0289641 2.2356 
1 
PA0996_at pqsA probable coenzyme A ligase 0.00016627 
3 
2.2288 
7 
PA5027_at --- --- 0.0113877 2.2219 
5 
PA4224_at pchG pyochelin biosynthetic protein 
PchG 
0.0106176 2.2201 
PA4237_rplQ_at rplQ 50S ribosomal protein L17 0.0450652 2.1995 
6 
PA4223_at --- --- 9.18E-05 2.1911 
3 
PA1789_at --- --- 0.0416973 2.1536 
PA3572_at --- --- 0.0416658 2.1129 
7 
PA2250_lpdV_a 
t 
lpdV lipoamide dehydrogenase-Val 0.0257921 2.1061 
7 
PA4231_pchA_a pchA salicylate biosynthesis 1.52E-05 2.0964 
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t  isochorismate synthase  3 
PA2146_i_at --- --- 0.0447527 2.0775 
9 
PA0345_at --- --- 0.0166682 2.0395 
3 
PA3788_at --- --- 0.0101504 2.0361 
6 
PA2402_at --- --- 0.0142658 2.0313 
1 
PA1101_fliF_at fliF Flagella M-ring outer membrane 
protein precursor 
0.00690666 2.0096 
9 
PA2424_at pvdL PvdL 0.00081280 
2 
2.0086 
8 
PA0740_at --- --- 0.0474676 - 
2.0087 
4 
PA4638_at --- --- 0.0275454 - 
2.0127 
3 
PA3874_narH_a 
t 
narH respiratory nitrate reductase beta 
chain 
0.0104611 - 
2.0326 
5 
PA0445_s_at --- --- 0.0298365 -2.0611 
PA4033_at --- --- 0.0417178 - 
2.1204 
8 
PA2029_i_at --- --- 0.0134619 - 
2.3736 
8 
PA3600_at --- --- 0.01666 - 
2.4018 
3 
PA1942_at --- --- 0.0121489 - 
2.4749 
4 
PA3577_i_at --- --- 0.00269391 - 
2.5233 
5 
PA4877_at --- --- 0.00759684 - 
2.5459 
6 
PA5250_at --- --- 0.0346362 -2.719 
134 
 
3.3.9 Gene-Ontology Enrichment Analysis of P. aeruginosa Treated with 
Thymol or Carvacrol 
 
 
 
Gene ontology (GO) enrichment analysis of P. aeruginosa with 6 h and 24 h 
thymol treatment and 24 h carvacrol treatment revealed significant changes to various 
groups of expressed genes (Table 2.3). Six hour thymol exposure caused a significant 
enrichment in transcripts of 10 gene groups, of which the most enriched gene group was 
that of antibiotic biosynthetic processes which were enriched by a factor of 15.26 with 
50% of the genes in the group significantly affected. Other major gene groups affected 
include those involved in the extracellular region and those dealing with siderophore 
transmembrane transporter activity, whose transcripts were enriched by a factor of 5.61 
and 5.49 respectively. In addition genes groups related to DNA transcription and 
initiation, and protein folding and transport were enriched after the 6 h treatment of 
thymol. 
 
GO-enrichment analysis of the 24 h thymol treatment resulted in less reliable 
results. With only three genes showing significant up-regulation (≥ ±2 fold change) the 
ability to group genes based on similarities in function is reduced. Therefore although 
many gene groups display enrichment scores of significance (Table 2.3 B), the true 
significance of the data is only based on a very small number of genes indicated by the 
low percentage of genes responding and significantly altered by the treatment in each 
group. Therefore data presented in Table 2.3 B should be taken as inconclusive. In 
relation to the three genes which were significantly upregulated with the 24 h thymol 
treatment GO-enrichment analysis showed increased enrichment for iron-sulfur cluster 
135 
 
assembly, siderophore transmembrane transporter activity, response to antibiotics, and 
type II protein secretion system. 
 
With the 24 h carvacrol GO-enrichment analysis several gene groups relating to 
ribosome structure and function were enriched (Table 2.3 C). Of particular importance, 
gene groups relating to the structural constituent of ribosomes, translation, and RNA 
binding were given enrichment scores of 67.62, 51.49, and 49.86 respectively. The 
percentage of genes present in each of threse groupings ranged from approximately 30- 
52%. Gene groups of ribonuclease activity, regulation of translation, and ribosome 
biogenesis were similarly enriched with 24 h carvacrol treatment. Enrichment of 
intracellular and cellular protein metabolic genes was also found with scores of 35.82 and 
34.44. Protein binding, cell adhesion, and fatty acid biosynthesis gene groups were also 
enriched with the 24 h carvacrol treatment. 
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Table 2.3: Gene ontology (GO) enrichment analysis of P. aeruginosa after exposure 
to the thymol or carvacrol. From genes deemed significantly increased by a factor of 
≥2.0 fold change, genes were grouped based on similar GO functions and differences in 
overall group enrichment compared to the control was performed through a Fisher’s 
Exact Test. Only those gene groups with an enrichment p-value > 0.05 are displayed. 
 
Table 2.3 A: GO-enrichment of 6 h thymol treatment (n=3) compared to 6 h control 
(n=3) 
 
Function Type Enrichme 
nt Score 
Enrichmen 
t p-value 
% genes 
in group 
that are 
present 
antibiotic biosynthetic process biological 
process 
15.2649 2.34713E- 
07 
50 
extracellular region cellular 
componen 
t 
5.61263 0.00365145 15.7895 
siderophore transmembrane 
transporter activity 
molecular 
function 
5.49565 0.00410459 33.3333 
oxidoreductase activity, acting on 
CH-OH group of donors 
molecular 
function 
4.89265 0.00750153 25 
metalloendopeptidase activity molecular 
function 
4.6519 0.00954348 22.2222 
DNA-templated transcription, 
initiation 
biological 
process 
4.6519 0.00954348 22.2222 
ATP biosynthetic process biological 
process 
4.43931 0.0118041 20 
oxidoreductase activity, acting on 
the aldehyde or oxo group of 
donors, NAD or NADP as 
acceptor 
molecular 
function 
3.77724 0.0228858 14.2857 
protein folding biological 
process 
3.59544 0.0274485 7.69231 
protein transport biological 
process   
3.11241 0.0444937 6.38298 
 
 
Table 2.3 B: GO-enrichment of 24 h thymol treatment (n=3) compared to 24 h 
control (n=3) 
 
Function Type Enrichmen 
t Score 
Enrichme 
nt p-value 
% genes 
in group 
that are 
present 
ACP phosphopantetheine 
  attachment site binding involved   
molecular 
function   
5.04199 0.0064608 
6   
33.3333 
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in fatty acid biosynthetic process 
alkaline phosphatase activity molecular 
function 
5.04199 0.0064608 
6 
33.3333 
chorismate mutase activity molecular 
function 
5.04199 0.0064608 
6 
33.3333 
cysteine synthase activity molecular 
function 
5.04199 0.0064608 
6 
33.3333 
glucose-6-phosphate 
dehydrogenase activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
glutamate-cysteine ligase activity molecular 
function 
5.04199 0.0064608 
6 
33.3333 
phosphoribosylglycinamide 
formyltransferase activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
phosphorylase activity molecular 
function 
5.04199 0.0064608 
6 
33.3333 
protein kinase activity molecular 
function 
5.04199 0.0064608 
6 
33.3333 
protein tyrosine phosphatase 
activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
shikimate 3-dehydrogenase 
(NADP+) activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
spermidine synthase activity molecular 
function 
5.04199 0.0064608 
6 
33.3333 
inorganic phosphate 
transmembrane transporter 
activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
sugar:hydrogen symporter 
activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
extracellular space cellular 
component 
5.04199 0.0064608 
6 
33.3333 
transposition, DNA-mediated biological 
process 
5.04199 0.0064608 
6 
33.3333 
transcription initiation from RNA 
polymerase II promoter 
biological 
process 
5.04199 0.0064608 
6 
33.3333 
protein dephosphorylation biological 
process 
5.04199 0.0064608 
6 
33.3333 
L-serine biosynthetic process biological 
process 
5.04199 0.0064608 
6 
33.3333 
heme-copper terminal oxidase 
activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
DNA integration biological 
process 
5.04199 0.0064608 
6 
33.3333 
sulfate transmembrane 
transporter activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
polyamine-transporting ATPase 
  activity   
molecular 
function   
5.04199 0.0064608 
6   
33.3333 
138 
 
 
organic phosphonate transport biological 
process 
5.04199 0.0064608 
6 
33.3333 
carbohydrate biosynthetic 
process 
biological 
process 
5.04199 0.0064608 
6 
33.3333 
oxidoreductase activity, acting on 
the aldehyde or oxo group of 
donors, disulfide as acceptor 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
sodium:dicarboxylate symporter 
activity 
molecular 
function 
5.04199 0.0064608 
6 
33.3333 
metal ion transport biological 
process 
5.04199 0.0064608 
6 
33.3333 
type III protein secretion system 
complex 
cellular 
component 
5.04199 0.0064608 
6 
33.3333 
adenyl nucleotide binding molecular 
function 
5.04199 0.0064608 
6 
33.3333 
peptidyl-tyrosine 
dephosphorylation 
biological 
process 
5.04199 0.0064608 
6 
33.3333 
'de novo' CTP biosynthetic 
process 
biological 
process 
5.04199 0.0064608 
6 
33.3333 
ATP metabolic process biological 
process 
5.04199 0.0064608 
6 
33.3333 
chorismate metabolic process biological 
process 
5.04199 0.0064608 
6 
33.3333 
protein insertion into membrane biological 
process 
5.04199 0.0064608 
6 
33.3333 
polysaccharide biosynthetic 
process 
biological 
process 
4.75503 0.0086082 
8 
25 
translation initiation factor 
activity 
molecular 
function 
4.75503 0.0086082 
8 
25 
aminomethyltransferase activity molecular 
function 
4.75503 0.0086082 
8 
25 
biotin carboxylase activity molecular 
function 
4.75503 0.0086082 
8 
25 
fumarate hydratase activity molecular 
function 
4.75503 0.0086082 
8 
25 
glutamate-ammonia ligase 
activity 
molecular 
function 
4.75503 0.0086082 
8 
25 
protein serine/threonine kinase 
activity 
molecular 
function 
4.75503 0.0086082 
8 
25 
amino sugar metabolic process biological 
process 
4.75503 0.0086082 
8 
25 
glycerol-3-phosphate metabolic 
process 
biological 
process 
4.75503 0.0086082 
8 
25 
DNA-templated transcription, 
termination 
biological 
process 
4.75503 0.0086082 
8 
25 
translational termination biological 4.75503 0.0086082 25 
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process 8 
protein complex assembly biological 
process 
4.75503 0.0086082 25 
8 
cysteine biosynthetic process 
from serine 
biological 
process 
4.75503 0.0086082 25 
8 
glutamate biosynthetic process biological 
process 
glutamine biosynthetic process biological 
process 
glutathione biosynthetic process biological 
process 
iron-sulfur cluster assembly biological 
process 
acetyltransferase activity molecular 
function 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
oxidoreductase activity, acting on 
single donors with incorporation 
of molecular oxygen, 
incorporation of two atoms of 
oxygen 
molecular 
function 
4.75503 0.0086082 25 
8 
molybdenum ion binding molecular 
function 
protein catabolic process biological 
process 
carbohydrate binding molecular 
function 
cell division site cellular 
component 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
precorrin-2 dehydrogenase 
activity 
extracellular polysaccharide 
biosynthetic process 
carbohydrate derivative 
metabolic process 
carbohydrate derivative 
biosynthetic process 
organic substance biosynthetic 
process 
organophosphate metabolic 
process 
molecular 
function 
biological 
process 
biological 
process 
biological 
process 
biological 
process 
biological 
process 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
8 
phosphorus metabolic process biological 
process 
4.75503 0.0086082 25 
8 
phosphate-containing compound 
metabolic process 
organophosphate biosynthetic 
biological 
process 
biological 
4.75503 0.0086082 25 
8 
4.75503 0.0086082 25 
  process  process  8   
140 
 
 
biosynthetic process biological 
process 
4.75503 0.0086082 
8 
25 
aminoacyl-tRNA editing activity molecular 
function 
4.53261 0.0107526 20 
aminopeptidase activity molecular 
function 
4.53261 0.0107526 20 
serine-type endopeptidase 
activity 
molecular 
function 
4.53261 0.0107526 20 
ribonuclease activity molecular 
function 
4.53261 0.0107526 20 
glucose metabolic process biological 
process 
4.53261 0.0107526 20 
translational initiation biological 
process 
4.53261 0.0107526 20 
regulation of translation biological 
process 
4.53261 0.0107526 20 
dephosphorylation biological 
process 
4.53261 0.0107526 20 
oxidoreductase activity, acting on 
paired donors, with incorporation 
or reduction of molecular oxygen 
molecular 
function 
4.53261 0.0107526 20 
rRNA methylation biological 
process 
4.53261 0.0107526 20 
ribosome biogenesis biological 
process 
4.53261 0.0107526 20 
Gram-negative-bacterium-type 
cell outer membrane assembly 
biological 
process 
4.53261 0.0107526 20 
organic cyclic compound 
metabolic process 
biological 
process 
4.53261 0.0107526 20 
cellular metabolic process biological 
process 
4.53261 0.0107526 20 
small molecule metabolic process biological 
process 
4.53261 0.0107526 20 
single-organism process biological 
process 
4.53261 0.0107526 20 
single-organism metabolic 
process 
biological 
process 
4.53261 0.0107526 20 
single-organism cellular process biological 
process 
4.53261 0.0107526 20 
cellular aromatic compound 
metabolic process 
biological 
process 
4.53261 0.0107526 20 
organic substance metabolic 
process 
biological 
process 
4.53261 0.0107526 20 
metabolic process biological 
process 
4.53261 0.0107526 20 
cellular process biological 4.53261 0.0107526 20 
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process 
pseudouridine synthesis biological 
process 
4.35101 0.0128938 16.6667 
glycerol metabolic process biological 
process 
4.35101 0.0128938 16.6667 
regulation of translational fidelity biological 
process 
4.35101 0.0128938 16.6667 
amino acid transmembrane 
transporter activity 
molecular 
function 
4.35101 0.0128938 16.6667 
siderophore transmembrane 
transporter activity 
molecular 
function 
4.35101 0.0128938 16.6667 
tetrapyrrole biosynthetic process biological 
process 
4.35101 0.0128938 16.6667 
ATP synthesis coupled electron 
transport 
biological 
process 
4.35101 0.0128938 16.6667 
pilus organization biological 
process 
4.35101 0.0128938 16.6667 
biological_process biological 
process 
4.35101 0.0128938 16.6667 
amino acid transmembrane 
transport 
biological 
process 
4.19757 0.015032 14.2857 
ATP-dependent DNA helicase 
activity 
molecular 
function 
4.19757 0.015032 14.2857 
hydrolase activity, hydrolyzing 
O-glycosyl compounds 
molecular 
function 
4.19757 0.015032 14.2857 
peroxidase activity molecular 
function 
4.19757 0.015032 14.2857 
protein histidine kinase activity molecular 
function 
4.19757 0.015032 14.2857 
tRNA modification biological 
process 
4.19757 0.015032 14.2857 
protein disulfide oxidoreductase 
activity 
molecular 
function 
4.19757 0.015032 14.2857 
lipid catabolic process biological 
process 
4.19757 0.015032 14.2857 
nickel cation binding molecular 
function 
4.19757 0.015032 14.2857 
hydroxymethyl-, formyl- and 
related transferase activity 
molecular 
function 
4.19757 0.015032 14.2857 
cell wall organization biological 
process 
4.19757 0.015032 14.2857 
3-oxoacyl-[acyl-carrier-protein] 
synthase activity 
molecular 
function 
4.06477 0.017167 12.5 
arginine catabolic process biological 
process 
4.06477 0.017167 12.5 
glycine catabolic process biological 4.06477 0.017167 12.5 
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process 
oxidoreductase activity, acting on 
CH-OH group of donors 
molecular 
function 
4.06477 0.017167 12.5 
oxidoreductase activity, acting on 
the CH-CH group of donors 
molecular 
function 
4.06477 0.017167 12.5 
transferase activity, transferring 
pentosyl groups 
molecular 
function 
4.06477 0.017167 12.5 
metalloendopeptidase activity molecular 
function 
3.9477 0.019299 11.1111 
copper ion binding molecular 
function 
3.9477 0.019299 11.1111 
protein binding molecular 
function 
3.9477 0.019299 11.1111 
DNA-templated transcription, 
initiation 
biological 
process 
3.9477 0.019299 11.1111 
cell adhesion biological 
process 
3.9477 0.019299 11.1111 
ATPase activity, coupled to 
transmembrane movement of 
substances 
molecular 
function 
3.9477 0.019299 11.1111 
pyrimidine nucleotide 
biosynthetic process 
biological 
process 
3.84307 0.0214278 10 
rRNA processing biological 
process 
3.84307 0.0214278 10 
histidine metabolic process biological 
process 
3.84307 0.0214278 10 
tyrosine biosynthetic process biological 
process 
3.84307 0.0214278 10 
cellular aromatic compound 
metabolic process 
biological 
process 
3.84307 0.0214278 10 
ubiquinone biosynthetic process biological 
process 
3.84307 0.0214278 10 
ATP biosynthetic process biological 
process 
3.84307 0.0214278 10 
oxidoreductase activity, acting on 
NAD(P)H 
molecular 
function 
3.84307 0.0214278 10 
phosphotransferase activity, 
alcohol group as acceptor 
molecular 
function 
3.84307 0.0214278 10 
antibiotic biosynthetic process biological 
process 
3.84307 0.0214278 10 
cytochrome complex assembly biological 
process 
3.84307 0.0214278 10 
protein secretion by the type III 
secretion system 
biological 
process 
3.84307 0.0214278 10 
protein peptidyl-prolyl 
  isomerization   
biological 
process   
3.74848 0.0235536 9.09091 
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peptidyl-prolyl cis-trans 
isomerase activity 
molecular 
function 
3.74848 0.0235536 9.09091 
exonuclease activity molecular 
function 
3.74848 0.0235536 9.09091 
cellular protein modification 
process 
biological 
process 
3.74848 0.0235536 9.09091 
type II protein secretion system 
complex 
cellular 
component 
3.74848 0.0235536 9.09091 
cellular metabolic process biological 
process 
3.74848 0.0235536 9.09091 
Mo-molybdopterin cofactor 
biosynthetic process 
biological 
process 
3.66219 0.0256763 8.33333 
arginine biosynthetic process biological 
process 
3.58286 0.027796 7.69231 
coenzyme binding molecular 
function 
3.58286 0.027796 7.69231 
histidine biosynthetic process biological 
process 
3.50948 0.0299125 7.14286 
glutamine metabolic process biological 
process 
3.50948 0.0299125 7.14286 
oxidoreductase activity, acting on 
the aldehyde or oxo group of 
donors, NAD or NADP as 
acceptor 
molecular 
function 
3.50948 0.0299125 7.14286 
transferase activity, transferring 
acyl groups other than amino- 
acyl groups 
molecular 
function 
3.50948 0.0299125 7.14286 
cell redox homeostasis biological 
process 
3.50948 0.0299125 7.14286 
NADH dehydrogenase (quinone) 
activity 
molecular 
function 
3.50948 0.0299125 7.14286 
purine nucleotide metabolic 
process 
biological 
process 
3.44121 0.032026 6.66667 
manganese ion binding molecular 
function 
3.44121 0.032026 6.66667 
fatty acid metabolic process biological 
process 
3.37739 0.0341364 6.25 
dioxygenase activity molecular 
function 
3.37739 0.0341364 6.25 
tryptophan biosynthetic process biological 
process 
3.31749 0.0362438 5.88235 
oxidoreductase activity, acting on 
the CH-OH group of donors, 
NAD or NADP as acceptor 
molecular 
function 
3.31749 0.0362438 5.88235 
2 iron, 2 sulfur cluster binding molecular 
function   
3.31749 0.0362438 5.88235 
144 
 
 
phosphorelay sensor kinase 
activity 
molecular 
function 
3.26105 0.038348 5.55556 
signal transduction by 
phosphorylation 
biological 
process 
3.26105 0.038348 5.55556 
NADP binding molecular 
function 
3.26105 0.038348 5.55556 
extracellular region cellular 
component 
3.20771 0.0404492 5.26316 
fatty acid biosynthetic process biological 
process 
3.20771 0.0404492 5.26316 
arginine metabolic process biological 
process 
3.15714 0.0425474 5 
response to antibiotic biological 
process 
3.15714 0.0425474 5 
DNA replication biological 
process 
3.06327 0.0467345 4.54545 
DNA recombination biological 
process 
3.01955 0.0488234 4.34783 
sequence-specific DNA binding molecular 
function   
3.01955 0.0488234 4.34783 
 
 
Table 2.3 C: GO-enrichment of 24 h carvacrol treatment (n=2) compared to 24 h 
control (n=3) 
 
Function Type Enrichme 
nt Score 
Enrichment 
p-value 
% genes 
in group 
that are 
present 
structural constituent of ribosome molecular 
function 
67.621 4.29134E- 
30 
51.8519 
translation biological 
process 
51.4926 4.33576E- 
23 
30.5263 
RNA binding molecular 
function 
49.8652 2.20702E- 
22 
35.6164 
intracellular cellular 
component 
35.8216 2.77262E- 
16 
30.8824 
cellular protein metabolic process biological 
process 
34.4494 1.09346E- 
15 
17.5758 
3-oxoacyl-[acyl-carrier-protein] 
synthase activity 
molecular 
function 
6.13909 0.00215688 37.5 
glucose-6-phosphate 
dehydrogenase activity 
molecular 
function 
5.59569 0.00371384 66.6667 
ribonuclease activity molecular 
function 
4.43816 0.0118177 40 
regulation of translation biological 
process   
4.43816 0.0118177 40 
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ribosome biogenesis biological 
process 
4.43816 0.0118177 40 
transferase activity, transferring 
acyl groups other than amino- 
acyl groups 
molecular 
function 
4.42021 0.0120317 21.4286 
fatty acid biosynthetic process biological 
process 
3.5676 0.0282235 15.7895 
protein binding molecular 
function 
3.24942 0.0387968 22.2222 
cell adhesion biological 
process 
3.24942 0.0387968 22.2222 
ubiquinone biosynthetic process biological 
process 
3.04917 0.0473981 20 
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3.3.10 Pathway Enrichment Analysis of P. aeruginosa Treated with Thymol 
or Carvacrol 
 
 
 
Further analysis looking at pathway enrichment revealed three significant 
pathways affected by the 6 h thymol treatment. These pathways in order of ascending 
enrichment were RNA degradation, propanoate metabolism, and phenylalanine, tyrosine, 
and tryptophan biosynthesis (Table 2.4 A). For all three pathways low percentages of 
genes involved were statistically altered in expression. Due to the very minimal number 
of genes significantly affected by the 24 h thymol exposure, collectively no single 
pathway was affected by this treatment. 
 
After 24 h, carvacrol treatment significantly enriched two pathways, ribosome and 
siderophore biosynthesis (Table 2.4 C). In the ribosomal pathway, 50% of the genes were 
significantly affected with a pathway enrichment score of 60.32. Compared to the 24 h 
thymol treatment, carvacrol treatment enriched both the ribosome pathway and that of 
valine, leucine, and isoleucine degradation. 
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Table 2.4: Pathway enrichment analysis of P. aeruginosa after exposure to thymol or 
carvacrol. From the sample of genes deemed significantly increased by a factor of ≥2.0 
fold change, genes were grouped based similarity in the pathways which they function 
through KEGG pathway analysis. Calculation of differences in pathway enrichment 
compared to the control was performed through a Fisher’s Exact Test. Only those 
pathways with an enrichment p-value > 0.05 are displayed. 
 
Table 2.4 A: Pathway analysis of 6 h thymol treatment (n=3) compared to 6 h 
control (n=3) 
 
Pathway Name Enrichment 
Score 
Enrichment 
p-value 
% genes in pathway 
that are present 
RNA degradation 4.5173 0.0109185 16.6667 
Propanoate metabolism 3.83369 0.0216296 11.7647 
Phenylalanine, tyrosine and 
tryptophan biosynthesis 
3.26017 0.038382 8.69565 
Inositol phosphate metabolism 2.90756 0.0546088 25 
 
 
Table 2.4 B: Pathway analysis of 24 h carvacrol treatment (n=2) compared to 24 h 
control (n=3) 
 
Pathway Name Enrichment 
Score 
Enrichmen 
t p-value 
% genes in pathway 
that are present 
Ribosome 60.3255 6.32351E- 
27 
50.9434 
Biosynthesis of siderophore 
  group nonribosomal peptides   
6.475 0.0015415 50 
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3.4 Discussion 
 
 
 
Isometric phenolic compounds thymol and carvacrol extracted from either thyme 
or oregano have shown antibacterial properties to various species of bacteria (Helander, 
Alakomi et al. 1998, Walsh, Maillard et al. 2003, Oussalah, Caillet et al. 2007). In this 
study the antibacterial properties and effects of thymol and carvacrol towards the 
pathogenicity of P. aeruginosa were assessed by examining their effects against the 
laboratory strain PAO1and two clinical isolates. MIC experiments revealed bacteriostatic 
effects towards the clinical P. aeruginosa isolates, but not towards PAO1 when tested in 
M9 minimal salts media. Our data are consistent with those reported by others, where 
concentrations up to 1000 µg/ml did not attenuate growth (Walsh, Maillard et al. 2003). 
Concentrations of up to 3 mM and 3-5 mM have been reported as MIC concentrations for 
carvacrol and thymol respectively, against Escherichia coli (Helander, Alakomi et al. 
1998, Trombetta, Castelli et al. 2005). In our study, such high concentrations were not 
assessed, but it is reasonable to suggest that concentrations at this high level may have 
inhibited the growth of PAO1. However, in a neutral medium such as the MHCA, 
bacteriostatic effects of either compound were seen towards PAO1. 
 
Inhibitory growth action towards both clinical isolates was displayed for thymol 
and carvacrol. The mucoid clinical isolate growth was inhibited at 1200 µg/ml and 1000 
µg/ml in M9 media and 150 µg/ml and 450 µg/ml in MHCA media for thymol and 
carvacrol respectively. Inhibitory concentrations were lower for the non-mucoid strain for 
either compound in MHCA and M9 media. It is difficult to decide whether if this is strain 
specific effect or an effect of the mucoid phenotype. Thymol and carvacrol act as 
antimicrobial agents through their ability to insert into the cell membrane causing 
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disruption, which leads to cell leakage and lysis at higher concentrations (Trombetta, 
Castelli et al. 2005). Speculation regarding the role of the mucoid phenotype in the 
efficacy of thymol or carvacrol as antibiotics will need to be further explored with larger 
sample sizes of clinical isolates. 
 
Growth curve analysis revealed little effect of either compound on the growth rate 
of P. aeruginosa at sub-inhibitory concentrations. Minimal attenuation towards bacterial 
growth suggests these compounds would not be very effective in aiding the clearance of 
bacterial infections if administered at low concentrations. However, reducing bacterial 
growth is only one mechanism for alleviating infection, reduction of key virulence factors 
or adherence in the presence of either compound would be beneficial mechanism(s) of 
action of a novel antibiotic. 
 
Pathway analysis for the 6 h thymol incubation displayed enrichment of the 
energy metabolism pathway ofpropanoate metabolism; however, only ~12% of the genes 
in this pathway were affected, therefore it is unlikely that larger overall changes in this 
pathway occurred with treatment (Table 2.2 A). Increased expression in two genes 
involved in ethanol oxidation, exaA and exaB were recorded (Gorisch 2003), and likely 
reflect the dilution of either compound into ethanol before dilution into the media. Day- 
long thymol incubation showed very little expressional differences related to energy 
metabolism in the bacteria. Expression analysis was not completed for a 6 h incubation 
with carvacrol, however few genes of interest related to bacterial metabolism were 
effected after 24 h of incubation. Two genes primarily involved in the metabolism of 
valine, leucine, and isoleucine were significantly upregulated. Gene bkdA2 encodes two 
subunits of the branched chain keto-acid dehydrogenase, an enzyme in the metabolism of 
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valine, leucine, and isoleucine (Debarbouille, Gardan et al. 1999), while lpdV which 
encodes a lipamide dehydrogenase which works in concert with the bkd operon to which 
bkdA2 also belongs (Madhusudhan, Lorenz et al. 1993). 
 
In the presence of either thymol or carvacrol, reduced adherence was only 
demonstrated for the mucoid clinical isolate (Figure 2.4). Preformed biofilms were 
treated with suprainhibitory concentrations of either compound; showing reductions in 
biofilm formation only in the mucoid clinical isolate (Figure 2.5). As suggested earlier, it 
cannot be stated whether these findings are mucoid phenotype dependent without further 
studies implementing larger sample sizes. 
 
Previous studies monitoring the effects of thymol and carvacrol on biofilm 
formation and bacterial adherence have revealed inconsistent results. With gram-positive 
bacteria such as Staphylococcus aureus and Staphylococcus epidermidis, reduced 
bacterial adherence and preformed biofilm reduction with thymol or carvacrol treatment 
have been found (Nostro, Sudano Roccaro et al. 2007). Carvacrol treatment has also been 
shown to decrease naïve and mature biofilm formation of dual-species biofilms composed 
of S. aureus and Salmonella enterica Serovar Typhimuirum (Knowles, Roller et al. 
2005). Dual-species biofilms subjected to a mixture of thymol and eugenol, another 
naturally produced plant phenol, displayed no significant changes in biofilm arichitecture 
(Lebert, Leroy et al. 2007).  Thymol has also been tested against planktonic and biofilm 
cultures of S. epidermidis alone and in combination with chlorohexidine digluconate 
(CHG), a common skin antisepsis antimicrobial (Karpanen, Worthington et al. 2008). 
Decreased growth of planktonic and biofilm S. epidermidis was found with only thymol 
treatment, however no synergistic effects were found in combination with CGH 
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(Karpanen, Worthington et al. 2008). Carvacrol administered in polymeric nanocapsules 
disrupted preformed S. epidermidis biofilms allowing further penetration of the particles 
to the core of the biofilms, an area hard to reach with traditional antibiotics (Iannitelli, 
Grande et al. 2011). Further research into the mechanism of how thymol and carvacrol 
affect bacterial surface interactions would provide a more complete picture of ability of 
these compounds to reduce bacterial biofilm formation, and could enhance treatment of 
P. aeruginosa biofilms. 
 
Bacterial adherence to abiotic surfaces is mediated by cell-surface structures, such 
as LecB encoded by the lecB gene which was decreased in expression after incubation 
with thymol for 6 h (Table 2.2 A). The absence of lecB expression negatively effects pili 
biogenesis (Sonawane, Jyot et al. 2006). As detailed in Chapter 2, mutants of lecB lost 
twitching motility (Sonawane, Jyot et al. 2006), due to lecB mutants displaying reduced 
levels of the pilJ gene, an essential gene in the pilGHIJK operon for pili biogenesis 
(Kearns, Robinson et al. 2001). Decreasing lectin production or completely repressing the 
expression of lecB through treatment has potential to reduce P.aeruginosa’s 
pathogenicity. 
 
 
Conversion to a mucoid phenotype is a detrimental change during P. aeruginosa 
chronic infections. After the 24 h incubation with carvacrol the mucA gene, which 
negatively regulates the genes encoding alginate production and subsequent conversion to 
mucoid phenotype, was significantly increased (Table 2.2 C) (Martin, Schurr et al. 1993). 
Increased expression of mucA represses alginate production and conversion to the mucoid 
phenotype. If reduced of mucoid conversion through carvacrol treatment occurred, this 
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treatment has potential to greatly reduce P. aeruginosa pathogenicity during chronic 
infections. 
 
Incubation in the presence of carvacrol for 24 h increased expression of two genes 
encoding flagellar structural components (Table 2.2 C). Gene fliF codes for a precursor to 
the M-ring outer membrane protein (Thomas, Morgan et al. 2001), and fliD encodes a 
flagellar capping protein (Arora, Ritchings et al. 1998). As discussed in Chapter 2, fliD 
has been shown experimentally to be involved in mucin adhesion, an important feature of 
infectious lung pathogens (Arora, Ritchings et al. 1998). The full assembly and regulation 
of flagellar synthesis involves many more genes than the two found to be increase with 
the carvacrol incubation (Arora, Ritchings et al. 1998, Thomas, Morgan et al. 2001). 
Therefore it is unlikely that significant production increases in functional flagella would 
occur from exposure to carvacrol for 24 h. 
 
In fact, experimental data from this study demonstrated decreased flagellar 
swimming motility for PAO1 when treated with either thymol or carvacrol at sub- 
inhibitory concentrations (Figure 2.9 A). The ethanol vehicle also displayed significantly 
decreased motility in comparison to the control for the PAO1 strain, but only minimally 
reduced motility for the non-mucoid strain and produced no effect against the mucoid 
strain. The clinical isolates showed significantly reduced motility with both compounds at 
subinhibitory concentrations (Figure 2.9: B, C). Had higher concentrations been tested, 
complete attenuation of motility may have been seen with either compound treatment, an 
attribute which could significantly decrease initial bacterial establishment during 
infection. 
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Two studies with E. coli found reduced motility with exposure of the bacteria to 
carvacrol. Reduced motility in the study conducted by Gill & Holley (2006) deemed 
E.coli subjected to carvacrol at a concentration of 10 mM non-motile, and those treated at 
5 mM as reduced in motility. Protein analysis by Burt SA et al (2007) revealed significant 
decreases in flagellum to the point of extinguishing motility when E.coli was treated with 
carvacrol at 1mM overnight. Interestingly, these authros also noted that the decrease in 
motility was both concentration and time dependent (in agreement with Gill & Holley 
(2006). 
 
The importance of excreted enzymes towards bacterial virulence is critical. In this 
study the measurement of secreted protease and lipase was taken from culture 
supernatants grown in the presence of subinhibitory concentrations of either thymol or 
carvacrol. Growth in the presence of either compound significantly reduced PAO1 
protease production at a 0.5 MIC concentration (Figure 2.7 A). Expression analysis after 
6 h of growth in the presence of thymol also displayed decreased expression of the lasB 
gene which encodes a P. aeruginosa elastase (Table 2.2 A) (Hentzer, Wu et al. 2003). 
Expression analysis after only 6 h of incubation with carvacrol may also have displayed 
similar decreases in lasB gene expression. 
 
No significant changes in secreted protease were measured for the mucoid clinical 
isolate (Figure 2.7 B) however complete attenuation of protease production was displayed 
for the non-mucoid clinical isolate with 0.5 MIC treatment of thymol or carvacrol, and 
the vehicle control (Figure 2.7 C). Interestingly, the 0.25 MIC concentration for both 
thymol and carvacrol had a rescue effect on the protease production in the non-mucoid 
isolate. It is unclear why the vehicle control created such attenuation, and why it only 
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affected the non-mucoid clinical isolate. It is possible that this outcome is strain specific, 
and not at all indicative of what would be seen for a larger sample size of clinical isolates. 
 
Lipase production, assessed through a tween 20 hydrolysis reaction, showed 
carvacrol and thymol treatment resulted in significant increases in lipase production for 
PAO1 (Figure 2.8 A). Contrastingly, the mucoid isolate, displayed decreases with either 
treatment as well as with the vehicle control (Figure 2.8 B). Results from the non-mucoid 
isolate were inconclusive with only carvacrol at a 0.5 MIC concentration showing any 
significant attenuation however the vehicle control significantly decreased the measured 
lipase secretion (Figure 2.8 C). Unlike with the protease assay, no expressional evidence 
was found for an increase in lipase associated genes in the microarray analysis. 
 
The regulation of global signalling systems, like qurorum sensing, can also cause 
changes in the expression of virulence associated factors without altering the gene 
expression of the synthesis genes involved. An increased expression after 6 h of 
incubation with thymol was found for rsmA, a global translation regulator which when 
overexpression significantly reduces excreted metabolites such as proteases, elastase, 
hydrogen cyanide and pyocyanin (Table 2.2 A) (Pessi, Williams et al. 2001). Expression 
of rsmA has a negative effect on quorum sensing by down regulating the production of N- 
acylhomoserine lactones (Pessi, Williams et al. 2001). Expessional increases in rsmA 
after the 6 h incubation may be in part responsible for the decrease in LasB observed in 
our study. Gene rsmA affects translation greastest during the late exponential phase of 
growth (Pessi, Williams et al. 2001) anda therefore no expressional changes were found 
with the carvacrol treatment. 
155  
Although rsmA was not affected by the 24 h incubation with carvacrol, four genes 
involved in the Pseudomonas quinolone signalling (PQS) system were significantly 
upregulated after carvacrol exposure (Table 2.2 C). The PQS system is an intermediate 
system between las and rhl quorum sensing pathways, and is involved in the synthesis of 
secondary metabolites (Pesci, Milbank et al. 1999), such as elastase B and pyocyanin 
(McKnight, Iglewski et al. 2000, Gallagher, McKnight et al. 2002).  The genes 
upregulated with treatment were the psqABCD operon. Gene psqA activates anthranilite 
while psqBCD produce long-chain hydrocarbons which then react with anthranilite 
during the biosynthetic pathway of PQS (Calfee, Coleman et al. 2001). Increasesd 
expression of these genes did not correlate with increased production of secondary 
metabolites controlled by the PQS pathway due to the additional control of the rhl 
quorum sensing pathways and various other control systems for the synthesis of these 
secondary metabolites. 
 
The production of pigments which aid both in iron acquisition and cytoxicity are 
important virulence factors of P. aeruginosa. Through absorbance readings of cultures 
supernants grown in the presence of either thymol or carvacrol, the production of 
pyoverdine was assessed. Towards PAO1 very little change was found with treatment of 
either compound except an increase in pyoveredine was found with the 0.25 MIC 
concentration treatment of thymol (Figure 2.6 A). The mucoid isolate displayed 
significant reductions in pyoverdine for either compound. The vehicle control was again 
found to only affect the non-mucoid isolate with a significant decrease that of measured 
for the 0.5 MIC concentration of either extract on the non-mucoid isoalte. The 0.25 MIC 
concentration of carvacrol treatment displayed a rescue effect of pyoverdine production 
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for the non-mucoid isolate but as stated it is unclear why these results are only found in 
the non-mucoid isolate. 
 
Genes involved in both pyoverdine and pyochelin biosynthesis were significantly 
increased with thymol or carvacrol exposure after 6 h and 24 h respectively (Table 2.2: A, 
C). The 24 h carvacrol incubation increased pvdH, pvdJ, pvdD, and pvdL (pyoverdine) as 
well as pchA, pchF, and pchG (pyochelin). The 6 h thymol incubation increased pvdA, 
pvdS, pvdO, and pvdH (pyvoerdine) as well as pchD and pchC (pyochelin) were 
significantly increased. As detailed in Chapter 2, both pyoverdine and pycohelin are 
siderophore pigments synthesized and secreted by P. aeruginosa as primary iron 
acquisition molecules (Budzikiewicz 1993, Lamont, Beare et al. 2002). Increased 
expression of synthesis genes for both siderophore pigments suggests treatment with 
thymol or carvacrol disruptes the bacteria’s ability to sequester iron, or by unknown 
mechanisms triggers the increased expression and synthesis of genes for either pigment. 
Overall increases in pyoverdine production were not directly measured for the PAO1 as 
only a few genes involved in the synthesis pathways were increased in expression. 
Increased expression of siderophore pigments during an infection could increase P. 
aeruginosa’s iron sequestering capabilities which could lead to growth stability in an 
otherwise growth restrictive environment. Pyoverdine is involved in various other iron- 
dependent signalling pathways within the cell, and therefore increase production of 
pyoverdine could have multiple final effects (Lamont, Beare et al. 2002). 
 
Increased expression of bacterioferritin (bfrB), an iron storage protein, was also 
significantly increased after the 24 h carvacrol exposure (Table 2.2 C) (Burrowes, Baysse 
et al. 2006).  In constrast, the 24 h thymol exposure reduced bfrB expression (Table 2.2 
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B). Differences in the expression of bfrB after the exposure to either compound may be 
indicative of differences in a time dependent effect of the compounds towards the 
bacteria or in how either compound effects bacterial iron allocation. 
 
After exposure to thymol for 6 h, three additionaly genes involved in iron 
acquisition were also increased in expression (Table 2.2 A). Gene tonB, an essential 
protein involved in the internalization of siderophore pigments and heme utilization 
(Takase, Nitanai et al. 2000),  phuR a heme/hemeoglobin outer membrane receptor 
protein (Ochsner, Johnson et al. 2000), and hitA a ferric-binding protein involved in 
perplasmic transfer were all increased in expression (Sanders, Cope et al. 1994). The 
protein encoded by phuR is involved in the TonB dependent heme uptake system which 
involves several other genes in the phuSTUVW (Ochsner, Johnson et al. 2000). Increased 
expression of multiple iron acquisition genes, paired with the increase in pyoverdine and 
pyochelin synthesis suggest an increased need for iron acquisition after treatment with 
thymol or carvacrol. Stress from the treatment of the bacteria with either compound may 
be triggering a response in the bacteria to focus on growth requirements, and therefore 
iron sequestering mechanisms would be engaged. 
 
An additional virulence associated pigment of P. aeruginosa is pyocyanin.As 
addressed in Chapter 2, pyocyanin synthesis involves the operons 
phzA1B1C1D1E1F1G1/phzA2B2C2D2E2F2G2 and three modifying enzymes phzM, 
phzS, and phzH (Mavrodi, Bonsall et al. 2001). Incubation with thymol for 6 h decreased 
the expression of phzB1/phzB2, phzC1/phzC2, phzE1/phzE2, phzF1/phzF2, phzG2, phzS 
(Table 2.2 A). Reduction of an important virulence factor such as pyocyanin could 
decrease P. aeruginosa’s pathogenic potential during an infection. 
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Finally, as seen with the 24 h aqueous extract exposure, 24 h of exposure to 
carvacrol caused significant upregulations to genes involved in ribosomal structure and 
function (Table 2.2 C).  Pathway analysis revealed an enrichment of 60.32 with just over 
50% of the genes in the pathway significantly affected (Table 2.4 B). Overall 18 genes 
encoding ribosomal 50S proteins and 9 genes encoding ribosomal 30S proteins were 
significantly up-regulated. In combination with this, both elongation factor G (fusA1) and 
a DNA directed RNA polymerase (rpoA) were both increased in expression (Gil, Silva et 
al. 2004). As described in Chapter 2, increases in the ribosome pathway may be 
indicative of a great deal of protein turnover in the cell. Recycling of unnecessary 
proteins to create metabolites for the assembly of new proteins conserves the need to 
acquire raw materials which is an important strategy in situations, such as infections, 
where extracellular materials may be limited. No increases in ribosomal structure or 
function were found after the 24 h exposure to thymol, which suggests a fundamental 
difference in the way carvacrol and thymol affect and the growth of P. aeruginosa.Such 
differences may also be indicative of differences in growth-phase dependent effects of 
either compound against P. aeruinogsa. 
 
Although many similarities were found between the two compound treatements 
effects towards P. aeruignosa growth, metabolism, and virulence, fundamental 
similarities and differences were detected. Both compounds were capable of reducing P. 
aerguinosa growth to the point of inhibition for all strains dependent on the media used. 
Although adherence in the presence of either compound did not alter PAO1 or the non- 
mucoid strain response, however the mucoid clinical isolate adherence was reduced. This 
provides evidence for the possibility of either compound to be effective against clinical 
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isolates in regards to biofilm establishment. These results were corroborated for 
preformed biofilms treated with either compound. Pyoverdine and pyochelin synthesis 
genes were both found to increase in expression with treatment of either compound, 
however pyoverdine directly measured in culture supernatants displayed strain specific 
results. Increased expression of siderophore pigment synthesis genes may be indicative of 
future increases in pigment production, suggesting an increasing need for iron 
acquisition. Decreased expression of phenazine synthesis genes were also found for the 
 
6hr thymol incubation, although it is possible that decreases with carvacrol may also have 
been found if RNA had been assessed after only 6 h. 
 
Differences between the effects of thymol and carvacrol for both protease and 
lipase production were minimal. Decreases in protease expression were found for both 
PAO1 and the non-mucoid isolate; however inconclusive results were obtained for the 
mucoid isolate. Lipid hydrolysis assays displayed increased amounts of lipase with either 
treatment for PAO1, while significant decreases were found for the mucoid isolate, and 
inconclusive results were presented in the non-mucoid isolate. Swimming motility was 
fairly universally decreased in all strains after the exposure to either compound. 
 
The greatest difference between the two compounds was found with respect to the 
ribosomal pathway enrichment after the 24 h carvacrol treatment. This suggests a 
fundamental difference in either the timing of thymol’s or carvacrol’s action on P. 
aeruginosa, or a difference in the mechanism in which they affect the bacteria. Further 
exploration into this area may produce a better understanding of why such dramatic 
increases in ribosomal activity were found. 
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In regards to pathogenicity, there is potential for either compound to work as a 
growth inhibiting treatment. However, it would likely be most effective when bacteria are 
growing planktonically and therefore is not well suited for chronic state infections of P. 
aeruginosa. Mixed effects regarding virulence factor production suggest that side effects 
of thymol or carvacrol treatment may cause more harm than good in complicated 
infection situations, however only two clinical isolates were analyzed in this study. To 
make a firm assessment of the efficacy of either compound as a therapeutic agent towards 
P. aeruginosa infections, larger sample sizes and repeated standardized testing would 
provide more concrete evidence for the adoption of these compounds as future 
antibacterial therapies. 
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Conclusion 
 
 
 
Evidence acquired during this in vitro analysis of P. aeruginosa pathogenicity in the 
presence of multiple plant extracts revealed the ability of naturally derived compounds to 
inhibit bacterial virulence and growth in multiple ways. Reduction of bacterial growth, 
biofilm formation, bacterial virulence factor secretion and synthesis, and bacterial 
motility after exposure to the aqueous ginseng extract of Panax quinquefolius provide 
evidence and encouragement for further development of this extract. Although such 
intriguing results were not found with the alcoholic ginseng extract, development of 
purified compounds from the extract may produce compounds with more promising 
antibacterial properties. Due to the low concentrations needed to inhibit bacterial growth 
with either thymol or carvacrol, both show potential for future development as 
antibacterial treatments. Continued exploration into the efficacy of these plant derived 
components against other species of bacteria, in synergy with current antibacterial drugs 
and each other, as well as further purification and chemical analysis will undoubtedly 
help to define the proper dosage and medicinal use for each of these compounds. 
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